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Abstract 
 
Stimuli-responsive delivery systems are capable of site-specific drug delivery through the 
temporal and spatial control over drug release.  To date, the clinical relevance of photoresponsive 
systems has been stifled by: (i) a lack biocompatible photoresponsive materials, and (ii) the 
reliance on ultraviolet (UV) light for reliable activation.  UV light is genotoxic and unable to 
penetrate tissues; near infrared (NIR) light is biologically benign and tissue transparent.  
However, the low energy density of NIR light has made the activation of NIR-responsive 
chromophores unreliable.  Therefore, there remains a critical need to develop a photoresponsive 
delivery system that is biocompatible, and can be reliably activated with clinically relevant NIR 
light.  In order to address this need we evaluated a new class of photoresponsive materials, the 
alkoxyphenacyl-based polycarbonates (APP), which are constructed from biocompatible 
polymeric and chromophoric units.  The construct of the APP polymers contains the chromophore 
within the polymer backbone such that exposure to the photo-trigger (250-320 nm light) causes 
photo-induced chain scission.   
First, we set out to characterize the biocompatibility of the APP homopolymer and 
copolymers with polycaprolactone (PCL) and polyethylene glycol (PEG).  The APP polymers 
and nanoparticles (NPs) prepared from the APP polymers (APP-NPs) via nanoprecipitation were 
comparable to poly(lactic-co-glycolic acid) (PLGA) before and after exposure to the photo-
trigger during in vitro studies of cytotoxicity, macrophage activation, and red blood cell (RBC) 
lysis.  In vivo biocompatibility evaluation in BALB/c mice revealed that liver and kidney 
functions were not distorted in mice treated with APP polymers, and this was corroborated by 
histopathological assessments. Measurements of plasma cytokines (TNF-α, IL-6) indicated that 
the APP polymers did not trigger an immune response. 
Subsequently, the efficacy of APP-NPs as photoresponsive delivery systems was 
evaluated by loading doxorubicin (DOX) as a model drug (DOX-APP-NPs).  In order to identify 
and evaluate formulation and photoirradiation parameters that influenced photoresponsive 
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efficacy, the resultant NPs were characterized for: size, stability, morphology, zeta potential, 
DOX loading, and DOX release.  Stable, spherical DOX-loaded NPs were prepared from the 
homopolymer and PCL copolymer with diameters between 70-180 nm depending on the polymer 
concentration (10-40 mg/mL) and polymer type.  Exposure to the photo-trigger disrupted the 
surface of the NPs without visibly altering the core, and increased the rate and extent of DOX 
release.  Photoresponsive DOX release was markedly influenced by the polymer type, frequency 
of photoirradiation, and polymer concentration.  Photoirradiation did not negatively impact the 
functional efficacy of released DOX as assessed by cytotoxicity studies in Lewis lung carcinoma 
(LLC) cells.  Studies in BALB/c mice indicated that drug release from DOX-APP-NPs was not 
subjected to dose dumping following photoirradiation.  
The final portion of the project was devoted to the design and development of an APP 
delivery system that can respond to NIR.  In this approach we adopted the process of photon 
upconversion to generate the photo-trigger (UV light) in situ from clinically relevant NIR light.  
As such, upconverting nanocrystals (UCNCs) were synthesized via a solvothermal method, and 
optimized for emissions in the UV region by varying the concentrations of the dopants (Yb
3+
 and 
Tm
3+
) and the particle architecture (core-alone and core-shell).  UCNC-loaded APP-NPs (UCNC-
NPs) were prepared from the APP homopolymer and characterized.  The NaYF4(30% 
Yb
3+
/0.15% Tm
3+
)@NaYbF4@NaYF4 UCNC formulation produced the most intense emissions in 
the UV region when exposed to NIR light (980 nm).  UCNC-NPs had mean sizes between 153-
393 nm depending on the UCNC concentration (0.5-5 mg/mL), and their morphology more 
closely resembled that of the parent UCNCs than APP-NPs prepared without UCNCs.  DOX 
loading was not significantly affected by the inclusion of UCNCs in the NP formulation (p > 
0.05).  UCNC-NPs were unstable, forming visible precipitates within 72 hr.  Inclusion of UCNCs 
in APP-NPs did not affect biocompatibility as well as in vivo biodistribution in tumor-bearing 
athymic mice.  Exposure to NIR light was not effective in achieving photoresponsive drug release 
from the as-prepared delivery system during in vitro or ex vivo studies; plausibly due to 
insufficient generation of the photo-trigger as a result of minimal overlap between the 
wavelengths of light emitted from the UCNCs and chromophore’s photo-trigger.   
Overall, this work demonstrated the design and evaluation of a new class of 
photoresponsive polymers in drug delivery.  Particular attention was paid to identify and assess 
the impact of various formulation, photoirradiation, and therapeutic parameters that will affect 
specificity of photoresponsive drug release using the APP polymers. 
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Chapter 1 
Background and Literature Review 
 
1.1. Conventional delivery systems 
The development of new drugs with enhanced potency makes the development of novel 
delivery systems increasing important.  Nowhere is this more pronounced than in oncology.  The 
therapeutic agents used to treat cancer have low therapeutic indexes due to the nonspecific 
cytotoxic/cytostatic mechanisms through which they function.   Delivering these therapeutic 
agents via conventional drug delivery systems that operate through nonspecific distribution of the 
drug throughout the body is not clinically ideal.  This indiscriminate distribution of drug into both 
healthy and diseased tissues often requires large and/or frequent dosing in order to achieve a 
therapeutically relevant drug concentration in the desired tissue(s).  Such dosing regimens often: 
(i) impose substantial physical and/or financial burden(s) on both patient and care-giver, (ii) stifle 
therapeutic efficacy, (iii) increase the risk of adverse effects, and (iv) are implicated in the 
development of drug resistance (Ismael et al., 2008).  Alternative strategies utilizing advanced 
delivery systems aim to address these limitations by delivering the drug only to the desired tissue; 
achieving “site-specific” delivery.  Site-specific delivery permits the use of less stringent dosing 
regimens without compromising therapeutic efficacy.  This alleviates the physical and/or 
financial burden(s) on the patient and care-giver, as well as prevents adverse effects caused by the 
indiscriminate distribution of drug into healthy tissues.  Furthermore, the risk of developing drug 
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resistance is also reduced since chronic exposure to sub-therapeutic drug concentrations is 
avoided (Davies et al., 2014). 
1.2. Nanoparticulate delivery systems 
 Delivery systems with one or more dimensions in the nanometer range (1-1,000 nm) have 
shown great promise as vehicles for site-specific drug delivery.  The term “nanoparticle” (NP) is 
defined by the International Union of Pure and Applied Chemistry as any material whose 
dimensions are measured in nanometers (i.e. < 1,000 nm).  Extensive diversity exists within this 
ambiguous definition and in the context of drug delivery the term “nanoparticles” includes: 
nanospheres, nanoemulsions, nanocapsules, liposomes, micelles, polymersomes, nanocrystals, 
carbon nanotubes, and dendrimers.  The first nanoparticulate delivery system approved by the 
FDA was DOXIL, a liposomal formulation containing doxorubicin.  Since the introduction of 
DOXIL in 1995, four more nanoparticulate formulations have received FDA approval 
(DaunoXome, Marqibo, Abraxane, and Lipodox) and others such as ThermoDOX are currently in 
late-stage clinical trials (Dawidczyk et al., 2014).  NPs can enhance a drug’s therapeutic index by 
decoupling the properties of the drug molecule from the properties of the final formulation.  This 
allows the pharmacokinetics (absorption, distribution, metabolism, elimination) to be tailored to 
the drug rather than dictated by the drug.  Additional advantages of nanoparticulate formulations 
include: (a) enhanced bioavailability of hydrophobic drugs, (b) avoidance of toxic co-solvents, (c) 
protection of the therapeutic payload from degradation, (d) overcome drug resistance, (e) able to 
cross biological barriers (e.g. blood-brain barrier), (f) controlled drug release, and (g) targeted 
delivery (passive and/or active) (Harush-Frenkel et al., 2007; Geldenhuys et al., 2015; Singh and 
Lamprecht, 2015; Thangavel et al., 2015).  Once administered NPs must overcome multiple 
physiological barriers and release their therapeutic payload within the desired tissue in order for 
the delivery system to be effective (Fig. 1.1).  The ability for NPs to overcome the various 
biological barriers is largely a function of the physiochemical properties of the NPs, most notably 
the size, morphology, and surface characteristics.  The ideal characteristics depend on the NPs’ 
specific composition and the pathology of the disease being treated.  Some groups have suggested 
that spherical, neutrally charged particles with a hydrophilic surface and a size between 10-100 
nm are ideal for delivery to solid tumors (Roser et al., 1998; Smith and Nie, 2008; Shan et al., 
2009; Cabral et al., 2011; Tang et al., 2014).  The results from studies conducted in humans and 
animal models indicate that sizes up to 200 nm are still capable of efficient delivery to solid 
tumors.   These studies report that NPs with sizes below 10 nm are rapidly cleared from 
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circulation by the kidneys, while increasing the size above 200 nm inhibits efficient extravasation 
(Symon et al., 1999; Smith and Nie, 2008; Schipper et al., 2009).   
 To date, all FDA approved NP formulations rely on passive targeting to achieve site-
specific delivery to solid tumors.  Passive targeting is achieved through the enhanced permeation 
and retention (EPR) effect; the term given to the preferential accumulation of NPs in solid tumors 
due to a combination of leaky neovasculature and insufficient lymphatic drainage (Dawidczyk et 
al., 2014).  To efficiently deliver drugs via passive targeting the NPs must remain in circulation 
for an extended period of time.  This requires that the NPs: (i) are stable under the shear stresses 
present in the circulation, (ii) evade recognition and removal by the phagocytic cells of the 
reticuloendothelial system (RES), and (iii) do not exit the circulation and enter healthy tissues.  
Furthermore, the drug must be retained while the NPs are in circulation but must be released once 
inside the tumor in order to interact with the target molecule(s) and exert its therapeutic effect(s).  
This controlled release of drug has proved to be a significant challenge in NP development.  One 
approach for controlling drug release is by engineering the NPs from materials with selectively 
modulatable properties.  These materials, and the delivery systems prepared from them, are 
termed “stimuli-responsive” and represent a promising means for controlling drug release.        
1.3. Stimuli-responsive delivery systems  
Stimuli-responsive (also known as “smart”) delivery systems are one type of advanced 
delivery system capable of site-specific drug delivery through the temporal and spatial control 
over drug release (Meyer et al., 2001; Allen and Cullis, 2004; Sengupta et al., 2005).  Drug 
release from these systems is dictated by a specific stimulus or “trigger.” Upon exposure to the 
stimulus, the system undergoes “activation,” during which a drastic change in the physical and/or 
chemical properties of the system occurs.  This change causes the release of entrapped drug to 
become favored (Fig. 1.2).  Some of the mechanisms used to control drug release from stimuli-
responsive delivery systems are hydrophobic-hydrophilic shift, isomer switching, and controlled 
degradation (Table 1.1) (Jiang et al., 2006; Lu et al., 2008; Fomina et al., 2010).  A wide variety 
of potential stimuli can be used to activate stimuli-responsive delivery systems.  Stimuli can be 
broadly classified as either “internal” (disease-specific) or “external” (non-disease specific).   
1.3.1. Internal stimuli 
 The use of internal stimuli for activation has been widely explored.  These systems utilize 
the existing disease pathology to trigger drug release.  Some of the pathological changes in the 
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microenvironment of the diseased/target tissue that have been investigated include: pH, redox 
potential, ionic strength, shear stress, enzyme overexpression, and the presence of endogenous 
molecules such as glucose (Fischel-Ghodsian et al., 1988; Tauro et al., 2008; Pedersen et al., 
2010; Liu et al., 2011; Poon et al., 2011; Korin et al., 2012; Chiang et al., 2015).  Of these, 
systems that respond to changes in pH have received considerable attention.  By designing 
delivery systems that can respond to pH drug release can be controlled at both the tissue and 
cellular levels.   
Healthy tissues maintain pH values around 7.4, however pathological conditions such as 
ischemia and cancer exhibit a marked reduction in local pH.  Multiple factors conspire to 
decrease intra-tumor pH to 4-5 including hypoxia, the upregulation of anaerobic metabolic 
pathways (Warburg effect), and the accumulation of lactic acid because of insufficient lymphatic 
drainage (Deacon et al., 2015).  By shielding positively charged nanoparticles with a neutral outer 
layer of poly(ethylene glycol) (PEG) attached via a pH labile bond, Poon et al, demonstrated the 
merits of pH-responsive systems (Poon et al., 2011).  In the low pH environment of the tumor, 
the shedding of the PEG layer exposed the nanoparticles’ positive surface charge.  The 
electrostatic attraction between the nanoparticles and the plasma membrane increased cellular 
uptake and retention of the nanoparticles in the tumor in vivo, and this effect was independent of 
the type of cancer. 
At the cellular level, pH varies between organelles.  The cytosol is maintained near 
neutral (pH 7.2), however, within the lysosome/late endosome the pH is around 5.5.  Drugs that 
enter the cell via endocytosis must be able to survive the harsh environment of the endosome, and 
escape into to cytosol in order to reach their targets.  This difference in pH between the endosome 
and the cytosol has been used to promote the escape of drugs from the early endosome into the 
cytoplasm.  Many of these systems have utilized materials containing a large quantity of histidine 
residues (poly-histidine) which acts as a “proton sponge” and rupture the endosomal membrane 
by increasing osmotic pressure.  This approach was utilized to prepared doxorubicin loaded 
micelles which were found to increase the concentration of doxorubicin at its therapeutic target 
(the nucleus) compared to controls (Lee et al., 2005).   
The presence or absence of endogenous molecules has been used to control the pH of the 
microenvironment.  Coupling this ability to selectively alter the local pH with pH-responsive 
materials permits the presence or absence of endogenous molecules to control drug release 
though pH. This approach has been applied to release insulin in response to high plasma glucose 
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levels, and stop the release of insulin when plasma glucose levels are not elevated.  The general 
design of these systems has insulin contained within a pH-responsive polymeric matrix and 
glucose oxidase attached to the polymer.  High plasma glucose levels cause glucose to enter the 
polymeric matrix, where glucose oxidase converts it to gluconic acid, lowering the local pH (Kost 
and Langer, 2001).  The pH-responsive polymer then allows insulin to be released from the 
system.  This approach was used by Fischel-Ghodsian et al., to release insulin in response to 
plasma glucose levels (Fischel-Ghodsian et al., 1988).  Their system utilized the pH-dependent 
solubility of modified insulin to control its release.  Insulin was first modified to have its 
isoelectric point at 7.4 (physiological pH).  Afterwards, this modified insulin, along with glucose 
oxidase immobilized to sepharose beads, were loaded within a polymer matrix created from an 
ethylene/vinyl acetate copolymer.  Glucose molecules that diffused from the plasma into the 
polymer matrix were converted to gluconic acid, lowering the pH within the polymer matrix.  The 
enhanced solubility of the modified insulin at pH values below 7.4 permitted rapid release of 
insulin from the polymer matrix.  In vivo studies demonstrated that the concentration of insulin in 
the plasma rapidly increased by 180% following infusion of a glucose solution (Fischel-Ghodsian 
et al., 1988). 
1.3.2. External stimuli 
Like internal stimuli, a wide variety of external stimuli have been studied for the 
activation of drug release including: local temperature, ultrasound, magnetic fields, electrical 
fields, and light (Saslawski et al., 1988; Balakrishnaiah et al., 2009; Stanley et al., 2012; Chou et 
al., 2013; Yi et al., 2013; Burke et al., 2014; Ta et al., 2014; Carling et al., 2015).  The 
exogenous nature of the stimulus is beneficial, as it facilitates reliable and reproducible 
activation.  Furthermore, it can easily be manipulated and monitored, allowing for a specific 
combination of parameters (e.g. duration, intensity, and exposed area) to be correlated to the 
release of a specific amount of drug.  A major drawback to external stimuli is that they require the 
patient and/or care-giver to do additional steps after the drug is administered in order to activate 
drug release.   
An example of an external stimuli-responsive delivery system is ThermoDOX (Celsion, 
Lawrenceville, NJ).  ThermoDOX is a liposomal formulation of doxorubicin that contains heat-
sensitive lipids in the bilayer of the liposome.  Upon local heating (39-42ᵒC) by radiofrequency 
thermal ablation, microwave hyperthermia, or high-intensity focused ultrasound, the heat-
sensitive lipids lyse and create pores in the bilayer through which doxorubicin is released.  This 
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strategy leverages three mechanisms to enhance therapeutic efficacy: (i) passive targeting via 
liposomal entrapment, (ii) increased tumor perfusion due to local hyperthermia, and (iii) stimuli-
responsive drug release.  Studies in mice demonstrated that ThermoDOX and local heating 
increased tumor accumulation of doxorubicin by 3.5-fold compared to mice treated with 
ThermoDOX but without local heating (Dromi et al., 2007).  ThermoDOX is currently in phase 
III clinical trials.  
1.3.3. Comparison of internal and external stimuli 
The important distinctions between activation with internal or external stimuli are 
outlined in Table 1.2.  Activation via internal stimuli is attractive since such systems are “user-
friendly,” requiring no additional action(s) by the patient or care-giver after the formulation is 
administered.  Furthermore, such systems sidestep any potential complications arising from an 
external stimulus that is not biocompatible.  However, in order for activation to occur, the 
formulation must physically interact with the stimulus.  Furthermore, the stimuli are inherently 
disease-specific, and therefore subject to fluctuations at different disease stages as well as in 
different patients.  This makes internal stimuli not conducive to reproducible activation.  In 
contrast to internal stimuli, external stimuli provide a more robust means for achieving 
reproducible activation.  External stimuli originate from exogenously applied sources, and are 
therefore independent of the microenvironment of the diseased tissue.  However, this enhanced 
reproducibility comes at the expense of patient convenience, since additional steps must be taken 
to activate drug release after the formulation is administered.  Additional testing is also required 
to ensure that the stimulus required for activation is safe.  Delivery systems that use external 
stimuli can serve as generic platforms capable of treating multiple diseases simply by changing 
the therapeutic payload. 
1.4. Light-responsive delivery systems 
Stimuli-responsive delivery systems that utilize light for activation are termed 
“photoresponsive.” The use of light for activation is very attractive due to its: (i) non-invasive 
nature, (ii) ease of application, (iii) patient acceptance, (iv) high versatility, and (v) high precision 
of activation.  The extreme precision over the activation of photoresponsive delivery systems 
comes as the result of the multitude of parameters of the activating light that can be precisely and 
independently manipulated.  These parameters include the inherent properties of the activating 
light (i.e. wavelength, intensity, and polarity), as well as the irradiation conditions (i.e. duration, 
frequency, and location).  By manipulating each of these parameters independently the activation 
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of photoresponsive systems can be precisely controlled temporally and spatially (Lu et al., 2008).  
The addition of optical lenses to focus the activating light further increases the precision of 
activation, enabling the focal volume to be as small as 1 femtoliter (So et al., 2000).  Changing 
the properties of the light being applied has been used to alter the system’s response, imparting an 
additional degree of spatial and temporal control over drug release.  Photoirradiation with 
different wavelengths of light has been shown to be capable of turning drug release “on” and 
“off” (Garcia-Amoros et al., 2012; Yuan et al., 2012).  This allows the amount of drug released to 
be controlled in real time, and tailored to meet the specific needs of individual patients.  Also, 
controlling the sequence of photoirradiation with different wavelengths of light enables the 
sequence in which multiple drugs are released from a single vehicle to be controlled.  This is a 
critical attribute as the synergistic effect of combination therapies often depends on the order and 
timing of administration (Achenbach et al., 2000; Garnett et al., 2008).  Photoresponsive delivery 
systems also facilitate the use of multi-modal treatment strategies, such as coupling 
photodynamic therapy to chemotherapeutic delivery (Ungun et al., 2009; Cui et al., 2012; Cui et 
al., 2013).  A technique known as photochemical internalization (PCI) is of particular interest for 
drugs and macromolecules that cannot withstand the harsh environment of the endosome such as 
peptides and miRNA/siRNA.  PCI utilizes a photoresponsive molecule that ruptures the 
endosome when exposed to light through the production of reactive oxygen species (ROS) 
(Jayakumar et al., 2014).  This technique is similar to photodynamic therapy with the critical 
distinction that ROS production is minimal and not cytotoxic.  Only enough ROS are produced to 
disrupt the endosomal membrane.  Finally, photoresponsive systems can directly link site-specific 
drug delivery to image-guided drug therapy (Lepage et al., 2007).  These unique and highly 
advantageous traits have driven researchers to develop a copious variety of photoresponsive 
systems; however photoresponsive drug delivery has yet to become clinically viable. 
1.5. Review of photoresponsive delivery systems 
1.5.1. Current limitations to photoresponsive delivery systems 
The fundamental limitations to the clinical application of photoresponsive drug delivery 
are: (i) the lack of photoresponsive materials that are biocompatible and biodegradable, and (ii) 
the reliance on ultraviolet (UV) light for reliable activation.  Over the last two decades numerous 
novel photoresponsive delivery system have been reported.  However, the majority of these 
reports focus on the material’s photochemistry and preliminary studies of potential applications, 
with little or no attention given to the material’s biocompatibility.  To this end, many of these 
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reports studied the photoresponsive materials under conditions, such as organic solvent systems, 
that are not biologically relevant.  While such studies are crucial to understanding the system on 
the molecular level, the lack of accompanying studies of biocompatibility, biodegradability, and 
efficacy under biologically relevant conditions hinders the identification of materials that may be 
applicable to therapeutic applications.   
1.5.2. The ultraviolet spectrum 
The reliance on UV light for reliable activation has severely limited the utility of novel 
materials in clinical applications.  Per Planck’s relation, the wavelength of light is inversely 
proportional to its energy content (Fig. 1.3).  As such, a single photon of short wavelength UV 
light contains sufficient energy to drive a photochemical reaction, enabling fast and reliable 
activation of UV-responsive chromophores.  However, the energy contained in a photon of UV 
light can also drive undesirable photochemical reactions, such as thymine dimer formation which 
makes UV light genotoxic (McMillan et al., 2008).  Furthermore, very little UV light makes it 
past the epidermis, and the little that does reach the dermis is rapidly attenuated.  This is due to 
extensive scattering and absorption of UV light by many of the fundamental components of 
biological tissue (Sowa et al., 2013).  As such, UV-responsive systems are relegated to superficial 
applications, namely topical and ophthalmic drug delivery (Wells LA, 2012).  Strategies have 
been proposed to extend the utility of UV-responsive systems beyond topical and ophthalmic 
applications.  Some research groups have postulated on the merits of delivering UV light via 
intubation/fiber optics, and keeping the dose of light administered below the threshold for tissue 
damage (Ito et al., 2008; Chen et al., 2011).  While this approach may circumvent UV light’s 
inability to penetrate tissue, such delivery negates the non-invasive nature of photoresponsive 
systems.  Furthermore, dose reduction is not a practical solution for clinical applications.  This 
has driven the development of photoresponsive systems that can respond to longer wavelengths 
(λ) of light in the visible and infrared (IR) regions. 
1.5.3. The visible spectrum 
Patient acceptance and the relatively high energy density of light in the visible region (λ 
= 400-700 nm) makes it a clinically attractive alternative to UV light.  A single photon of blue 
light (400-500 nm) contains enough energy to activate a chromophore via a one-photon 
mechanism without damaging biological tissues.  This was demonstrated by Carling et al., who 
utilized a butane-diol derivative of the 2-(4’-(N,N-dimethylamino)-4-nitro-[1,1’-biphenyl]-3-yl) 
propyl carbonyl chromophore (ANBP) to produce a polymer that degraded upon exposure to blue 
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light (Carling et al., 2015).  The photoresponsive polymer (ANBP) was used to prepare 
microparticles which released entrapped Nile Red upon irradiation with blue light at a 
biologically benign power density (0.21 W/cm
2
).  Blue light has also been used to trigger the 
release of the anticancer drug doxorubicin from nanoparticles (He et al., 2015).  In this system, 
ruthenium complexes were grated onto the surface of mesoporous silica loaded with doxorubicin 
to create photoresponsive molecular valves.  Upon irradiation with blue light (470 nm, 1 
mW/cm
2
) the ruthenium complexes underwent photocleavage, releasing the entrapped 
doxorubicin. 
The utility of visible light is largely precluded by very low tissue penetration.  In the 
visible region a variety of fundamental components of biological systems, most notably melanin 
(400-550 nm) and hemoglobin (500-650 nm), absorb strongly and rapidly attenuate the photo-
trigger (Zonios et al., 2001).  Red light (650-700 nm) has the highest tissue penetrating capacity, 
however it is still only able to penetrate to a depth of 8 mm before being completely attenuated 
(Wang et al., 2011).  Furthermore, caution must be exercised when utilizing materials that can be 
activated with visible light, as the ubiquitous presence of the activating light enables premature 
activation of the delivery system and/or activation outside of the target tissue (Byrnes et al., 2005; 
Tong and Kohane, 2012; Wu et al., 2013).    
1.5.4. The infrared spectrum 
The infrared (IR) spectrum, which consists of light with a wavelength between 700 nm 
and 1 mm, has been the focus of many research groups.  The IR spectrum is divided into three 
classes based on wavelength; IR-C, IR-B, and IR-A.  The IR-C spectrum’s utility (λ = 3 µm–
1,000 µm) is precluded by its complete inability to penetrate the stratum corneum (Ziegelberger, 
2006).  The utility of the IR-B spectrum (λ = 1.4–3 µm) is hampered due to light in this range 
being strongly absorbed by water, leading to tissue heating.  As such, research efforts have 
focused primarily on the IR-A, or near infrared (NIR), spectrum (λ = 700-1,400 nm).  Tissue 
transparency is at its maximum in this region, enabling NIR light to achieve substantial 
penetration into biological tissues (up to 10 cm) without causing deleterious effects (Byrnes et al., 
2005; Chen et al., 2006).  This has made NIR-responsive systems the most attractive clinically; 
however, to date NIR-responsive systems have failed to provide an alternative to UV-responsive 
systems. 
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1.6. NIR-responsive delivery systems 
NIR-responsive systems have suffered from unreliable activation, low sensitivity, 
instability, and prohibitively long irradiation times with high-powered (10
6–109  W/cm2) 
femtosecond-pulsed lasers (Miller et al., 2002; Zhao, 2007; Fomina et al., 2011).  These 
limitations are an inherent property of the multi-photon absorption mechanism of activation (most 
often two photons are absorbed, giving rise to the term “two-photon absorption”).  The low 
energy density of photons in the NIR region requires that multiple photons (e.g.  two photons) 
must be absorbed by the same molecule to overcome the energy barrier of the reaction.  The 
absorption of these two photons must occur simultaneously, since the excitation of the 
chromophore proceeds through a virtual (non-real) excited state which exists for only a few 
femtoseconds (Pawlicki et al., 2009).  Therefore, the two-photon absorption cross section, a 
measure of the probability of chromophore activation, must incorporate the area of two photons 
as well as a term for time.  The result of this is that the probability of activating a NIR-responsive 
chromophore increases nonlinearly with the power of the excitation light (equation 1.1).  
𝑅𝑎𝑡𝑒 𝑜𝑓 𝑎𝑐𝑡𝑖𝑣𝑎𝑡𝑖𝑜𝑛 ∝ 𝐸𝑥𝑐𝑖𝑡𝑎𝑡𝑖𝑜𝑛 𝐿𝑖𝑔ℎ𝑡 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦2  (1.1) 
In contrast to the nonlinear relationship between the intensity of the activating light and the 
probability of activating a NIR-responsive chromophore, the probability of activating a 
chromophore via a one photon process (i.e.  UV-responsive chromophores) increases linearly 
with increasing excitation power density.   
1.6.1. Efforts to enhance the utility of NIR-responsive delivery systems 
In order for NIR-responsive delivery systems to be a viable, reproducible means of 
controlling drug release extensive efforts have been devoted to increasing the two-photon 
absorption cross section.  Well-establish ways to increase a chromophore’s two-photon 
absorption cross section include: (i) extension of the π-bond conjugated system, (ii) the addition 
of an electron donating group and an electron withdrawing group into the chromophore, and (iii) 
the addition of a transition metal ion (Pawlicki et al., 2009; Bergendahl and Paterson, 2012).  
Efforts to increase the two-photon absorption cross section have produced encouraging results, 
however, the limitations of prolonged irradiation times and specialized high-powered pulsed 
lasers as the light source remain.  Goodwin et al.  utilized two-photon absorption to selectively 
control the release of the fluorescent dye Nile Red from micelles by irradiation with 795 nm light 
at 1.7 x 10
8
 W/cm
2
 (Goodwin et al., 2005).  Other groups have employed a series of molecular 
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rearrangements to exacerbate the effects of the activation of a single NIR-responsive 
chromophore (Fomina et al., 2010; Qian and Wang, 2010; Fomina et al., 2011).  This approach 
has increased sensitivity but has not been successful in reducing the irradiation time required.  For 
example, nanoparticles prepared by Fomina et al.  released 67% of entrapped Nile Red following 
one minute of UV irradiation (350 nm), whereas 4 hours of NIR irradiation (750 nm) was 
required to release the same amount of Nile Red (Fomina et al., 2010). 
1.7. Alternatives to NIR-responsive chromophores 
In order to circumvent the limitations of NIR-responsive chromophores, alternative 
approaches have been studied that utilize NIR light as the photo-trigger.  These strategies have 
utilized NIR light to induce local heating which selectively releases drug from the carrier.  In 
many of these systems gold nanoparticles have been employed to absorb the NIR light and 
convert it to heat.   The merits of this approach were demonstrated by the NIR-controllable 
release of fluorescently labeled dextrans from gold nanospheres entrapped within microparticles 
prepared from the thermally responsive polymer poly(diallyldimethylammonium chloride) 
(Bédard et al., 2008).  The thermal responsive swelling/shrinkage and permeability changes of the 
polymeric matrix enabled NIR light to control the release of the entrapped dextrans from this 
system.  Entrapping hollow gold nanospheres within poly(lactic-co-glycolic acid) microparticles 
enabled drug release to be controlled with NIR light (You et al., 2010).  Absorption of the NIR 
light (808 nm) by the gold nanospheres increased the temperature inside the microparticles, 
increasing the flexibility of the polymer chains and releasing the drug paclitaxel.  The efficacy of 
this system was demonstrated in vitro and in vivo, and the release of paclitaxel could be 
controlled by varying the NIR excitation power, the frequency of NIR irradiation, and the 
irradiation duration.  Localized heating of gold nanospheres by NIR light has also been used to 
disrupt the membrane of liposomes, enabling the release of the payload to be controlled with NIR 
light (Wu et al., 2008).  More recently, the process of photon upconversion has been explored for 
the activation of drug release with NIR light (Jayakumar et al., 2012; Liu et al., 2013; Fedoryshin 
et al., 2014; Michael Dcona et al., 2015) .    
1.8. Photon upconversion 
Photon upconversion is defined as the process in which the absorption of two or more 
photons of light results in an anti-Stokes type emission (i.e. emission of light at a shorter 
wavelength than that absorbed).  This phenomenon can be achieved in trivalent lanthanides that 
are incorporated (“doped”) into a suitable matrix.  The structure of the matrix in which the 
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lanthanide ions are housed is crucial to the process of upconversion, and is commonly a 
crystalline structure with dimensions on the nano-scale (1-1,000 nm).  Such systems are 
commonly referred to as “upconverting nanocrystals” (UCNCs).  Since photon upconversion was 
first described in 1966 it has attracted intense interest from a variety of disciplines including 
photoresponsive drug/gene delivery (Carling et al., 2010; Jayakumar et al., 2012), bioimaging (Li 
et al., 2013), solar cells (Shalav et al., 2007), and liquid crystal displays (Tang et al., 1989).  In 
medical applications such as bioimaging and drug delivery, upconversion has several unique 
advantages over conventional organic dyes and quantum dots, namely: (i) photochemical 
stability, (ii) resistant to photo-bleaching, (iii) narrow, tunable emission bands, (iv) achievable at 
clinically relevant power densities, (v) utilizes excitation light at a wavelength within the “tissue 
transparent window” (i.e. 700-1,100 nm), (vi) extremely low auto-fluorescence, (vii) use of non-
toxic materials, and (viii) achievable with continuous wave (CW) diode lasers rather than 
expensive femtosecond pulsed lasers (Haase and Schäfer, 2011).   
1.8.1. Basic photophysics of upconversion in trivalent lanthanides 
Trivalent lanthanide ions are well suited for upconversion due to their ladder-like spacing 
of excited states and unique electron configurations.  By having multiple excited states separated 
by equal energy gaps (i.e. ladder-like spacing), a single wavelength of light can be used to 
promote electrons into and through multiple excited states.  Moreover, trivalent lanthanides 
possess a unique electron configuration which is crucial to their utility in upconversion.  The 
electron configuration of trivalent lanthanides in the ground state is [Xe]4f
n
 where the 4f orbital is 
the valence orbital, and n = 0-14.  As dictated by the Aufbau principle, electrons fill the 5s and 5p 
orbitals (5s
2
 and 5p
6
, respectively) before the 4f (the 5s and 5p orbitals are represented by [Xe] in 
the aforementioned electron configuration).  The 5s and 5p orbitals exhibit larger radial expansion 
(i.e. principle quantum number) than that of the 4f orbital, and as such the electrons in the 5s and 
5p orbitals shield the electrons in the 4f orbital (Fig. 1.4).  This electron shielding facilitates the 
stability of excited 4f electronic states, providing the basis for the trivalent lanthanides’ unique 
photoluminescent properties that enable photon upconversion to take place (Bünzli and Eliseeva, 
2011; Haase and Schäfer, 2011).   
The unique electron configuration and ladder-like spacing of excited states are paramount 
to the efficacy of trivalent lanthanide ions in photon upconversion; however, additional factors 
are also required to permit the upconversion of light via lanthanide ions.  Radiative emissions 
produced by photon upconversion are the result of intra-4f relaxations of excited electrons (Chen 
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et al., 2014).  These 4f-4f transitions are electronic dipole transitions, and therefore forbidden by 
the rules of quantum mechanics (e.g. Laporete’s parity selection rule).  In order to permit 4f-4f 
electronic transitions, the trivalent lanthanide ions must be incorporated within a host crystal.  By 
positioning the ions at sites within the crystal lattice that do not have inversion symmetry, the 
crystal-field forces the electronic states of adjacent ions to mix.  The mixing of electronic states 
that have opposite parity relaxes Laporete’s parity selection rule, thereby permitting the 4f-4f 
transitions to occur (Bünzli and Eliseeva, 2011).  For this reason, upconversion emissions from 
these 4f-4f transitions have been described as “forced dipole-dipole transitions” to denote that 
they obey the fundamental rules of quantum mechanics.  Additional electronic transitions such as 
4f-5d transitions and charge-transfer transitions are also possible, however the high energy 
required for such transitions largely precludes them from occurring (Withnall and Silver, 2012).  
Magnetic dipole transitions also produce radiative emissions.  The intensity of light emitted by 
these transitions is often dwarfed by that of the 4f-4f transitions.      
The profound importance of the host matrix on the process of photon upconversion has 
prompted intense research efforts to identify the ideal host matrix.  To date, NaYF4 has been the 
most heavily studied host crystal for biological applications due to its superior properties.  The 
specific attributes that have made NaYF4 the focus of many of the research efforts are its: (i) 
biocompatibility, (ii) low phonon energy, (iii) stability, (iv) low refractive index, and (v) crystal 
phase structures (Zhou et al., 2011; Das et al., 2014).  The NaYF4 lattice possesses exceptionally 
low phonon energy (300-400 cm
-1
), which is critical for limiting energy losses through 
nonradiative pathways (i.e. phonons) (Li et al., 2007).  Additionally, NaYF4 has two possible 
crystal phase structures: cubic (α), and hexagonal (β).  While both cubic and hexagonal phases 
have the same formula units, they differ in the symmetry surrounding the position of the trivalent 
lanthanide ions.  In the hexagonal phase the lanthanide ions are held in positions with less local 
symmetry which facilitates the mixing of 4f electronic states, thereby enhancing the probability of 
4f-4f electronic transitions that generate the radiant emissions.  Multiple groups have reported an 
enhancement in the upconversion luminescence intensity of the hexagonal phase over the cubic 
phase.  Luminescence intensity has been reported to be 4-fold higher from hexagonal phase 
crystals compared to cubic phase crystals with comparable size, morphology, and trivalent 
lanthanide composition (Krämer et al., 2004; Wang et al., 2009).  
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1.8.2. Comparison of photon upconversion to NIR-responsive chromophores  
Photon upconversion can be achieved through a multitude of energy absorption/transfer 
mechanisms, most notably: excited state absorption (two-step absorption), energy transfer 
upconversion, photon avalanche, cooperative sensitization, and cross relaxation (Auzel, 2004).  
These mechanisms facilitate efficiency by allowing photons of light to be absorbed both 
sequentially and simultaneously by one or more atoms (Fig. 1.5).  In stark contrast to this, NIR-
responsive chromophores rely on either two-photon absorption or second harmonic generation to 
harvest the energy of NIR photons.  Both of these mechanisms occur through a virtual (non-real) 
intermediate energy level, and therefore require that the two photons of light be absorbed 
simultaneously.  Since photon upconversion proceeds through real, metastable excited states 
rather than virtual excited states, it can be more than 10 orders of magnitude more efficient than 
NIR-responsive chromophores at utilizing the energy of NIR light (Auzel, 2004).  Furthermore, 
photon upconversion can be achieved with common, inexpensive continuous wave lasers 
operating at low power densities in the mW/cm
2
 range, rather than the high-powered (10
6
-10
8
 
W/cm
2
) and expensive femtosecond-pulsed lasers required for NIR-responsive chromophores.  
Refer to Appendix A for additional information on photon upconversion.   
1.8.3. Advantages of photon upconversion in photoresponsive drug delivery  
In addition to circumventing the need for high-powered pulsed lasers, photon 
upconversion possesses additional attributes that are attractive in photoresponsive drug delivery 
applications, including: (i) non-blinking, (ii) no photo-bleaching, (iii) biocompatibility of 
UCNCs, (iv) tunable emission wavelength(s), and (v) narrow emission bands (Wang et al., 2010).  
Photon upconversion allows the development of a photoresponsive delivery system that retains 
the benefits of UV-responsive chromophores (i.e. reliable and sensitive activation via a one-
photon mechanism), and the use of NIR light for activation (i.e. tissue transparency and 
biologically benign) while simultaneously avoiding the known limitations associated with each.  
Furthermore, the emission spectrum can be precisely controlled by changing the concentration 
and identity of the trivalent lanthanides. As such, photon upconversion is applicable to almost all 
chromophores as well as the activation of photo-labile prodrugs.  The addition of photon 
upconversion also enables photoresponsive drug delivery to be linked directly to multimodal 
treatment strategies and image guided drug therapy (theranostics).  Multimodal treatment 
strategies such as coupling drug delivery with photo-thermal ablation, radiosensitization, or 
photodynamic therapy can be achieved through the trivalent lanthanides used for upconversion or 
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through the NIR light used to activate drug release (Xiao et al., 2013; Xing et al., 2013; Wang et 
al., 2014).  Similarly, theranostic applications (diagnostics and therapy in a single vehicle) are 
imparted through the lanthanide ions which can function as MRI, X-ray, or CT contrast agents, or 
through the simultaneous emission of visible/NIR light (Chen et al., 2012; Hou et al., 2012; Li et 
al., 2013; Xing et al., 2013).  These theranostic applications could be used to non-invasively 
monitor biodistribution in real-time, enabling the dose administered to be tailored to the 
individual patient (Wang et al., 2011b).   
1.9. The alkoxyphenacyl-based polycarbonates  
The ideal photoresponsive delivery system is: (i) comprised of materials that are 
biocompatible before and after exposure to the photo-trigger, (ii) activated by biocompatible light 
that can penetrate tissues, (iii) biodegradable, (iv) highly sensitive to the photo-trigger, and (v) 
does not release drug in the absence of the photo-trigger (i.e.  non-specific release).  The 
alkoxylphenacyl-based polycarbonates (APP) are a new class of photoresponsive polymers that 
possess many properties that are conducive to the development of a photoresponsive delivery 
system with many of these ideal properties.  The molecular structure of APP contains the 
phenacyl chromophore within the polymer’s polycarbonate backbone.  This design permits 
exposure to the photo-trigger (250-320 nm light) to cause photo-induced chain scission of the 
polymer into oligomers (Fig.  1.6).  A brief exposure (5 min) to the photo-trigger (300 nm) caused 
a 75% reduction in the polymer’s molecular weight (Sun et al., 2012).  By designing the structure 
of APP with the chromophore incorporated within the polymer’s backbone, activation of a single 
chromophore alters the properties of the entire polymer chain.  Furthermore, the utilization of a 
chromophoric unit that belongs to the p-hydroxyphenacyl family of chromophores/photo-cages 
also facilitates APP’s application in photoresponsive drug delivery.  This family of 
chromophores/photo-cages are known for their utility in biological applications due to their: (i)  
high photosensitivity (high quantum efficiency and fast reaction rate), (ii) solubility and stability 
in biological systems, (iii) non-toxic photo-products, and (iv) robust photochemistry that is 
tolerant to numerous modifications and a wide pH range (Pelliccioli and Wirz, 2002; Givens et 
al., 2011; Ngoy et al., 2012).  APP contains both chromophoric and polymeric units that are 
known to be biodegradable (Sun et al., 2012).  Biodegradability is an important attribute of 
materials used in the fabrication of drug delivery systems as it facilitates clearance of the system 
from the body after it has performing its intended function (Naahidi et al., 2013).  Finally, APP 
exhibits exceptional thermal and mechanical stability.  These characteristics help ensure that the 
integrity of an APP-based delivery system is not compromised, thereby facilitating the retention 
16 
 
of the therapeutic cargo until exposed to the photo-trigger.  Furthermore, they permit delivery 
systems to be fabricated from APP polymers using common pharmaceutical fabrication 
processes, such as compression molding.  Together these properties make APP an attractive class 
of photoresponsive polymers for development into a photoresponsive drug delivery system.   
1.9.1. The p-hydroxyphenacyl chromophore  
 APP’s photoresponsive moiety, the phenacyl chromophore, is a member of the p-
hydroxyphenacyl (pHP) class of chromophores/photo-cages.  Studies utilizing pHP as the photo-
cage have shown that the photoreaction is fast (< 5 ns) even in biological systems, has a high 
quantum efficiency (ϕ ≈ 0.3), and the hypsochromic shift of biologically benign photoproducts 
allows for near quantitative release of the caged compound (Givens et al., 1997; Specht et al., 
2002; Klán et al., 2012).  Unlike other photo-caging groups, pHP is soluble in aqueous 
environments and does not introduce chiral centers into the released compounds (Pelliccioli and 
Wirz, 2002).  These traits have been exploited and the utility of pHP as a photo-uncage has been 
demonstrated for small compounds (ATP, GTP), neurotransmitters (γ-aminobutyric acid, 
glutamate), proteins/peptides (bradykinin, glutathione), oligonucleotides, and controlling 
enzymatic activating (protein kinase A, tyrosine phosphatases) (Givens et al., 1997; Chang et al., 
1998; Kandler et al., 1998; Arabaci et al., 1999; Conrad et al., 2000; Givens et al., 2000; Zou et 
al., 2001; Specht et al., 2002; Okamoto et al., 2003).       
The photochemical reaction pathway of pHP is dependent on the prevailing water 
concentration (Fig 1.7). When pHP absorbs a photon of photoactivating light it is excited into a 
singlet excited state followed by rapid intersystem crossing to produce the excited triplet.  After 
formation of the excited triplet fragmentation occurs at the carbonyl group’s α carbon.  The triplet 
either undergoes cyclization to form the spirodienedione intermediate, or fragments into the 
acetophenone derivative.  At this point the reaction can proceed through two pathways depending 
on the water concentration.  In the presence of a high water concentration, p-hydroxyphenylacetic 
acid is formed through a photo-Favorskii rearrangement that involves a total of two water 
molecules.  If the water concentration is low, decarbonylation of the spirodienedione intermediate 
produces p-hydroxybenzyl alcohol (Givens et al., 2008; Ngoy et al., 2012).  The prevailing water 
concentration dictates the major product of the reaction.  At high water concentrations (i.e. in 
biological systems), the major product is the biologically benign p-hydroxyphenylacetic acid.  
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Table 1.1: 
Mechanism Citation 
Hydrophobic-hydrophilic shift (Jiang et al., 2006) 
Pore formation (Dromi et al., 2007) 
Isomer switching (Lu et al., 2008) 
Oxidative degradation (Jayakumar et al., 2014) 
Polymer disassembly (Fomina et al., 2011) 
Swelling/hydration (Gemeinhart et al., 2000) 
 
Table 1.1: Examples of previously reported mechanisms for controlling drug release from 
stimuli-responsive delivery systems: Examples of the mechanisms used to release entrapped 
drug from stimuli-responsive delivery systems upon interaction of the delivery system with its 
stimulus (internal or external).    
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Table 1.2: 
Characteristics of Activation via Internal 
Stimuli 
Characteristics of Activation via External 
Stimuli 
Microenvironment of the target tissue(s) must 
be different from that of healthy/non-target 
tissues  
Microenvironment of the target tissue(s) can 
be the same or different from healthy/non-
target tissues 
Delivery system must interact physically with 
the stimulus 
No physical interaction between the stimulus 
and delivery system required 
Activation is subject to variability at both the 
intra- and inter-patient levels 
Activation is independent of variability at both 
the intra- and inter-patient levels 
No additional actions required after 
administration 
Additional actions required after 
administration 
Stimulus is inherently safe Safety of the stimulus must be determined 
 
Table 1.2: Key characteristics of stimuli-responsive delivery systems that rely on internal or 
external stimuli:  Summary of the key attributes of stimuli-responsive delivery systems that are 
activated by internal and external stimuli.  
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Figure 1.1: 
 
Fig. 1.1: Potential fates of nanoparticles following administration into the circulation:  
Schematic representation of the different fates for NPs after administration into the circulation.  
NPs must successfully avoiding distribution into healthy tissues and elimination pathways 
(uptake by the RES system, renal clearance) in order to preferentially accumulate in the tumor.  
The therapeutic cargo must be released from the NPs after reaching the tumor in order to achieve 
the desired therapeutic outcome.    
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Figure 1.2: 
 
Fig. 1.2: Order of events that lead to drug release from stimuli-responsive delivery systems:  
Schematic representation showing the order of events that leads to the release of drug from a 
stimuli-responsive delivery system.  The drug-loaded vehicle arrives at the target tissue where it 
interacts with the stimulus causing activation.  Activation of the material by the stimulus induces 
the release of entrapped drug.     
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Figure 1.3: 
2 0 0 3 0 0 4 0 0 5 0 0 6 0 0 7 0 0 8 0 0 9 0 0 1 0 0 0
0
2
4
6
8
1 0
W a v e le n g th  (n m )
J
/p
h
o
to
n
 (
x
 1
0
-1
9
)
U V V IS N IR
 
Fig. 1.3: Energy density of light as a function of wavelength: The energy density of light is 
inversely proportional to its wavelength per Plank’s relation.  Clinically relevant long wavelength 
light (i.e. NIR) contains less energy per photon than genotoxic, short wavelength UV light.  
 
  
 
 
 
 
 
 
 
 
22 
 
Figure 1.4: 
 
Fig. 1.4: Schematic depiction of the shielding of 4f electrons in trivalent lanthanides:  The 
shielding of the electrons in the 4f orbitals by electrons in the 5s and 5p orbitals enhances the 
stability of excited 4f electrons and enables photon upconversion to proceed with high efficiency 
in trivalent lanthanides.  Nucleus and orbitals are not drawn to scale.    
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Figure 1.5: 
 
Fig. 1.5: Representative depiction of possible energy transfer pathways between trivalent 
lanthanides houses in a host crystal:  Upconversion is capable of harnessing energy from 
photons of NIR light absorbed sequentially or simultaneously by a single or multiple atoms.  In 
this depiction, two photons of NIR light are absorbed by two separate Yb
3+ 
atoms, and the energy 
is then transferred to the same Tm
3+ 
atom which generates the radiative emission.  The absorption 
and transfer of energy between multiple atoms facilitates the efficiency of the upconversion 
process.   
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Figure 1.6: 
 
Fig. 1.6: Structure and photo-induced chain scission of APP: Chemical structure of the APP 
homopolymer and the products of photo-induced chain scission.  The incorporation of the 
phenacyl chromophore within the backbone of APP (A) permits exposure to the photo-trigger to 
induce chain scission of the polymer.  The products of photo-induced chain scission are (B) the 
acetophenone derivative and (C) the phenylacetic acid derivative.   
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Figure 1.7: 
 
Fig. 1.7: Photochemistry of the pHP chromophore:  Chemical pathways and photo-products 
produced by the activation of the pHP chromophore under different environmental conditions.  
(1) p-hydroxyphenacyl (pHP) chromophore with leaving group (R), (2) excited triplet 
intermediate, (3) p-hydroxyacetophenone, (4) spirodienedione intermediate, (5) p-
hydroxyphenylacetic acid, (6) p-hydroxybenzyl alcohol.  The photochemical pathway is dictated 
by the prevailing water concentration.  At high water concentrations (i.e. biological systems) the 
major product is the biologically benign p-hydroxyphenylacetic acid.  Scheme adapted from 
(Givens et al., 2008; Ngoy et al., 2012). 
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Chapter 2 
Project Overview and Research Plan 
2.1. Significance 
 The clinical relevance of photoresponsive delivery systems has been stifled by: (i) a lack 
of photoresponsive materials that are biocompatible and biodegradable; and (ii) the reliance on 
UV light to trigger drug release.  The objective of this work was to evaluate if these limitations 
could be addressed by engineering photoresponsive delivery systems from the APP polymers, and 
incorporating the process of photon upconversion.   
2.2. Hypotheses and research plan  
The overall hypothesis of this work was that nanoparticles engineered from APP will be 
biocompatible, release drug in response to the photo-trigger, and serve as a novel platform for 
therapeutic applications.  This hypothesis was broken down into three parts (specific aims) to test 
each component of the overall hypothesis.  The three specific aims were as follows:  
2.2.1. Specific aim #1: prepare and characterize nanoparticles from APP (APP-NPs)  
The objective of this aim sought to determine the suitability of the APP polymers in 
nanoparticulate drug delivery applications.  The working hypothesis for this aim is that the APP 
polymers will be biocompatible and form stable, biocompatible nanoparticles with mean 
diameters around 100 nm.  In vitro biocompatibility studies will be assessed in a murine 
macrophage cell line (RAW 264.7) while in vivo studies will utilize BALB/c mice.  
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Biocompatibility will be determined by comparison to a known biocompatible reference material, 
poly(lactic-co-glycolic acid) (PLGA).  A nanoprecipitation method will be used to prepare NPs 
from APP polymers and reference NPs from PLGA. 
2.2.2. Specific aim #2: assess photo-controlled drug release from APP-NPs  
The objective of this aim is to characterize the drug release profile from APP-NPs 
following exposure to the photo-trigger.  The working hypothesis is that drug release from APP-
NPs can be controlled by exposure to the photo-trigger.  The nanoprecipitation method 
established in specific aim #1 will be optimized and used to prepare APP-NPs loaded with the 
model drug doxorubicin (DOX).  The effects of the photo-trigger on drug release will be assessed 
in vitro.  Formulation and photoirradiation parameters will be varied and the effects on drug 
release evaluated in order to identity key parameters that alter photoresponsive efficacy.  The 
effect of the photo-trigger on the functional efficacy of DOX will be assessed based on 
cytotoxicity studies conducted in Lewis lung carcinoma (LLC) cells.  Lung cancer was chosen as 
a model disease on the basis that lung cancer is responsible for more cancer-related deaths than 
any other type of cancer (Fitzmaurice et al., 2015).    
2.2.3. Specific aim #3: assess photon upconversion for controlling drug release with NIR 
light  
The objective of this aim is to enhance the safety and potential utility of APP-NPs as a 
photoresponsive delivery system by utilizing photon upconversion to control drug release with 
clinically relevant near-infrared (NIR) light.  The working hypothesis is that UV light emitted 
from UCNCs (NaYF4; Yb
3+
/Tm
3+
) entrapped within APP-NPs will enable drug release from 
APP-NPs to be controlled with clinically relevant 980 nm light.  UCNCs will be synthesized via a 
solvothermal method and characterized for size, morphology, emission spectrum, and trivalent 
lanthanide composition in order to select the optimal formulation for subsequent studies in APP-
NPs.  The effects of altering the quantity of the trivalent lanthanide dopants (Yb
3+ 
and Tm
3+
) and 
particle architecture (core-alone and core-shell) on the emission of UV light upon irradiation with 
NIR light (980 nm) will be studied.  UCNC-loaded APP-NPs will be prepared by minor 
modification of the nanoprecipitation method to accommodate the inclusion of UCNCs in the 
formulation.  The resultant NPs will be characterized to assess the effects of UCNC loading on: 
size, stability, zeta potential, size distribution, morphology, DOX loading, nonspecific DOX 
release, and in vitro biocompatibility profile.  The efficacy of controlling DOX release with NIR 
light will be assessed in vitro and in an ex vivo mock tissue model.  Finally, tumor bearing mice 
will be used for biodistribution and tumor accumulation studies. 
28 
 
2.3. Outline of this dissertation 
In Chapter 3 the suitability of APP polymers for applications in drug delivery was 
assessed (specific aim #1).  The biocompatibility and tolerability of the APP polymers was 
evaluated in vitro and in vivo.  NPs were prepared from the APP polymers as a model delivery 
system, and the biocompatibility of the resultant delivery system was assessed.   
In Chapter 4 the utility of APP-NPs as a platform for photoresponsive drug delivery was 
determined (specific aim #2).  Doxorubicin (DOX) was employed as model drug to prepared 
drug-loaded APP-NPs.  The resultant NPs were characterized, and the effects of exposing the NPs 
to the photo-trigger were studied.  The release of DOX was assessed in the presence and absence 
of the photo-trigger, and formulation and photoirradiation parameters that were influential in 
photoresponsive DOX release were identified.   
In Chapter 5 photon upconversion was applied to APP-NPs to enhance the safety and 
potential utility of APP-NPs as a photoresponsive delivery system by enabling drug release to be 
controlled with clinically relevant near-infrared light (specific aim #3).  Upconverting 
nanocrystals (UCNCs) were synthesized and optimized for UV emissions upon NIR excitation by 
varying the quantity of the trivalent lanthanide dopants (Yb
3+ 
and Tm
3+
).  The optimized UCNCs 
were then loaded into APP-NPs to create UCNC-NPs.  The safety of the resultant UCNC-NPs 
was evaluated along with the efficacy of controlling drug release with a clinically relevant 
wavelength of light (980 nm).    
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Chapter 3 
Assessment of APP’s Suitability for Drug Delivery Applications 
3.1. Abstract 
Potential toxicities of chromophoric or polymeric units of most photoresponsive delivery 
systems have impacted clinical relevance.  Herein, we evaluated the biocompatibility and 
tolerability of alkoxylphenacyl based polycarbonates (APP) as a new class of photoresponsive 
polymers. The polymers were applied as homopolymer or copolymers of polyethylene glycol 
(PEG-10% w/w) or polycaprolactone (PCL-10% w/w).  APP polymers were comparable to 
PLGA based on cytotoxicity, macrophage activation, and blood compatibility.  Data from 
biodistribution studies in BALB/c mice showed preferential accumulation in kidney and liver.  
Meanwhile, application of APP polymers as immediate or sustained (implants) drug delivery 
systems indicated that liver and kidney functions were not distorted.  Also, plasma levels of 
tumor necrosis factor-α and interleukin-6 were comparable to PLGA-treated mice (p > 0.05).  
Histological analysis of liver and kidney sections showed no detectable damage from APP 
polymers.  The overall data support the potential suitability of APP polymers in drug delivery 
applications, especially as photoresponsive implants and tissue-mimicking photo-patterned 
biomaterials.  
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3.2. Introduction 
 The advent of ‘smart’ biomaterials has afforded the capability of designing and 
developing delivery systems that are responsive to various stimuli such as pH, temperature, light, 
ultrasound, redox, or chemical changes (Saslawski et al., 1988; Jabr-Milane et al., 2008; Onaca et 
al., 2009).  As such, smart delivery systems can offer great therapeutic advantages over 
traditional systems in that release of active/diagnostic agents can be controlled according to 
disease-specific (internal) or non-disease specific (external) stimuli (You et al., 2010b). In 
general, internal stimuli (disease-specific) such as local pH, temperature, or enzyme expression 
levels, require physical interaction with delivery systems for activation, whereas external stimuli 
(non-disease specific) such as magnetic fields, ultrasound, or light, can be operated remotely 
without the need for physical interaction (Zhao, 2009; Liu and Dong, 2012).  A major concern for 
systems that rely on internal stimuli (disease-specific) is that the levels of these triggers can 
fluctuate widely from patient to patient and even within the same patient at different times or 
stages of the disease (Galaev and Mattiasson, 1999; Gemeinhart et al., 2000; Sivadas and Cryan, 
2011).  Variations in levels of internal stimuli could translate into poor reproducibility of 
therapeutic effectiveness. Meanwhile, systems that utilize external stimuli are amenable to many 
disease cases since stimuli responsiveness is not dependent on differences in biological processes 
between diseased tissue and healthy tissue (Jiang et al., 2005; Sivadas and Cryan, 2011).  We are 
of the opinion that delivery systems that operate on external stimuli will ensure consistent 
responsiveness when applied alone or in combination with internal responsive systems.  Of 
special interest to this work are photoresponsive delivery systems that are able to achieve spatial 
and temporal release of the therapeutic payload through remote activation with light 
(photoresponsive).  As such, the trigger can be precisely controlled through manipulation of the 
wavelength, intensity, and duration of the light (Yavlovich et al., 2010).  
 To date, the vast majority of work regarding photoresponsive materials has focused on 
the photochemistry of different chromophores while little attention has been paid to 
biocompatibility and biodegradability of chromophoric and polymeric units. It is noteworthy that 
photoresponsive polymers that are biocompatible and biodegradable are highly desirable for 
potential translation into clinical applications. In this regard, we recently reported, for the first 
time, the synthesis of alkoxylphenacyl-based polycarbonates (APP) as a new class of 
photoresponsive polymers (Sun et al., 2012).  APP polymers responded efficiently to light 
between 250 and 320 nm which resulted in controlled chain scission and photoresponsive release 
of incorporated payloads (Sun et al., 2012).  Another important earlier observation was the 
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demonstration of thermal and mechanical stability of APP polymers which are considered as 
desirable qualities in designing and developing implantable delivery systems while guarding 
against premature leakage of incorporated therapeutic agents.  The biodegradable nature of the 
phenacyl chromophore contained within these polycarbonates will be relevant in the context of 
their suitability as a drug delivery platform.  These aforementioned advantages prompted the 
current investigation of the biocompatibility and tolerability assessments of APP polymers as 
important aspects for their consideration as a platform for applications in drug delivery.  The 
studies were carried out using the APP homopolymer as well as copolymers with polyethylene 
glycol (PEG-10% w/w) and polycaprolactone (PCL-10% w/w).  In vitro assessments were based 
on cytotoxicity, macrophage activation, and blood compatibility.  Particular attention was paid to 
biodistribution, blood biochemical parameters, and histopathological examination of tissue 
sections after intravenous or subcutaneous injection (implants) in BALB/c mice.  The study 
included biocompatibility and tolerability assessment of APP polymers before and after 
photoirradiation (activation) with the understanding that the studies on APP polymer (without 
photoactivation) will be relevant in potential applications as implantable or photo-patterned 
biomaterials.         
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3.3. Materials and methods 
3.3.1. Materials 
Phosphate buffered saline (PBS), Pluronic F-127 ®, dimethyl sulfoxide (DMSO) and 
dialysis tubing (MWCO 12,500 Da) were obtained from Fisher Scientific (Pittsburgh, PA).  Poly 
(lactic-co-glycolic acid) (PLGA) was obtained from Boehringer Ingelheim (Ingelheim, 
Germany).   Kits to measure alanine aminotransferase and creatinine were obtained from Teco 
Diagnostics (Anaheim, CA) and Invitrogen (Grand Island, NY) respectively.  eBioscience (San 
Diego, CA) provided the kits for measuring cytokine levels.  Thiazolyl blue tetrazolium blue 
(MTT) dye, lipopolysaccharides (LPS) and 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA) 
was obtained from Sigma Aldrich (St. Louis, MO).  Fetal bovine serum (FBS) was obtained from 
Atlanta Biologicals (Lawrenceville, GA).     
3.3.2. Synthesis of APP polymers 
The synthesis of the APP polymer (homopolymer and copolymers) was carried out based 
on the method described earlier (Sun et al., 2012).  Briefly, hydroxyacetophenone was chain 
extended with a hydroxyl terminated spacer.  The product was converted to the corresponding 
bromide without purification and then reacted with sodium acetate to yield the acetate protected 
derivative in high yield.  Following de-protection, the alkoxylphenacyl diol was reacted with 
triphosgene to provide the corresponding polycarbonates.  The homopolymer (APP-H) and 
copolymers with polyethylene glycol (APP-PEG) and polycaprolactone (APP-PCL) were 
synthesized and purified accordingly (Sun et al., 2012). 
3.3.3. APP nanoparticle (APP-NP) preparation 
Nanoparticles were prepared from APP polymers (APP-NPs) using a modified 
nanoprecipitation method (Sanson et al., 2010).  In this process, the APP polymers (2 mg/mL) 
were solubilized in 0.25 mL of DMSO, and then added dropwise into 1 mL of a 0-5% w/v 
solution of Pluronic F-127 ® at 40°C under vigorous stirring.  The resultant APP-NPs were then 
purified by dialyzing against water for 2 hr (MWCO 12,500 Da).  APP-NPs were characterized 
based on size, size distribution, and stability in biological relevant media.  Fluorescent-labeled 
APP-NPs were prepared containing coumarin-6 for assessing biodistribution in accordance with 
our earlier reported method (Wehrung et al., 2012).  Additional assessment on fluorescent-labeled 
APP-NPs included determination of entrapment efficiency and retention of coumarin-6 within 
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APP-NPs after incubation in 10% FBS in PBS (pH 7.4; 37
o
C).  Using the same procedure, 
reference NPs were prepared from PLGA (PLGA-NPs). 
3.3.4. Characterization of APP-NPs  
3.3.4.1. Particle size 
Sizes of the NPs were measured using Zetasizer Nano-ZS90 (Malvern Instruments) at 
25
o
C.  Prior to particle measurements, NP suspensions were diluted (1:5 v/v) with filtered water 
(0.22 µm filter, Nalgene International) to ensure that light scattering signals were within the 
sensitivity of the instrument. 
   
3.3.4.2. Entrapment efficiency of coumarin-6  
Microcon Ultracel YM-100 centrifugal devices (MWCO 10 kDa) Millipore, Billerica, MA, 
USA) were used to determine the entrapment efficiency of the fluorescent dye coumarin-6.  Briefly, 
400 µL of NP suspensions was added to the Microcon tube and spun for 30 min at 4,000 x g.  The 
collected filtrate was labeled as free fluorescent dye (not entrapped in NPs).  The percentage of the 
dye entrapped was obtained from the ratio of amount of retained (entrapped in NPs) and total 
amount added to NP preparation 
 
3.3.5. Cell culture 
A macrophage cell line (RAW 264.7) was obtained from ATCC (Manassas, VA).  The 
cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% 
fetal bovine serum and antibiotics (100 µg/mL streptomycin and 100 units/mL penicillin) in a 
humidified incubator at 37°C and 5% CO2. 
3.3.5.1. In vitro cytotoxicity assay  
RAW 264.7 cells were plated overnight (5 x 10
4
 cells/well; 96 well plates) in complete 
growth medium.  Afterwards, the cells were treated with various concentrations of APP polymers 
or PLGA for 24-72 hr.  The treatments were aspirated and the cells were rinsed twice with PBS.  
The MTT dye was incubated with cells for 4 hr (37
o
C) followed by addition of DMSO and 
glycine buffer (0.1M; 15 µL).  The absorbance of each well was immediately measured using a 
microplate reader (Spectramax-340PC, Bucher Biotec AG, Basel, Switzerland) at 570 nm.  The 
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percentage of cell viability was based on the ratio of absorbance from treated cells compared to 
untreated control cells. 
3.3.5.2. Macrophage activation assay 
 Macrophage activation was assessed by monitoring production of reactive oxygen 
species (ROS) after incubation of APP polymers with RAW 264.7 cells (Wehrung et al., 2012).  
RAW 264.7 cells were plated (5x10
4
 cells/well) in complete growth medium.  Treatment 
solutions containing various concentrations of the polymers in growth media were added to cell 
monolayer and incubated for 24 hr.  Afterwards, the treatments were aspirated and cells were 
rinsed with PBS prior to incubation with DCFH-DA for 60 min (37
o
C).  The cells were rinsed 
with PBS before the fluorescence intensity was measured (excitation 485 nm, emission 528 nm).  
The protein content of each well was measured using the Pierce BCA Protein Assay Kit (Fisher 
Scientific, Pittsburgh, Pennsylvania).  Each data-point was expressed as the fluorescence intensity 
normalized per µg of protein, using LPS-treated cells as the reference.   
In a similar setting, macrophage activation was assessed by measuring the production of 
nitrite.  RAW 264.7 cells were plated at a density of 5x10
4 
cells per well and incubated for 48 hr 
with various concentrations of APP polymers.  Afterwards, levels of nitrite in the growth medium 
were measured using the Griess reagent system (Cayman, Ann Arbor, MI).  Each data-point was 
plotted as the percentage of nitrite production using LPS-treated cells as the reference. 
3.3.5.3. Cytotoxicity and biocompatibility of photoirradiated APP polymers 
Photoirradiation of APP polymer solutions was carried out with a handheld UVM-57 UV 
lamp (UVP Inc; Upland CA) with peak emission at 302 nm for 15 min.  The cytotoxicity in RAW 
264.7 cells of polymer degradation products (after photoirradiation) was evaluated by the MTT 
assay.  The procedure for the MTT assay was as described earlier for non-irradiated polymer 
samples.  Similarly, the extent of macrophage activation was assessed by monitoring nitrite 
production by RAW 264.7 cells following incubation (24 hr; 37
o
C) with photoirradiated polymer 
products.  Nitrite produced was measured as previously described for non-irradiated samples.  
Additional separate MTT and macrophage activation studies were conducted using polymer 
solutions in DMSO (5 mg/mL) that were irradiated (4 min; 300 nm) in a Rayonet reactor (16 
tubes, 0.64 mW/cm
2
).  These photoirradiation conditions were selected based on our earlier report 
that demonstrated that these conditions reduced the polymer’s molecular weight by 75% (Sun et 
al., 2012).   
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3.3.6. In vitro hemocompatibility 
The hemocompatibility of APP polymers was determined using a previously reported 
method for assessing red blood cell (RBC) lysis (Wehrung et al., 2012b).  Briefly, treatment 
solutions containing the polymers were mixed (1:1 v/v) with citrated rate whole blood (Pel-Freez, 
Rogers AK).  Rat whole blood mixed with water served as the positive control while PBS was 
used as the negative control.  All samples were incubated (37°C; 0.5-6 hr) in an orbital shaker and 
later centrifuged at 600 x g for 5 min.  The supernatant was allowed to stand at 25°C for 30 min 
for hemoglobin oxidation.  The absorbance of oxyhemoglobin was measured at 540 nm 
wavelength.  Background absorbance values from PBS-treated blood were deducted from all 
samples.  Each data-point was expressed as a percentage of values obtained from the positive 
control (water).     
3.3.7. In vivo studies 
In vivo studies were carried out in BALB/c mice (20-25 g; Charles River Laboratories; 
Raleigh, NC).  All experiments involving animals were approved by the Institutional Animal 
Care and Use Committee of NEOMED in accordance with NIH guidelines. 
3.3.7.1. Biodistribution   
Coumarin-6-labeled APP-NPs were applied in biodistribution studies based on the method 
previously described (Wehrung et al., 2012).  Each mouse was injected (via the tail vein) with 0.1 
mL of APP-NP suspensions (10 mg/kg body weight).  At 72 hr post-injection the mice were 
sacrificed and selected tissues were excised.  Coumarin-6 was extracted from the tissues with 
acetonitrile according to the method earlier reported (Zhao et al., 2007; Shan et al., 2009; Wehrung 
et al., 2012).  The fluorescence from coumarin-6 was measured at 538 nm (485 nm excitation), 
and the fluorescence intensity was normalized to tissue weight (fluorescence intensity per gram of 
tissue).   
3.3.7.2. In vivo tolerability and biocompatibility  
The in vivo tolerability and biocompatibility studies were divided into two groups 
according to the route of treatment administration.  Intravenous (I.V.; 10 mg/kg body weight) 
injection of APP-NPs via the tail vein was designed to mimic possible applications as 
nanoparticulate/immediate release delivery systems.  While subcutaneous (S.C.; 80 mg/kg body 
weight) injection of APP polymer suspensions in PBS was employed to simulate the potential 
36 
 
application of the polymers as implants (sustained release).  At predetermined time points, blood 
samples were collected from the tail vein of each mouse.  The blood was applied in measuring 
plasma levels of alanine aminotransferase (ALT) and creatinine which are indicators of liver and 
kidney function, respectively.  Plasma levels of ALT and creatinine were assayed using 
commercially available kits according to the manufacturers’ instructions.  In addition, plasma 
levels of inflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) 
were measured using commercially available kits using the manufacturers’ instructions.  The 
study with the mice that received treatments via I.V. injection was terminated at 72 hr post-
injection, while mice that received treatments via S.C. injections were sacrificed on day 14 post-
injection.  Afterwards, liver and kidney samples were excised, rinsed with PBS and fixed in 4% 
paraformaldehyde (4°C) before embedding in paraffin.  Each representative tissue sample was 
sliced at a thickness of 10 µm and then stained with hematoxylin and eosin (H&E) for 
histological examination. 
3.3.8. Data Analysis 
Statistical analysis was carried out using Student’s t-test and ANOVA followed by 
Dunnett’s post-hoc test for multiple comparisons.  Significance was assessed at a p-value of < 
0.05.   
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3.4. Results and discussion 
3.4.1. APP polymers and NP preparation 
  This work focused on assessing the biocompatibility and tolerability of APP as a new 
class of photoresponsive polymers.  The polymers studied were the alkoxylphenacyl-based 
polycarbonate homopolymer and copolymers with PEG and PCL.  The chemical structure of the 
repeating unit of APP-H is shown in Fig. 3.1A.  The processes of polymer synthesis, purification, 
and characterization were carried out based on our earlier reported methods (Sun et al., 2012).  
Previous studies of photoresponsiveness demonstrated that the polymers underwent chain scission 
after photoirradiation at 300 nm, resulting in controlled release of incorporated fluorescence dye 
(Nile Red) (Sun et al., 2012).  The photodegradation (i.e. chain scission) was substantiated by 
NMR spectra obtained before and after photoirradiation of the APP polymers.  Analysis of the 
polymers before and after photoirradiation by gel permeation chromatography showed that the 
polymers’ molecular weights decreased by 75% within 5 minutes of photoirradiation (Sun et al., 
2012).  Apart from photoresponsiveness, the polymers showed mechanical and thermal stability 
which are important properties for drug delivery applications.  These attractive qualities prompted 
the current work that focused on assessing the polymers’ biocompatibility and tolerability for 
potential consideration in drug delivery applications.  NPs were prepared using the APP 
homopolymer (APP-H-NPs) and copolymers with PEG (APP-PEG-NPs) and PCL (APP-PCL-
NPs) through a nanoprecipitation method.  The average sizes of APP-H-NPs, APP-PEG-NPs, and 
APP-PCL-NPs were 98 ± 2 nm; 174 ± 2 nm; and 113 ± 8 nm, respectively (Fig. 3.1B).  The 
presence of PEG groups (10% w/w) may have conferred amphiphilic properties to the polymer 
that resulted in the observed larger particle sizes of APP-PEG-NPs compared to APP-H-NPs and 
APP-PCL-NPs.  The APP-H-NPs and APP-PCL-NPs were stable when stored as aqueous 
suspensions; however the APP-PEG-NPs did not show the same stability characteristics.  For 
instance, the average size of NPs made from APP-H was maintained at about 100 nm after 
storage for 14 days (Fig. 3.2).  A similar trend was observed with NPs made from APP-PCL in 
that the average NP size immediately after preparation was comparable to the size measured after 
storage at 25
o
C for 7 days (Fig. 3.1C; p > 0.05).  For APP-PEG-NPs, the average NP size 
increased up to 3 fold within 24 hr.  The potential instability of APP-PEG-NPs was closely 
associated with observed zeta potential values for different APP-NP formulations. Throughout the 
stability studies, both APP-H-NPs and APP-PCL-NPs showed strongly negative zeta potentials (-
20 mV) which most likely supported colloidal stability (data not shown).  APP-PEG-NPs showed 
a markedly different zeta potential of -3 mV which may not have been effective in preventing 
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particle destabilization and aggregation (data not shown).  The observed instability of APP-PEG-
NPs was not able to be rectified by changing the surfactant concentration or composition (data 
not shown).    
3.4.2. In vitro cytotoxicity and macrophage activation 
 In accordance with ISO 10993-5:2009(E), cytotoxicity was assessed via the MTT assay.  
Cytotoxicity and macrophage activation were assessed after incubating APP polymers with RAW 
264.7 cells (Fig. 3.3).  Since DMSO was used in dissolving all the polymers, particular attention 
was placed on negating the possible effects of the solvent on cell viability.  Initial studies 
indicated that there was no significant (p > 0.05) affect from DMSO on cell viability at polymer 
concentrations ≤ 25 µg/mL (data not shown).  Thus, cytotoxicity studies were carried out at 
polymer concentrations that ranged from 2.5-25 µg/mL (Fig. 3.3A).  At all the concentrations 
tested, no significant decrease in cellular viability was observed for APP polymers or PLGA (p > 
0.05).  A set of follow up studies evaluated cellular viability at incubation times longer than 24 hr 
(Fig. 3.4).  Overall the data indicated that APP polymers did not induce detectable cytotoxicity, 
and were comparable to PLGA at the concentrations studied.   
Macrophage activation was assessed by investigating the extent of ROS production after 
treating RAW 264.7 cells with the polymers.  The suitability of the study is expressed in that 
macrophages are involved in the host defense mechanism against pathogenic microorganisms, 
parasites, and particles recognized as “foreign” or “strange” to the body (Kuo et al., 2008).  Being 
phagocytic, macrophages participate in antigen presentation to T cells, and when activated by 
foreign particles or pathogens, produce reactive oxygen and nitrogen metabolites (such as ROS, 
nitric oxide, and cytokines) with actions ranging from induction of cell growth to cell death (Iles 
and Forman, 2002; Kuo et al., 2008).  In order to assess macrophage activation ROS production 
was monitored by treating cells with DCFH-DA which is a sensitive and widely used probe for 
detecting intracellular oxidant production.  DCFH-DA in its native form is cell-permeable and 
non-fluorescent but once inside the cell it is de-esterified, and oxidized by ROS to the highly 
fluorescent compound 2’7’-dichlorofluorescein.  At the lowest polymer concentration studied (5 
µg/mL) no significant increase in ROS production was observed for any of the APP polymers 
compared to PLGA (Fig. 3.3B; p > 0.05).  While at a polymer concentration of 25 µg/mL, APP-
PEG showed markedly reduced ROS production compared to the other APP polymers as well as 
PLGA (p < 0.05).  In a related study, macrophage activation was monitored by assaying the level 
of nitrite produced after incubating RAW 264.7 cells with APP polymers for 48 hr.  The results 
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indicated that the APP polymers do not activate macrophages as evidenced by comparable nitrite 
production between cells treated with the APP polymers and the negative control (untreated cells) 
or PLGA-treated cells (p > 0.05; Fig. 3.3C).  The overall trend from the measurements of ROS 
and nitrite production indicated that APP polymers did not activate macrophages, and were 
comparable to PLGA within the incubation time and concentration range studied.   
3.4.3. Cytotoxicity and macrophage activation of photoirradiated polymers 
The biocompatibility of the photo-products produced by photoirradiation of the APP 
polymers is an important aspect of this work.  It is anticipated that the potential application of the 
polymers will involve gradual and/or continual photo-induced degradation.  As such, 
photoirradiation with a handheld UV lamp (low intensity) was performed to simulate low level, 
gradual photodegradation.  Additionally, the APP polymers were photoirradiated in a Rayonet 
reactor (high intensity) using conditions demonstrated previously to induce extensive chain 
scission (reduce the molecular weight by 75%) and produce the corresponding phenylacetic acid 
derivative and reduced acetophenone derivative (Sun et al., 2012).  The results of the cytotoxicity 
and macrophage activation assays utilizing photoirradiated polymer samples that were exposed to 
low level photoirradiation (with the handheld UV lamp) are shown in Fig. 3.5A&B.  The MTT 
assay showed that the photodegradation products did not cause cytotoxicity (Fig. 3.5A).  Cell 
viability after treating with the photoirradiated APP polymers was comparable to that of PLGA (p 
> 0.05) suggesting that photoactivation of the APP polymers in photoresponsive delivery 
applications will not produce cytotoxic photo-products.  Additionally, macrophage activation was 
assessed through evaluation of nitrite production after treating RAW 264.7 cells with the 
photoirradiated APP polymers (Fig. 3.5B) using LPS-treated cells and untreated cells as the 
positive and negative controls, respectively.  There was no statistically significant difference in 
the nitrite levels between the untreated control cells and cells treated with photoirradiated APP 
polymers (p > 0.05; Fig. 3.5B).  A similar comparison can be made between photoirradiated APP 
polymers and PLGA-treated cells indicating that the products of photo-induced chain scission are 
biocompatible (p > 0.05; Fig. 3.5B).  The trend from the handheld UV lamp was confirmed by 
additional studies employing polymer samples irradiated in a Rayonet reactor (high intensity).  
These studies indicating that there was no statistical difference between RAW 264.7 cells treated 
with photoirradiated APP polymers and the untreated controls  as assessed by nitrite production 
and cell viability (Fig. 3.5C&D, respectively; p > 0.05).  
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3.4.4. In vitro hemocompatibility 
 RBC lysis is an important biocompatibility parameter since the potential utility of APP 
polymers as photoresponsive delivery systems will require extensive interaction with blood.  In 
the RBC lysis studies, water served as a positive control (100% RBC lysis), and PBS served as 
the negative control.  Following the initial incubation duration of 30 min there was a slight 
increase in RBC lysis as polymer concentrations increased from 25 to 50 µg/mL (p < 0.05; Fig. 
3.6A).  However, at all concentrations studied the APP polymers were comparable to PLGA as 
judged from % RBC lysis (p > 0.05; Fig. 3.6A).  Additional studies indicated that regardless of 
the incubation time (0.5-6 hr) the % RBC lysis following treatments with APP polymers was not 
distinguishable from PLGA (p > 0.05; Fig. 3.6B). 
3.4.5. In vitro biocompatibility of APP-NPs 
 After the initial assessment determined that APP polymers alone exhibited 
biocompatibility comparable to PLGA, follow up studies were conducted using NPs prepared 
from APP-H (APP-H-NPs) and APP-PCL (APP-PCL-NPs).  APP-PEG-NPs were not included in 
these studies due to their instability noted previously (Fig. 3.1C).  The effect on the NP treatments 
on the viability of RAW 264.7 cells was assessed using intact (non-irradiated) NPs as well as NPs 
that had been exposed to the photo-trigger (handheld UV lamp).  After treating for 48 hr, cellular 
viabilities for all treatment groups remained comparable to the untreated control (p > 0.05; Fig. 
3.7A).  Increasing the duration of incubation to 72 hr reduced the cellular viabilities of all 
treatment groups compared to the untreated control; however, the viability of RAW 264.7 cells 
treated with APP-H-NPs or APP-PCL-NPs with or without photoirradiation remained comparable 
to cells treated with PLGA-NPs (p > 0.05; data not shown).  The ability for APP-NPs to activate 
macrophages was also assessed using nitrite production as a marker of macrophage activation.  
Nitrite production was comparable between the untreated controls and RAW 264.7 cells treated 
(48 hr) with APP-H-NPs, APP-PCL-NPs, or PLGA-NPs (p > 0.05; Fig. 3.7B).  Taken together, 
the data demonstrate that NPs prepared from the APP-H and APP-PCL are biocompatible, 
exhibiting comparable effects on cellular viability and macrophage activation to that of PLGA-
NPs.   
 DMSO is capable of altering the permeability of the cell membrane, potentially causing 
false negative results in the RBC lysis assessment (Gurtovenko and Anwar, 2007).  Therefore, 
studies utilizing APP-NPs rather than solutions of the APP polymers in DMSO were conducted to 
rule out this possibility.  The trend from the data was similar to that obtained from the original 
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assessment utilizing polymer solutions.  RBC lysis following treating for the maximum duration 
studied (6 hr) with NPs prepared from APP-H or APP-PCL was comparable to PLGA-NPs at all 
concentrations tested (p > 0.05; Fig. 3.8A).  Varying the duration of incubation at a fixed polymer 
concentration (50 µg/mL) did not alter this trend.  RBC lysis following incubation with APP-H-
NPs or APP-PCL-NPs was comparable to PLGA-NPs at all time-points studied (p > 0.05; Fig. 
3.8B).  Taken together, the trend from the cellular proliferation, macrophage activation, and 
hemocompatibility studies suggests that NPs prepared from APP-H and APP-PCL have 
biocompatibility comparable to that of PLGA-NPs.     
3.4.6. Biodistribution and in vivo cytokine production 
  Biodistribution studies were conducted with APP-NPs loaded with coumarin-6 as a 
fluorescence dye.  The fluorescent-labeled NPs were injected intravenously in BALB/c mice for 
subsequent evaluation of the extent of distribution to various tissues.  The procedure was 
developed based on other studies that successfully applied fluorescent-labeled nanocarriers in 
biodistribution studies (Shan et al., 2009; Wehrung et al., 2012).  Initial experiments were 
conducted to demonstrate the entrapment efficiency of coumarin-6 in APP-NPs as well as 
establish that the NPs (loaded with coumarin-6) were stable when incubated in biologically 
simulated media (10% fetal bovine serum in PBS, 37
o
C).  These relevant background studies 
were important to verify that the biodistribution of APP-NPs would be assessed without the 
concern that free coumarin-6 would compromise the integrity of the results.  A point of note is 
that only APP-H and APP-PCL were applied in the in vivo studies on the basis of: (i) the 
instability of APP-PEG-NPs (Fig. 3.1C); and (ii) the expectation that copolymerization with PEG 
(APP-PEG) will not negatively impact biocompatibility.  
Considering APP-H, at 72 hr post-injection, the highest fluorescence intensity was 
observed in the kidneys followed by the liver (Fig. 3.9).  The levels in the kidneys were 2 times 
higher than the liver.  While fluorescence intensities in other tissues such as spleen, lungs, heart, 
and brain were about 4 times lower than the kidneys.  Mainly, these observations indicated 
preferential distributions to the liver and kidneys.  The low accumulation in the lungs likely 
reflected that the NPs were stable in blood circulation, perhaps due to possible effects of the 
surfactant (Pluronic F-127®) included during NP preparation.  Earlier work has indicated that 
extensive NP accumulation in the lungs could connote NP instability associated with precipitation 
or aggregate formation in blood circulation (Li and Huang, 2008).  A similar trend was observed 
with APP-PCL-NPs and PLGA-NPs in which the distributions into liver and kidneys were 
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markedly higher than other tissues (Fig. 3.9).  Based on the results from the biodistribution 
studies, special attention was paid to characterize the possible effects of APP polymers on liver 
and kidney function while simulating immediate and sustained release drug delivery applications.  
In separate studies, levels of inflammatory mediators (TNF-α; IL-6) were assayed 
following injection of APP-NPs.  Cytokine levels were monitored in order to assess if the 
polymers triggered an immune responses that would be indicative of inflammation/toxicity.  The 
first experiment involved I.V. injection of APP-NPs at a polymer dose of 10 mg/kg into BALB/c 
mice and assaying the plasma levels of cytokines (TNF-α, IL-6) 72 hr post-injection.  The data 
showed that mice treated with APP-H-NPs or APP-PCL-NPs did not show elevated plasma 
cytokine concentrations when compared to mice that received PLGA-NPs (p > 0.05; Fig. 3.10).  
In a related study, cytokine production following S.C. injection of APP polymers (80 mg/kg) was 
investigated.  In this follow up study, levels of TNF-α and IL-6 measured on day 14 post-
injection were comparable to that observed following I.V. injections (data not shown).  In both 
studies (I.V. and S.C. administration) the plasma concentrations of TNF-α and IL-6 were 
comparable to the reported normal range for BALB/c mice (Blanque et al., 1998; Lv et al., 2014).   
3.4.7. Blood biochemical parameters and histopathological examination 
 The results of blood biochemical parameters obtained at various time periods after I.V. 
injections of APP polymers are shown in Fig 3.11.  Plasma levels of ALT and creatinine were 
used as indicators of liver and kidney function, respectively.  The established normal range for 
plasma ALT levels in mice is 26-77 IU/L (Carpenter, 2005).  The baseline (control) plasma ALT 
for untreated mice in our study was 56 ± 3 IU/L which is within the expected normal range for 
healthy mice.  Following I.V. injection of APP polymers into BALB/c mice, ALT levels 
remained within the normal range for time-points ranging from 3-48 hr post-injection (Fig. 
3.11A).  At 72 hr time-point all the animal groups had mean ALT levels that were above the 
baseline levels, and outside the normal range (p < 0.05).  Although the mean ALT level for mice 
that received APP-H-NPs (94 ± 10 IU/L) was slightly higher than mice that received APP-PCL-
NPs (84 ± 11 IU/L), the difference was not significant (p = 0.22; Fig. 3.11A).  Focusing on 72 hr 
time-point, additional observations were made by comparing the ALT levels from mice treated 
with APP-H and APP-PCL to mice treated with PLGA (Fig. 3.11A).  The results showed that the 
ALT levels from APP-H treated mice were significantly higher than that of PLGA treated mice (p 
< 0.01), while the ALT levels from mice treated with APP-PCL were not distinguishable from 
PLGA (p > 0.05).  The baseline (control) level of plasma creatinine in our study of 1.0 ± 0.2 
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mg/dL was within the established normal range of 0.3-1.0 mg/dL (Carpenter, 2005).  It was 
observed that at all the time-points after I.V. injection plasma creatinine levels for APP-H and 
APP-PCL were comparable to PLGA (p = 0.08; Fig. 3.11B).  
 The studies on S.C. administration of APP polymers were conducted to assess possible 
applications as implantable/sustained release delivery systems.  As such, the polymer dose 
administered (80 mg/kg) was more than 7 times higher than the dose used in the I.V. studies.  
Blood biochemical parameters were assessed on days 7 and 14 post-injection.  ALT levels on day 
7 were within the normal range for all the treatment groups (Fig. 3.12A).  The significant increase 
in ALT levels on day 14 for APP polymers as compared to the baseline level (p < 0.05) was also 
observed for PLGA.  It is worth noting that irrespective of the time of measurement (days 7 and 
14), ALT levels for APP-H or APP-PCL were comparable to PLGA (p > 0.05; Fig. 3.12A).  This 
trend was also observed for plasma creatinine levels measured on days 7 and 14 post-injection 
(Fig. 3.12B). 
Data from blood biochemical parameters were substantiated by histopathological 
examination of kidney and liver tissues obtained from mice after I.V. or S.C. administration.  This 
is particularly important in the S.C. administration studies that showed elevation of plasma ALT 
on day 14.  Tissue sections were obtained at 72 hr post-I.V. injection and on day 14 following 
S.C. injection (Fig. 3.13A-B).  Histopathology was carried out qualitatively by a blinded 
independent assessor.  For kidney sections, H&E images were examined for signs of vascular 
congestion, tubular necrosis, and glomerular atrophy, which are indicators of kidney toxicity.  In 
all evaluations tissue sections from mice that received PLGA were used as the reference.  The 
selection of PLGA as the reference for the histopathological examination was based on the initial 
studies that determined that there were no detectable differences between PBS-treated controls 
and PLGA-treated mice.  It was observed that kidney sections from animals in the I.V. and S.C. 
groups were comparable to that from PLGA, suggesting that the APP polymers did not induce 
kidney morphological changes/toxicity (Fig. 3.13A-B).  Using the same histopathological 
examination process H&E images of liver sections from animals that received APP polymers or 
PLGA were examined for signs of vascular and cellular changes (Fig. 3.13A-B).  In all cases, the 
images did not show signs of cellular injury that are observable through microabscess formation 
or cytoplasmic condensation.  Also, there were no detectable areas of necrosis, cholestasis, 
steatosis or nuclear changes in liver parenchyma across tissue sections (Fig 3.13A-B).  Taken 
together, the data demonstrated the biocompatibility and tolerability of APP polymers 
administered as I.V. or S.C. injections.  
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3.5. Conclusions 
 The work has critically evaluated for the first time biocompatibility and tolerability of 
APP polymers as a new class of photoresponsive polymers.  APP polymers (homopolymer and 
copolymers with PEG and PCL) as well as the products produced by photoirradiation did not 
cause macrophage activation or trigger cytotoxicity.  Also, the polymers did not induce RBC lysis 
nor trigger an immune response as assessed through the levels of plasma cytokines (IL-6 and 
TNF-α).  NPs prepared from APP-H and APP-PCL were stable and biocompatible, whereas APP-
PEG-NPs were not stable beyond the day of preparation.  Results from the biodistribution studies 
in BALB/c mice demonstrated preferential accumulation of the APP-NPs in the liver and kidney 
compared to other tissues.  Plasma creatine levels were maintained after I.V. and S.C. 
administrations.  Also, plasma ALT was comparable to baseline levels until day 7 post-
administration.  The observed elevation of plasma ALT levels on day 15 (S.C. groups) and 72 hr 
(I.V. groups) was not substantiated by corresponding histopathological assessments.  In all, the 
H&E images of tissue sections from animals that received APP polymers did not show detectable 
signs of morphological changes/toxicity.  Taken together, APP polymers could be suitable 
candidates for the development of drug delivery systems, especially as photoresponsive delivery 
systems where biocompatibility and tolerability of the polymers before and after photoirradiation 
are required.      
3.6. Acknowledgements 
The research was supported by research funds from NEOMED and the University of 
Akron.  Authors are grateful to Ms. Sharon Usip (NEOMED) for assistance with histological 
studies.  
 
*The contents of this chapter were published in part in the Journal of Pharmaceutical Sciences: 
Wehrung D., Sun S., Chamsaz E.A., Joy A., Oyewumi M.O. Biocompatibility and in-vivo 
tolerability of a new class of photoresponsive alkoxylphenacyl-based polycarbonates. J. Pharm. 
Sci., 2013 May;102(5):1650-1660. 
 
 
 
 
45 
 
Figure 3.1: 
 
 
Fig. 3.1: Characterization of NPs prepared from the APP homopolymer and copolymers 
with PEG and PCL: NPs prepared from APP-H and APP-PCL were stable and had diameters 
around 100 nm, while NPs prepared from APP-PEG had diameters near 200 nm and were not 
stable beyond the day of preparation.  (A) Chemical structure of the APP homopolymer (APP-H).  
(B) Sizes (mean ± SD; n = 3) of nanoparticles prepared with APP homopolymer (APP-H) or 
copolymers with PEG and PCL (APP-PEG and APP-PCL).  (C) Size stability of NPs prepared 
from APP-H, APP-PEG and APP-PCL when stored as aqueous suspensions at 25
o
C.  Each data-
point is plotted as a mean ± SD (n = 3). 
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Figure 3.2: 
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Fig. 3.2: Size stability of APP-H-NPs over 14 days: APP-H-NPs remained stable over 14 days.  
Size measurements of NPs prepared from APP-H when stored as aqueous suspensions at 25°C for 
14 days.  Each data-point is plotted as the mean ± SD (n = 3).   
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Figure 3.3: 
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Fig. 3.3: Biocompatibility assessment of APP polymers in RAW 264.7 cells: APP polymers 
exhibited biocompatibility comparable to PLGA in vitro.  (A) Viability of RAW 264.7 cells after 
treatment (24 hr; 37
o
C) with APP polymers or PLGA.  Each data-point (mean ± SD; n = 5) is 
expressed as a percentage of untreated cells (set to 100%).  (B) ROS production in RAW 264.7 
cells treated with APP polymers or PLGA (24 hr; 37
o
C).  Each data-point (mean ± SEM; n = 4) is 
expressed as fluorescence intensity (per µg of protein) using LPS (10 µg/mL) as the positive 
control.  (C) Nitrite production in RAW 264.7 cells after treatment with APP polymers or PLGA 
(48 hr; 37
o
C).  Each data-point (mean ± SD; n = 7) is expressed as the percentage of nitrite 
production, using the LPS as the reference. Nitrite levels for APP polymers and PLGA were 
comparable to untreated control cells (p > 0.05).  * indicates significance, p < 0.05.  
 
 
48 
 
Figure 3.4:   
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Fig. 3.4: Cytotoxicity of APP polymers at extended incubation durations: The cytotoxicity of 
APP polymers was comparable to PLGA at all time-points studied.  Viability of RAW 264.7 cells 
after treatment with APP polymers for (A) 48 hr and (B) 72 hr.  Each data-point (mean ± SD; n = 
8) is plotted as a percentage of the untreated cells (set as 100%).     
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Figure 3.5: 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.5: Biocompatibility assessment of photoirradiated APP polymers in RAW 264.7 cells: 
Photoirradiation did not alter the biocompatibility of APP polymers.  (A) Cellular viability and 
(B) macrophage activation after treating RAW 264.7 cells (24 hr; 37°C) with photoirradiated 
APP polymers (handheld UV lamp; wavelength 302 nm; duration = 15 min).  Each data-point 
represents mean ± SD (n = 7).  (C) Macrophage activation and (D) Cellular viability after treating 
RAW 264.7 cells (24 hr; 37°C) with 25 µg/mL photoirradiated APP polymers (Rayonet reactor; 
300 nm; duration = 4 min).  Each data-point represents mean ± SD (n = 8).  Percentage cell 
viability data were based on untreated control cells.  Nitrite production data are expressed as the 
percentage of nitrite produced in LPS-treated cells.  Cell viability and levels of nitrite produced 
were comparable with untreated control cells (Untr. Control).  # indicates p > 0.05. 
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Figure 3.6: 
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Fig. 3.6: Hemocompatibility assessment of APP polymers: The APP polymers had 
hemocompatibility comparable to PLGA.  (A) Extent of RBC lysis following treatment with APP 
polymers or PLGA for 30 min at varying polymer concentrations.  (B) Effect of varying 
incubation time on RBC lysis.  Polymer solutions (25 µg/mL) were incubated with rat whole 
blood for 0.5-6 hr.  Each data-point (mean ± SD; n = 4) is expressed as a percentage of the 
positive control (water).   
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Figure 3.7: 
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Fig. 3.7: Biocompatibility assessment of APP-NPs in RAW 264.7 cells: APP-NPs were not 
cytotoxic and did not activate macrophages in vitro.  (A) Cellular viability after treating RAW 
264.7 cells (48 hr; 37ᵒC) with intact (non-irradiated) or photoirradiated (NPs + UV) NPs prepared 
from APP-H, APP-PCL, or PLGA.  Photoirradiation of NP suspensions was done using a 
handheld UV lamp (302 nm; 20 min duration).  None of the NP treatment groups reduced cellular 
viability compared to the untreated controls (p > 0.05).  Each data-point is plotted as a percentage 
of the untreated controls (100% viability; mean ± SD; n = 4).  (B) Macrophage activation, 
assessed by nitrite production, following treatment of RAW 264.7 cells (48 hr; 37ᵒC) with intact 
NPs (non-irradiated) or photoirradiated NPs (NPs + UV).  All NP treatment groups were 
comparable to untreated controls (p > 0.05).  Data-points are plotted as ng’s nitrite normalized to 
protein content (mean ± SD; n = 4).     
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Figure 3.8: 
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Fig. 3.8: Hemocompatibility assessment of APP-NPs: APP-NPs did not induce significantly 
more RBC lysis than PLGA-NPs.  (A) Extent of RBC lysis after incubating NPs prepared from 
APP-H, APP-PCL, and PLGA in citrate whole blood for 6 hr at varying polymer concentrations.  
NPs prepared from APP-H and APP-PCL induced a comparable degree of RBC lysis to that of 
PLGA-NPs (p > 0.05).  (B) Effects of varying incubation time (0.5-6 hr) on RBC lysis at a fixed 
polymer concentration (50 µg/mL).  RBC lysis was comparable between APP-NPs and PLGA-
NPs at all time-points studied (p > 0.05).  Data-points are plotted as the percentage of RBC lysis 
caused by water (mean ± SD; n = 3). 
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Figure 3.9:  
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Fig. 3.9: Biodistribution of APP-NPs in BALB/c mice: APP-NPs preferentially accumulated in 
the kidneys and liver following I.V. injection into BALB/c mice.  Distribution of fluorescently 
labeled NPs constructed from APP-H and APP-PCL 72 hr after I.V. injection.  Data-points are 
plotted as the fluorescence intensity per gram of tissue (mean ± SD; n = 3-4). 
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Figure 3.10: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.10: Cytokine production in BALB/c mice treated with APP-NPs: Plasma levels of pro-
inflammatory cytokines indicated that APP-NPs did not induce an immune response when 
administered to BALB/c mice.  (A) Plasma TNF-α and (B) plasma IL-6 levels72 hr post-I.V. 
injection of APP-NPs or PLGA-NPs (10 mg/kg) into BALB/c mice.  Plasma TNF-α and IL-6 
levels were comparable for APP-NPs and PLGA-NPs (mean ± SEM; n = 3-4 mice).  # indicates p 
> 0.05. 
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Figure 3.11: 
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Fig. 3.11: Blood biochemical parameters after I.V. injection of APP-NPs: Liver and kidney 
function were not adversely affected by treatment with APP-NPs.  Assessment of liver and 
kidney functions in BALB/c mice at 72 hr post-I.V. injection (10 mg/kg) of APP-NPs or PLGA-
NPs (mean ± SEM; n = 3-4 mice).  (A) Plasma ALT and (B) creatinine levels were measured by 
enzyme immunoassay kits.  * indicates significance, p < 0.05. 
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Figure 3.12: 
 
 
 
 
  
 
 
 
 
 
 
 
 
Fig. 3.12: Blood biochemical parameters after S.C. injection of APP polymers: Markers of 
liver and kidney function were comparable between mice treated with APP polymers or PLGA.  
(A) Plasma ALT and (B) creatinine levels indicating liver and kidney functions on  days 7 and 14 
after S.C. administration (80 mg/kg) of APP polymers or PLGA in BALB/c mice (mean ± SEM; 
n = 3-4 mice). 
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Figure 3.13: 
 
 
Fig. 3.13: Histopathological examination of liver and kidney sections from mice treated with 
APP polymers: APP polymers did not cause observable histopathological signs of toxicity to the 
liver or kidneys.  Representative images of H&E stained liver and kidney slices (200X 
magnification) following (A) I.V. injection of APP-NPs or PLGA-NPs or (B) S.C. injection of 
APP polymers or PLGA.  Controls (PBS treated) for both I.V. and S.C. groups are shown in 
panel A.  
  
A 
B 
58 
 
 
 
 
 
 
 
 
 
Chapter 4 
Evaluation of APP-NPs as a Platform for Photoresponsive Drug Delivery 
4.1. Abstract 
In the previous chapter the suitability of APP for drug delivery applications was 
demonstrated through assessments of biocompatibility and tolerability.  In this chapter, we 
evaluated the utility of APP as a platform for photoresponsive delivery.  Nanoparticles (NPs) 
were prepared and characterized from the APP homopolymer and polycaprolactone copolymer 
(APP-NPs) with doxorubicin (DOX) as a model drug.  The effects of exposure to the photo-
trigger were characterized.  Photoresponsive drug release was assessed in order to identify key 
formulation and photoirradiation parameters that influenced photoresponsive efficacy.  Stable, 
spherical NPs were prepared with diameters between 70-180 nm depending on the polymer 
concentration (10-40 mg/mL).  Drug release studies indicated that exposure to the photo-trigger 
was capable of altering the rate and extent of DOX release from NPs prepared from the 
homopolymer.  Photoresponsive DOX release was heavily influenced by the frequency of 
photoirradiation and the polymer concentration.  The influence from the polymer concentration 
was most likely propagated through its effect on particle size.  DOX released by photoirradiation 
retained its efficacy as assessed by cytotoxicity studies in Lewis lung carcinoma (LLC) cells.  
Studies in BALB/c mice indicated that DOX-APP-H-NPs induce less cardiotoxicity than DOX 
alone, and that DOX-APP-H-NPs are not susceptible to dose dumping after photoirradiation.  
 
59 
 
4.2. Introduction 
Stimuli-responsive or “smart” delivery systems are capable of controlling the release of 
drug in a spatial and temporal manner, and as such represent a promising means for achieving 
site-specific drug delivery (Meyer et al., 2001; Allen and Cullis, 2004; Sengupta et al., 2005; Zhu 
and Torchilin, 2013).  Drug release from these systems can be dictated by a specific stimulus or 
“trigger” which induces a drastic change in the physical and/or chemical properties of the system, 
triggering the release of drug.  Previous reports have identified hydrophobic/hydrophilic shift, 
isomer switching and controlled degradation as effective mechanisms for inducing drug release 
from stimuli-responsive systems (Jiang et al., 2006; Chen et al., 2011; Fomina et al., 2011).  
Stimuli-responsive delivery systems are capable of responding to a wide variety of stimuli, 
ranging from disease-specific (internal) to non-disease specific (external).  Internal stimuli, such 
as pH, redox potential and enzyme overexpression, require that the delivery system physically 
interact with the stimulus in order to trigger drug release (Jiang et al., 2004; Lee et al., 2008; Liu 
et al., 2011).  Since disease-specific conditions are subject to fluctuation at different stages of the 
disease as well as in different patients, systems that rely on internal stimuli are not conducive to 
reproducible activation in a clinical setting.  By contrast, external stimuli facilitate reliable and 
reproducible activation by virtue of their external nature.  Since external stimuli originate from 
exogenously applied sources, their ability to induce system activation is not affected by changes 
in the microenvironment of the diseased tissue.  Furthermore, systems that use external stimuli 
can serve as generic platforms capable of treating multiple diseases simply by changing the 
therapeutic payload.  Previously reported stimuli-responsive systems have utilized external 
stimuli such as local heating, ultrasound, magnetic fields and light (Saslawski et al., 1988; Kost et 
al., 1989; Liu and Dong, 2012; Chou et al., 2013).  
We are of the opinion that systems that respond to light (photoresponsive) offer 
additional advantages over other external stimuli.  The inherent properties of light (wavelength, 
intensity and polarity) can be independently manipulated, enabling exquisite control over 
activation as well as extensive versatility in system design (Lu et al., 2008).  Furthermore, 
manipulation of these same properties enables a single photoresponsive system to be capable of 
multiple responses.  Photoirradiation with different wavelengths of light has been shown to be 
capable of turning drug release “on” and “off,” thereby allowing the dose of drug administered to 
be controlled in real time (Garcia-Amoros et al., 2012; Yuan et al., 2013).  Finally, 
photoresponsive systems can facilitate the use of multi-modal treatment strategies as well as 
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directly link site-specific drug delivery to image guided drug therapy (i.e. theranostics) (Rai et al., 
2010; Cui et al., 2012).       
The alkoxylphenacyl-based polycarbonates (APP) are a new class of photoresponsive 
polymers.  The construct of these polymers incorporates the photoactive phenacyl moiety within 
the backbone of the polymer.  This design allows for photoactivated chain scission to occur upon 
photoirradiation (250-320 nm).  To this end, we have previously  characterized photoactivated 
chain scission of APP as well as photoresponsive release of Nile Red from an APP-based delivery 
system (Sun et al., 2012).  Furthermore, our earlier reports also detailed the high thermal stability 
and biodegradability of APP, and the biocompatibility and tolerability was detailed in the 
previous chapter (Sun et al., 2012).  These advantageous characteristics warrant further 
investigation into the utility of APP and its photoactivated chain scission mechanism in 
photoresponsive drug delivery.  We describe herein the development and characterization of 
nanoparticulate delivery systems engineered from the APP homopolymer and polycaprolactone 
(PCL) copolymer.  Doxorubicin (DOX) was employed as a model drug on the basis of its well 
documented efficacy against a wide range of malignancies, and its lethal cardiotoxic side effects 
attributed to its nonspecific distribution (Lefrak et al., 1973; Simunek et al., 2009; Xiao et al., 
2011). APP-NPs and DOX-loaded APP-NPs (DOX-APP-NPs) were prepared and characterized 
while varying the following formulation parameters: (i) surfactant concentration, (ii) polymer 
concentration, and (iii) DOX concentration.  The photoresponsive release of DOX was assessed 
while investigating the influence of the following photoirradiation and formulation parameters: 
(a) photonic dose of the light administered, (b) timing of photoirradiation administration, (c) 
frequency of photoirradiation, and (d) polymer concentration.  The effectiveness of DOX-APP-
NPs in limiting off-target exposure of DOX to healthy tissues was investigated through the 
assessment of DOX-induced cardiotoxicity in BALB/c mice.  This chapter details the 
development and assessment of APP as a photoresponsive drug delivery platform.  
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4.3. Materials and methods  
4.3.1. Materials 
Dimethyl sulfoxide (DMSO), Pluronic F-127 ®, dialysis tubing (molecular weight cutoff, 
MWCO 3,500 Da), 96 well plates, and phosphate buffered saline (PBS) were obtained from 
Fisher Scientific (Pittsburgh, PA).  Micron Ultracel YM-100 centrifugal devices (MWCO 10,000 
Da) were obtained from Millipore (Billerica, MA).  LC Labs (Woburn, MA) provided 
doxorubicin HCl.  Dulbecco’s modified eagles medium (DMEM), thiazolyl blue tetrazolium 
bromide (MTT), triethylamine (TEA), 4’, 6-diamidino-2-phenylindole dihydrochloride (DAPI), 
and penicillin/streptomycin were obtained from Sigma Aldrich (St.  Louis, MO); while fetal 
bovine serum (FBS) came from Atlanta Biologicals (Lawrenceville, GA).        
4.3.2. Polymer synthesis 
APP was synthesized as previously described (Sun et al., 2012).  In this process, the 
hydroxyacetophenone chain was extended with a hydroxyl terminated spacer.  The product was 
subsequently converted to the corresponding bromide before reacting with sodium acetate to yield 
the acetate protected derivative.  Following de-protection, the alkoxylphenacyl diol was reacted 
with triphosgene to provide the corresponding polycarbonate.  The polycaprolactone copolymer 
(APP-PCL; 10 wt%) was prepared by the inclusion of PCL diol monomers (2,000 Da) during 
polymerization.          
4.3.3. Preparation of doxorubicin (DOX) free base 
Doxorubicin HCl was converted to its free base form using the procedure reported 
previously with minor modification (Kataoka et al., 2000).  The salt form was solubilized in 
DMSO (10 mg/mL) before adding 4 molar equivalents of TEA.  The reaction solution was kept at 
room temperature under constant stirring (350 rpm) for 30 min.  Initial assessments confirmed 
that these conditions converted the salt form to the free base.    
4.3.4. Preparation of DOX-loaded APP nanoparticles (DOX-APP-NPs) 
DOX-loaded nanoparticles (DOX-APP-NPs) were prepared by nanoprecipitation as 
described in Chapter 3.  Briefly, APP homopolymer (APP-H) or polycaprolactone copolymer 
(APP-PCL) was weighed out in a glass vial before being solubilized in DMSO (10-40 mg/mL).  
Once the polymer had completely solubilized, DOX was added (0-0.5 mg/mL) and mixed for 5 
min at 350 rpms.  This feed solution was then added dropwise into 1 mL of surfactant solution (1-
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5% w/v, Pluronic F-127 ®) at 40ᵒC under vigorous stirring.  Blank nanoparticles (APP-H-NPs or 
APP-PCL-NPs) were prepared by omitting DOX from the feed solution.  The resulting NPs were 
purified by dialyzing against purified water for 2 hr (MWCO 3,500 Da); replacing the water after 
60 min.  Chromatographic studies confirmed that these purification conditions were able to 
remove residual DMSO from the formulation.            
4.3.5. DOX-APP-NP characterization 
4.3.5.1. Particle size, zeta potential, stability, and morphology 
Size and zeta potential measurements were obtained using Zetasizer Nano-ZS-90 
(Malvern Instruments; Worestershire, United Kingdom).  All measurements were taken at 25ᵒC 
following a 1:10 v/v dilution with filtered water (0.22 µm filter; Nalgene International, Rochester, 
NY) in order to ensure that the light scattering signal was within the sensitivity range for the 
equipment.  Evaluation of particle size stability in biologically relevant fluids was conducted in 
accordance with an established method (Bi et al., 2013).  Briefly, NP suspensions were diluted 
(1:10 v/v) with 0.22 µm filtered water, PBS or 10% FBS (in PBS), and incubating at room 
temperature (23ᵒC) for 30 min.  Transmission electron microscopy (TEM) was employed to 
assess the morphology of the NPs as well as evaluate morphological changes induced by 
photoirradiation with 302 nm light from a handheld UV lamp (UVM-57; UVP Inc).   
4.3.5.2. DOX loading and entrapment efficiency  
NP suspensions were diluted with filtered water (1:4 v/v) before being passed through 
Microcon Ultracel YM-100 centrifugal devices (MWCO 10,000 Da; Millipore, Billerica, MA) by 
centrifugation at 4,000 x g for 30 min.  The retained fraction was then reconstituted to the original 
volume with filtered water, and both the retained and filtrate solutions were collected for analysis.  
DOX was quantified spectroscopically at 480 nm (Spectramax-340PC plate reader; Bucher 
Biotec AG, Basel, Switzerland).  DOX in the retained fraction was considered to be entrapped 
within the NPs, whereas DOX in the filtrate was considered as unentrapped.  Drug loading 
(%DL) and entrapment efficiency (%EE) were determined using equations (4.1) and (4.2), 
respectively: 
%𝐷𝐿 = (
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐷𝑂𝑋 𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑 𝑖𝑛 𝑁𝑃𝑠 
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑁𝑃𝑠
)  × 100                                           (4.1) 
%𝐸𝐸 = (
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐷𝑂𝑋 𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑 𝑖𝑛 𝑁𝑃𝑠 
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐷𝑂𝑋 
)  × 100                                           (4.2) 
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4.3.5.3. DSC analysis   
Differential scanning calorimetry (DSC) was conducted using a diamond differential 
scanning calorimeter (Perkin Elmer; Chicago, IL), operated under nitrogen gas (purge rate of 20 
mL/min).  Thermal transitions were obtained during the heating curve over 25-300ᵒC at a heating 
rate of 10ᵒC/min. 
4.3.6. Characterization of the photoresponsive properties of APP-NPs  
4.3.6.1. Photoirradiation conditions    
 Photoirradiation was conducted with a handheld UVM-57 UV lamp (UVP Inc.; Upland, 
CA) with peak emission at 302 nm.  The lamp was held in a fixed position with a ring stand.  NP 
suspensions (1 mL) were photoirradiated by placing the NP stock suspension 2.5 cm from the UV 
filter.  Using the manufacturer’s stated intensity of 0.0015 W/cm2 at 7.6 cm; we calculated the 
light’s intensity at 2.5 cm to be 0.0135 W/cm2 by the inverse square law (equation 4.3), which 
states that the intensity of light derived from a point source decreases as a function of the square 
of the distance from the light source (Frank L. Pedrotti, 2006). 
                                                    
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦1
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦2
=  
(𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒2)
2
(𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒1)2
                                      (4.3)                                       
“Intensity1” is the intensity of the light (0.0015 W/cm
2) at “Distance1” (7.6 cm) from the light 
source, and “Intensity2” is the calculated intensity of the light at “Distance2” (2.5 cm) from the 
light source.  Airflow through the fume hood was sufficient to maintain the solution at a 
consistent temperature during photoirradiation.  The amount of light administered (photonic dose) 
was controlled by manipulating the duration of photoirradiation.  To achieve a photonic dose of 
16.2 W∙sec/cm2, the NP suspension (1 mL) was irradiated for 20 min in a 6-well plate 2.5 cm 
away from the lamp’s UV filter.  The influence of the timing of photoirradiation administration 
was evaluated by irradiating NP suspensions at 0 hr (immediately after NP preparation and 
purification) and 24 hr (one day after NP preparation and purification).  
4.3.6.2. Molecular weight analysis 
 Gel permeation chromatography (GPC) was used to monitor changes in the molecular 
weight of APP following photoirradiation as earlier reported (Sun et al., 2012).  Changes in the 
molecular weight of APP are indicative of photoactivated chain scission.  GPC analysis was 
conducted on a TOSOH EcoSEC HLC-8320 GPC.  Two TSK-GEL ® Super-H 3,000 columns 
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and a TSK-GEL ® Super-H 4,000 column were used in series for the separation.  The mobile 
phase consisted of CHCl3.  The molecular weight was determined by extrapolation of a standard 
curve established with polystyrene standards. 
4.3.6.3. Photoresponsive drug release        
The release of DOX from non-irradiated DOX-APP-NPs was investigated by placing 1 
mL of DOX-APP-NP suspension into a dialysis bag (MWCO 3,500 Da), and dialyzed against 15 
mL of water.  At specified time-points the dialysate was collected for analysis, and replaced with 
15 mL of fresh water in order to maintain sink conditions.  The release from photoirradiated 
DOX-APP-NPs was studied in a similar manner that accommodated exposure of the DOX-APP-
NPs to the photo-trigger.  Photoirradiated DOX-APP-NPs received 1-3 photoirradiations 
administered in series (photonic dose of 16.2 W·sec/cm
2
/photoirradiation).  Photoirradiation of 
DOX-APP-NPs was performed at a single (1X) or multiple (2X, 3X) time-point(s) spaced 24 hr 
apart (i.e. 0, 24 and 48 hr).  Studies utilizing multiple sequential photoirradiations (i.e. 2X and 
3X) required the removal of the NP suspension from the dialysis bag prior to photoirradiation in 
order to avoid changes in intensity caused by the absorption and/or scattering of light by the 
dialysis membrane.  The time required to release 30% and 50% of entrapped DOX was denoted 
as T30% and T50%, respectively.   
4.3.7. Cell-based assessments 
4.3.7.1. Cell culture 
A murine lung cancer cell line (Lewis lung carcinoma, LLC) was a gracious gift from Dr. 
Charles Thodeti.  The cells were maintained in a humidified incubator (37ᵒC, 5% CO2) in 
Dulbecco’s modified eagle medium (DMEM) containing 10% FBS and antibiotics (100 µg/mL 
streptomycin and 100 units/mL penicillin).  Periodic subcultivation ensured that the cells 
remained in log phase.   
4.3.7.2. Cytotoxicity 
The functional efficacy of DOX released from photoirradiated DOX-APP-H-NPs was 
assessed in LLCs cells by the AlamarBlue ® assay in accordance with the manufacturer’s 
instructions.  DOX-APP-H-NPs (10 mg/mL APP-H; 0.25 mg/mL DOX) were photoirradiated 
(1X; 16.2 W·sec/cm
2
) and then incubated (23ᵒC) in the dark for 24 hr before being used to 
prepare treatment solutions in complete growth media.  Non-irradiated NPs received the same 24 
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hr incubation prior to the preparation of treatment solutions.  Cells were incubated with the 
treatment solutions for 24 hr at 37
o
C.  Cellular viability was determined as the percentage of the 
viability of untreated cells.  The cellular viability results obtained from the AlamarBlue ® assay 
were substantiated by assaying for apoptosis via terminal dUTP nick-end labeling (TUNEL).  
LLC cells were seeded on a chamber slide (50,000 cells/well), and allowed to adhere overnight.  
Treatments were incubated for 24 hr (37ᵒC) before being aspirated, and the cells fixed with 4% 
paraformaldehyde.  TUNEL staining was conducted using the procedure specified by the 
manufacturer (Roche Applied Science, Indianapolis, IN).  After TUNEL staining the nuclei were 
counterstained with DAPI, and imaged at 200X magnification using an Axio Imager.M2 
microscope (Zeiss; Thornwood, NY).  TUNEL was pseudo-colored red and DAPI was pseudo-
colored blue.    
4.3.8. Assessment of DOX-induced cardiotoxicity 
All experiments involving animals were conducted in accordance with National Institute 
of Health guidelines, and approved by the Institutional Animal Care and Use Committee of 
Northeast Ohio Medical University.  BALB/c mice (6-8 weeks; 20-25 grams) obtained from 
Charles River Laboratories (Raleigh, NC) were used for all in vivo studies.  The mice were 
divided into four groups according to the following treatments: (a) DOX solution, (b) PBS 
(vehicle), (c) non-irradiated DOX-APP-H-NPs, and (d) photoirradiated DOX-APP-H-NPs.  
Photoirradiation of DOX-APP-H-NPs was conducted prior to injection (3X photoirradiations; 
16.2 W·sec/cm
2
/photoirradiation).  DOX-APP-H-NPs were prepared at APP-H concentration of 
10 mg/mL with 0.5 mg/mL DOX.  All the treatments were administered intravenously via the tail 
vein at a dose of 5 mg DOX/kg.  The mice received two treatments of DOX (5 mg/kg/treatment) 
on the first and third days of the study.  On day 5 (48 hr after the final injection) the mice were 
sacrificed and cardiac tissues were collected for analysis.  Excised cardiac tissue was rinsed with 
PBS and fixed in 4% paraformaldehyde at 4ᵒC before being embedded in paraffin.  Tissue 
sections were sliced (5 µm) and stained with hematoxylin and eosin (H&E) for histological 
assessment by a blinded investigator.  Vacuolar degeneration of the myocardium, myofibrillar 
necrosis, hyalinization of arterioles, and myofibrillar disarrangement were considered as evidence 
of cardiotoxicity (Bozcali et al., 2012; Reagan et al., 2013; Segredo et al., 2013; Yuan et al., 
2013).  The percentage of apoptotic cardiomyocytes was determined through detection of DNA 
fragmentation via the TUNEL assay (Roche Applied Science, Indianapolis, IN).  Briefly, 5 µm 
sections of paraffin embedded cardiac tissue were deparrafinized and rehydrated before being 
labeled with TUNEL in accordance with the manufacturer’s instructions.  After labeling with 
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TUNEL, the tissue sections were counterstained with DAPI before being imaged.  Images were 
captured (320X magnification) using an Axio Zoom V16 microscope (Zeiss, Thornwood, NY).  
The number of apoptotic (TUNEL positive) cells was expressed as a percentage of the total 
number of cells (Pei et al., 2014).  Serum was obtained from whole blood samples by 
centrifugation at 1,500 x g for 15 min (4ᵒC).  Serum samples were analyzed for cardiac troponin-
1, an established marker of DOX-induced cardiotoxicity (Reagan et al., 2013), using an ELISA 
kit in accordance with the manufacturer’s instructions (Life Diagnostics, West Chester, PA).    
4.3.9. Statistical analysis 
Statistical analysis was conducted using Graph Pad Prism 6.0 (La Jolla, CA).  
Significance was determined via student’s t-test or analysis of variance followed by Dunnett’s 
post-hoc test for multiple comparisons with alpha set at 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
67 
 
4.4. Results and discussion 
The APP polymers represent a new class of photoresponsive polymers which utilize a 
unique molecular structure where the phenacyl chromophore is incorporated within the polymer’s 
backbone (Fig. 4.1A).  This design enables exposure to the photoactivating light to induce chain 
scission of the polymer into the acetophenone derivative (Fig. 4.1B) and the phenylacetic acid 
derivative (Fig. 4.1C).  Photo-induced chain scission of APP into oligomers provides an attractive 
means for controlling drug release due to the biocompatibility of the chain scission products (as 
described in Chapter 3).  Furthermore, APP possesses potentially advantageous characteristics for 
pharmaceutical applications including: (i) high thermal and mechanical stability, (ii) high 
photosensitivity, (iii) biodegradability, and (iv) biocompatibility.  These traits prompted this 
investigation into the utility of APP and its photo-induced chain scission mechanism as a platform 
for photoresponsive drug delivery.  In pursuit of this, we describe here the development of 
nanoparticulate delivery systems from the APP homopolymer and polycaprolactone copolymer 
(APP-PCL) with an emphasis on identifying formulation and photoirradiation parameters that 
influence the efficacy of APP in photoresponsive drug delivery.        
4.4.1. Evaluation of NPs prepared from APP-H 
4.4.1.1. Preparation and characterization of DOX-APP-H-NPs 
APP-H-NPs were prepared by a modified nanoprecipitation method and subsequently 
characterized in order to evaluate the effects of the following formulation parameters: (i) 
surfactant concentration, (ii) polymer concentration, and (iii) DOX concentration.  Initial studies 
established that NP preparation required a surfactant to prevent agglomeration during 
purification.  As such, Pluronic F-127 ® was chosen as the surfactant on the basis of: (a) cyto-
compatibility, (b) low immunogenicity, and (c) its lack of interference with the wavelengths of 
light required for photoactivation of APP (Fig. 4.2) (Batrakova et al., 2001; Menon et al., 2012).  
Pluronic F-127 ® is a non-ionic, bifunctional triblock copolymer consisting of two hydrophilic 
polyoxyethylene (PEO) blocks surrounding a hydrophobic polyoxypropylene (PPO) block 
(Monteiro-Riviere et al., 2005).  The surfactant concentration was optimized by monitoring 
changes in particle size and zeta potential at various concentrations (1-5% w/v; Fig. 4.3A).  At all 
surfactant concentrations studied, the average sizes of APP-H-NPs ranged from 77 ± 5 nm to 88 ± 
10 nm, and these sizes were maintained during the dialysis purification process.  The particle size 
distribution obtained from the dynamic light scattering (DLS) measurements showed formation of 
a single particle population at all surfactant concentrations (Fig. 4.4), and altering the surfactant 
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concentration did not significantly change the resultant polydispersity index (PDI) of APP-H-NPs 
(Table 4.1; p > 0.05).  Similarly, increasing the surfactant concentration did not significantly 
affect the mean zeta potential (p > 0.05).  The mean zeta potentials for NPs prepared from APP-H 
at the lowest and highest surfactant concentrations studied (1% and 5% w/v) were 15 ± 4 mV and 
12 ± 3 mV, respectively.  These values are not significantly higher (p > 0.05) than what is 
considered to be representative of a neutral/uncharged colloidal system (i.e.  -10 to +10 mV) 
(Clogston and Patri, 2011).  Further NP preparation was carried out at a surfactant concentration 
of 1% w/v since we were successful in obtaining stable APP-H-NPs and DOX-APP-H-NPs at this 
concentration.   
Additional characterization of the resultant NPs was conducted by DSC (Table 4.2).  
DSC identified a thermal transition at 50-65ᵒC for both blank APP-H-NPs and DOX-APP-H-NPs 
which corresponds to the reported glass transition temperature of APP-H (Sun et al., 2012).  A 
physical mixture of DOX and blank APP-H-NPs showed a thermal transition at 219ᵒC which was 
not pronounced in DOX-APP-H-NP sample.  Considering that the melting point of DOX has 
been reported to occur at 219ᵒC,  we believe the thermal transition observed at 219ᵒC to be the 
melting of DOX (Missirlis et al., 2006).  As such, the diminished DOX melting transition in 
DOX-APP-H-NP samples could connote possible entrapment of DOX (amorphous form) within 
the APP-H-NP matrix as has been previously reported for NP encapsulation of DOX (Sanson et 
al., 2010; Wang et al., 2012).   
 The effects of the polymer concentration (APP-H concentration) and DOX concentration 
on the resultant DOX-APP-H-NPs are shown in Fig. 4.3B and C, respectively.  At a constant 
surfactant concentration (1% w/v) DOX-APP-H-NPs were prepared at APP-H concentrations of 
10, 20, and 40 mg/mL (feed solution concentration).  As APP-H concentration increased from 10 
mg/mL to 40 mg/mL, the mean particle size increased from 92 ± 2 nm to 186 ± 12 nm (Fig. 
4.3B).  Additional data analysis indicated a linear relationship between APP-H concentration and 
particle size (R
2 
= 0.9447).  To evaluate the effect of the DOX concentration, DOX-APP-H-NPs 
were prepared using 10 mg/mL APP-H, and DOX concentrations of 0.25 and 0.5 mg/mL (Fig. 
4.3C).  Based on our previous observations, DOX concentrations above 0.5 mg/mL were not 
studied because we do not anticipate that DOX concentrations above 0.5 mg/mL will translate to 
substantial changes in drug loading (Wehrung and Oyewumi, 2012; Wehrung et al., 2012b; Bi et 
al., 2013).  The average size of blank (0 mg/mL DOX) APP-H-NPs (70 ± 2 nm) increased to 88 ± 
2 nm and 92 ± 1 nm at DOX concentrations of 0.25 and 0.5 mg/mL, respectively (Fig. 4.3C). 
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When compared to blank APP-H-NPs, the size of DOX-APP-H-NPs was increased by 25% and 
31% for formulations prepared with 0.25 and 0.5 mg/mL DOX, respectively. 
The influence of the APP-H concentration and DOX concentration on DOX loading was 
evaluated through measurements of entrapment efficiency (EE) and drug loading (DL).  At an 
APP-H concentration of 10 mg/mL the EE and DL were 63% and 11%, respectively (Fig. 4.5A).  
Increasing the APP-H concentration from 10 mg/mL to 40 mg/mL resulted in a corresponding 
increase in the EE; with the highest APP-H concentration (40 mg/mL) entrapping > 90% of DOX 
(Fig. 4.5A).  Further studies were conducted by maintaining the APP-H concentration at 10 
mg/mL while preparing DOX-APP-H-NPs at DOX concentrations of 0.25 and 0.5 mg/mL (Fig. 
4.5B).  At a DOX concentration of 0.25 mg/mL, the EE was 96%, which decreased to 63% when 
the DOX concentration was increased to 0.5 mg/mL.  The DL increased from 2% to 11% when 
the DOX concentration was doubled (from 0.25 mg/mL to 0.5 mg/mL).  NP entrapment of DOX 
was confirmed by gel permeation chromatography (GPC) using a Sephadex G-75 column (Fig. 
4.6).       
Size stability of DOX-APP-H-NPs in biologically relevant media was considered since 
instability can result in agglomeration and/or precipitation.  Such changes in particle size are 
reported to have profound effects on the biodistribution and pharmacokinetics of the delivery 
system (Liu et al., 1992; Driscoll, 2006).  The particle size stability of DOX-APP-H-NPs (APP-H 
concentration 10-40 mg/mL; DOX concentration 0.5 mg/mL) was evaluated following incubation 
(30 min) in various biologically relevant media such as: water, PBS, and 10% FBS (Fig. 4.5C).  
All DOX-APP-H-NP formulations remained stable following the 30 min incubation (p > 0.05).  
A follow up study was then conducted in which a representative formulation of DOX-APP-H-
NPs (10 mg/mL APP-H; 0.5 mg/mL DOX) was followed for 14 days (Fig. 4.7).  Under these 
conditions, DOX-APP-H-NPs incubated in water and PBS remained stable for the entire duration 
of the study (14 days; p > 0.05).   
4.4.1.2. Photoresponsive characterization of APP-H-NPs 
The synthesis and photoresponsive characterization of APP upon photoirradiation with 
the photo-trigger (300 nm light) was described previously (Sun et al., 2012).  APP was 
constructed such that the chromophore is contained within the polymer’s backbone.  This design 
allows for photoactivated chain scission to occur upon exposure to the activating light.  Herein we 
sought to: (i) characterize the photoresponsiveness of NPs prepared from APP; and (ii) assess the 
potential utility of APP in photoresponsive drug delivery applications.  As such, the 
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photoresponsiveness of APP-NPs and DOX-APP-NPs was evaluated while varying: (a) photonic 
dose administered, (b) timing of photoirradiation administration, (c) frequency of photoirradiation 
(i.e. number of irradiation episodes), and (d) polymer concentration.  Initial studies indicated that 
the lowest photonic dose of light required to induce the photoresponsive release of DOX from 
DOX-APP-H-NPs was 16.2 W∙sec/cm2 (Fig. 4.8).  TEM imaging was applied to monitor 
potential changes in NP morphology after photoirradiation (Fig. 4.9).  Prior to photoirradiation, 
the NPs (10 mg/mL APP-H; 0-0.25 mg/mL DOX) exhibited a spherical morphology with well-
defined surface characteristics (Fig. 4.9A-B).  After photoirradiation of blank APP-H-NPs 
(photonic dose of 16.2 W∙sec/cm2) the surface/boundary region became distorted and was no 
longer clearly defined (Fig. 4.9C).  Photoirradiation of DOX-APP-H-NPs produced a similar 
trend of disruption of the surface morphology more than the core of the particle even when the 
photonic dose was increased to 32.4 W∙sec/cm2 (Fig. 4.9D).  Additionally, we followed possible 
changes in APP-H’s molecular weight after exposing APP-H-NPs to the photo-trigger (Fig. 4.10).  
The GPC chromatogram of blank APP-H-NPs (10 mg/mL APP-H; 0 mg/mL DOX) before 
photoirradiation showed a single peak corresponding to the molecular weight of APP-H (Fig. 
4.10A).  Following photoirradiation (Fig. 4.10B) the GPC chromatogram contained an additional 
peak that corresponded to a molecular species with a molecular weight (MW) of approximately 
2,500 Da.  The trend from the TEM observations and GPC measurements suggests that exposure 
of APP-H-NPs to the photo-trigger was effective in disrupting NP surface morphology and 
boundaries while maintaining the NP core.  We envisioned that the photo-induced disruption at 
the surface could be a trigger for the sequential release of entrapped DOX, and that APP-H-NPs 
may not be susceptible to dose dumping after photoirradiation.  A follow up study was conducted 
to investigate the effect of photoirradiation at varying photonic doses on the mean sizes of APP-
H-NPs (10 mg/mL APP-H; 0 mg/mL DOX) as measured by dynamic light scattering (Fig. 
4.10C).  Photoirradiation at photonic dose that is three times higher than that used in the GPC and 
TEM studies (i.e. 48.6 W∙sec/cm2) decreased the mean particle size from 91 ± 4 nm (before 
photoirradiation) to 80 ± 2 nm (Fig. 4.10C).  This modest change in mean size following 
administration of a high photonic dose (48.6 W∙sec/cm2) provides additional evidence that APP-
H-NPs are unlikely to be prone to dose dumping following exposure to the photo-trigger.  It is 
also plausible that photoactivated chain scission could cause the formation of pores in the NP 
matrix that did not necessarily change the hydrodynamic diameters at the time of measurement.  
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4.4.1.3. Photoresponsive DOX release from APP-H-NPs     
In order to determine the utility of APP’s photoactivated chain scission mechanism in 
photoresponsive drug release applications the release of DOX from DOX-APP-H-NPs was 
studied while varying the following photoirradiation and formulation parameters: (i) timing at 
which photoirradiation was administered, (ii) frequency of photoirradiation, and (iii) polymer 
concentration (Fig. 4.11).  The release of DOX from DOX-APP-H-NPs (10 mg/mL APP-H; 0.25 
mg/mL DOX) after a single photoirradiation administered at different time-points is shown in 
Fig. 4.11A.  The time-point at which the NPs were photoirradiated was either 0 hr (immediately 
after NP preparation) or 24 hr (one day after NP preparation).  The data showed that altering the 
timing of photoirradiation administration did not have prominent effects on the rate and extent of 
DOX release.  At all time-points observed, there was no significant difference in the rate or extent 
of DOX released from NPs photoirradiated at the 0 hr or the 24 hr time-points (p > 0.05).  For 
NPs photoirradiated at 0 hr, the time at which 30% (T30%) and 50% (T50%) of the entrapped 
DOX was released was 30 hr and 50 hr, respectively (Fig. 4.11A).  For the non-irradiated NPs, 
the T30% and T50% are 50 hr and > 72 hr, respectively.  The trend showed that a single 
photoirradiation was not sufficient to achieve significantly higher DOX release at time-points 
before 48 hr.  However, at time-points after 48 hr, photoirradiation significantly increased the 
amount of DOX released compared to non-irradiated NPs (p < 0.01; Fig 4.11A).  For instance, at 
the 72 hr time-point 41 ± 5% of DOX was released from non-irradiated NPs as compared to 61 ± 
9% and 78 ± 9% of DOX released from NPs photoirradiated at the 0 hr and 24 hr time-points, 
respectively (Fig. 4.11A).  The inability to statistically differentiate irradiated from non-irradiated 
NPs at early time-points may imply that repeated exposure to the photo-trigger may be required.  
It is also possible that DOX release at early time-points was dominated by the nonspecific release 
of DOX at or near the NP surface regardless of photoirradiation.  As such, additional studies were 
conducted to investigate potential parameters that could improve photoresponsive DOX release 
while limiting DOX release from non-irradiated NPs.  We speculate that the release of DOX from 
non-irradiated NPs could be the result of factors including: (a) the diffusion of DOX; (b) 
hydrolytic degradation of APP; and/or (c) photoactivation by ambient light since release studies 
were not conducted under total dark conditions.  We consider that additional studies are 
warranted to elucidate the possible contribution of ambient light to the drug release kinetics from 
DOX-APP-H-NPs that were not exposed to the photo-trigger.  
Using the same DOX-APP-H-NP formulation (10 mg/mL APP-H; 0.25 mg/mL DOX), 
the influence of the frequency of photoirradiation was evaluated (Fig. 4.11B).  These studies 
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utilized photoirradiations administered sequentially every 24 hr (at the 0, 24 and 48 hr time-
points).  The frequency of photoirradiation was determined to significantly influence both the rate 
and extent of DOX release (p < 0.05).  The effect of the frequency of photoirradiation on the rate 
of DOX release is evident in the reduction in T50%.  DOX-APP-H-NPs that received 1X, 2X, 
and 3X photoirradiations achieved T50% at 50, 43, and 36 hr, respectively.  At 72 hr, 3X 
photoirradiated NPs released 95 ± 2% of entrapped DOX which is a 55% increase over 1X 
photoirradiated NPs that achieved 61 ± 9% DOX release at the same time-point (Fig. 4.11B).  
Furthermore, using multiple photoirradiations (3X) ensured that the rate and extent of DOX 
release was consistently higher than that observed for non-irradiated NPs at time-points beyond 
24 hr (p < 0.01; Fig. 4.11B). 
We also investigated the influence of the polymer concentration on the release of DOX.  
This assessment was conducted using DOX-APP-H-NPs prepared using 20 mg/mL APP-H (0.5 
mg/mL DOX; Fig. 4.11C) which is double the APP-H concentration used in the previously 
described formulation (10 mg/mL APP-H; Fig. 4.11A-B).  The rationale was that higher polymer 
concentrations plausibly decrease surface-associated DOX, and ensured that DOX was 
encapsulated within the polymer matrix.  As shown in Fig. 4.11C, increasing the APP-H 
concentration to 20 mg/mL markedly reduced the rate and extent of DOX released from non-
irradiated NPs; increasing the T30% by 186% (71 hr) compared to the T30% for non-irradiated 
NPs prepared using 10 mg/mL APP-H (T30% = 38 hr).  At both polymer concentrations (10 
mg/mL and 20 mg/mL) administration of multiple sequential photoirradiations (3X) increased the 
rate and extent of DOX released (Fig. 4.11B-C).  The increased difference between non-irradiated 
and photoirradiated NPs prepared from the higher polymer concentration is further depicted by 
the observation that at the 72 hr time-point 65 ± 6% of entrapped DOX was released from 
photoirradiated NPs as compared to 25 ± 12% from non-irradiated NPs (Fig. 4.11C).  The data 
demonstrate that the frequency of photoirradiation most likely drives the release of DOX in a 
manner that depends on the polymer concentration.  For instance, DOX-APP-H-NPs (20 mg/mL 
APP-H; 3X photoirradiation) achieved T50% at 49 hr, which is substantially higher than the 
T50% value of 38 hr for DOX-APP-H-NPs (10 mg/mL APP-H; 3X photoirradiation).  
Furthermore, the data also indicated that the polymer concentration played an influential role in 
the release of DOX in response to the photo-trigger.  The polymer concentration was previously 
identified as an influential parameter on the size of the resultant NPs (Fig. 4.3B).  Thus, there is a 
strong possibility that the effect of polymer concentration on photoresponsive DOX release was 
propagated through the increase in NP size as the polymer concentration was increased.  This 
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notion is supported by the fact that the mean size of DOX-APP-H-NPs at 20 mg/mL APP-H was 
140 nm (Fig. 4.11C); which is markedly higher than the average size of 88 nm for DOX-APP-H-
NPs made using 10 mg/mL APP-H (Figs. 4.11A-B).  This difference in mean particle size 
corresponds to a > 1.5 fold reduction in the surface area-to-volume ratio for DOX-APP-H-NPs 
prepared using 20 mg/mL APP-H.  A reduction in the surface area-to-volume ratio is expected to 
decrease the amount of surface-associated and near-surface DOX, and is the most plausible 
explanation for the difference in the DOX release profiles (non-irradiated and photoirradiated) 
from these NP formulations.  An important finding from our data was that photoactivation of 
DOX-APP-H-NPs did not lead into dumping of the entrapped DOX payload (dose dumping).  
This finding highlights the potential suitability of APP-H in sustained drug release and/or “on-
demand” dosing applications through exposure to the photo-trigger.  
To preliminarily assess the effect(s) of photoirradiation on the mechanism of DOX 
release the release data were analyzed with mathematical models; the Korsmeyer-Peppas model 
(equation 4.4), and the Higuchi release model (equation 4.5): 
𝑀𝑡
𝑀∞
⁄ =  𝑘𝑡𝑛     (4.4) 
𝑀𝑡
𝑀∞
⁄ = 𝑘𝑡1/2    (4.5) 
Where Mt/M∞ is the portion of drug released at time t, k is the rate constant, and n is the release 
exponent which describes the mechanism of release (Dash et al., 2010).  The equation for the 
non-irradiated 20 mg/mL DOX-APP-H-NPs gave n = 0.54 (R
2 
= 0.9415).  This value of n is close 
to that indicating a purely diffusion-driven release mechanism (n = 0.5).  Fitting the Korsmeyer-
Peppas model to the DOX release data from the same NP formulation exposed to the photo-
trigger gave n = 0.79 (R
2 
= 0.9526).  This n value is within the range (n = 0.5 – 0.89) that 
indicates that the release mechanism was a combination of multiple processes, in this case 
plausibly diffusion and erosion (Arora et al., 2011).  To further investigate the role of diffusion in 
DOX release with and without photoirradiation the release data was fitted to the Higuchi release 
model.  Using this model, the correlation coefficient obtained from non-irradiated NPs was R
2
 = 
0.9633, and R
2
 = 0.9016 for photoirradiated NPs.  The Higuchi release model describes drug 
released via diffusion.  On this basis the better fit of the release data from non-irradiated NPs to 
this model connotes that the release mechanism was predominately a diffusion-driven process.  
Conversely, the poor correlation coefficient obtained when this model was applied to 
photoirradiated NPs suggests that the release mechanism was not primarily a diffusion-driven 
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process.  This is in good agreement with the release mechanisms indicated by the Korsmeyer-
Peppas model.   
Taken together, the trend from the TEM, GPC, and DOX release studies suggests that the 
photoresponsive release of DOX from APP-H-NP formulations is likely dictated by a 
multifaceted mechanism which likely includes photoactivated surface erosion, pore 
formation/growth, and hydrolytic degradation.  While only surface erosion was observed during 
TEM analysis, it is plausible that photoactivated chain scission also causes the formation of pores 
in the NP matrix.  The influence of pore formation on drug release has been previously described 
for other particulate delivery systems such as polyester-based nanoparticles (Klose et al., 2006; 
Zhao et al., 2010).  The rate at which monomers/oligomers are generated has been reported to be 
a pivotal factor in pore formation and growth rates (Zhao et al., 2010).  Therefore it is a 
reasonable expectation that pore formation and growth could be accelerated by photoirradiation, 
thereby influencing the photoresponsive release of entrapped drug from APP-H-NPs.  Finally, it 
is worth noting that one of the products of photoactivated chain scission of APP-H is the 
phenylacetic acid derivative (pKa 3.5; Fig. 4.1C) (Sun et al., 2012).  The production of this acidic 
moiety upon photoirradiation may facilitate the degradation of APP-H through catalyzing the 
cleavage of the polymer’s ester groups (Lu et al., 1999).  Further studies are warranted to 
investigate the formation and growth of pores in the APP-H matrix, as well as the role of 
hydrolytic degradation in the photoresponsive release of DOX from DOX-APP-H-NPs.  
 As presented in this work, UV light (302 nm) was utilized to induce the photoresponsive 
release of DOX from DOX-APP-H-NPs.  The application of UV light is not clinically ideal due 
to its well-known genotoxic and cytotoxic effects along with its inability to penetrate tissues.  
Therefore, the potential applications of an APP-based delivery system are constrained to 
superficial anatomical locations (i.e. topical and ophthalmic drug delivery).  To ensure that only 
the delivery system is exposed to the photo-trigger we also consider potential clinical 
opportunities where APP is exposure to the photo-trigger prior to in vivo applications (e.g. photo-
patterned materials).  Also, advances in fiber optics could impart APP-based delivery systems 
with utility beyond superficial applications, as fiber optics can precisely delivering the activating 
light to deep tissues (Ito et al., 2008).  Additionally, the process of photon upconversion may 
enable APP-based delivery systems to be activated when exposed to biologically benign and 
tissue transparent near-infrared (NIR) light (Chen et al., 2006).  Photon upconversion is the 
process in which the absorption of two or more photons of light results in an anti-Stokes type 
emission (Auzel, 2004).     
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4.4.2. Evaluation of NPs prepared from APP-PCL 
4.4.2.1. Preparation and characterization of DOX-APP-PCL-NPs 
NP formulations prepared from the PCL copolymer (APP-PCL) were characterized while 
varying the same parameters as that of APP-H-NPs: (i) surfactant concentration, (ii) polymer 
concentration, and (iii) DOX concentration.  Varying the surfactant concentration used during the 
preparation of APP-PCL-NPs did not significantly alter the mean size of the resultant NPs, which 
ranged from 70 ± 14 nm to 86 ± 12 nm for the lowest (1% w/v) and highest (5% w/v) surfactant 
concentrations studied (Fig. 4.12A).  Likewise, the mean zeta potential of APP-PCL-NPs 
remained comparable at all surfactant concentrations studied (p > 0.05; Fig. 4.12A).  As was 
observed for APP-H-NPs, the mean zeta potential was not significantly different from what is 
considered to be representative of an uncharged/neutral system (p > 0.05).  All further preparation 
of APP-PCL-NPs was conducted using the 1% w/v surfactant concentration since this 
concentration was sufficient to prepare stable, unimodal NPs from APP-PCL.     
As was previously observed for formulations employing APP-H, the mean size of the 
resulting NPs increased as the polymer (APP-PCL) concentration was increased; however, the 
change in particle size was less pronounced than that observed for APP-H-NPs.  Increasing the 
concentration of APP-PCL from 10 mg/mL to 20 mg/mL increased the mean size of the resultant 
NPs by 15%; from 81 ± 3 nm to 93 ± 3 nm, respectively (Fig. 4.12B).  Further increasing the 
APP-PCL concentration to 30 mg/mL resulted in NPs with a mean size of 112 ± 3 nm, which is 
20% smaller than APP-H-NPs prepared at only 20 mg/mL (140 nm; Fig. 4.3A).   The mean zeta 
potential was not significantly affected by increasing the APP-PCL concentration (p > 0.05).   
DOX loading increased the mean size of APP-PCL-NPs.  Blank APP-PCL-NPs (0 
mg/mL DOX) had a mean size of 74 ± 4 nm which increased to 85 ± 4 nm when 0.25 mg/mL 
DOX was included in the formulation (p = 0.0282).  The mean zeta potential was not 
significantly altered by DOX loading, suggesting that cationic DOX was not associated with the 
NP surface (p > 0.05).  Changing the polymer concentration did not significantly alter the 
entrapment of DOX within APP-PCL-NP formulations (p > 0.05).  All APP-PCL formulations 
studied entrapped DOX with high efficiency (> 90%).  The EE of NPs prepared from 10 mg/mL 
APP-PCL and 0.25 mg/mL DOX (97 ± 1%) was comparable to that observed for the 
corresponding APP-H formulation (96 ± 4%; p > 0.05).  DOX entrapment was confirmed by GPC 
using a column packed with Sephadex G-75 (data not shown).  NPs prepared at a polymer 
concentration of 10 mg/mL exhibited comparable drug loading (DL) for both homopolymer and 
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PCL copolymer formulations (p > 0.05; Fig. 4.12C).  At the 20 mg/mL polymer concentration DL 
for APP-H-NPs was more than double that of APP-PCL-NPs (p < 0.001; Fig. 4.12C).  The lower 
DL for APP-PCL-NPs compared to the corresponding APP-H-NPs indicates that APP-PCL-NPs 
contained less DOX than the corresponding APP-H formulations.  This is likely the result of more 
extensive DOX removal during NP purification (dialysis).  The removal of DOX during dialysis 
was exacerbated in APP-PCL-NP formulations due to: (a) the smaller mean particle size and (b) 
the reported biphasic release pattern for particulate delivery systems formulated from copolymers 
containing PCL.  The smaller mean size increased the surface area-to-volume ratio, facilitating 
the removal of DOX by increasing the quantity of DOX in close proximity to the NP surface.  
Furthermore, reports in the literature indicate that surface/near surface association increases for 
particulate formulations containing PCL as the lipophilicity of the drug molecule decreases 
(Hombreiro Pérez et al., 2000; Raval et al., 2014).  This is reported to cause the biphasic release 
pattern (burst release followed by sustained release) observed for PCL formulations containing 
weakly lipophilic drugs.  In DOX-APP-PCL-NP formulations, the initial burst release of DOX 
at/near the NP surface would have occurred during dialysis purification, reducing the total 
amount of entrapped DOX.   
The size stability of DOX-APP-PCL-NPs was evaluated by incubating the 10 mg/mL 
APP-PCL formulation in water, PBS, and 10% FBS.  The mean size of DOX-APP-PCL-NPs 
stored in water remained constant over the entire course (14 days) of the study (p > 0.05; Fig. 
4.12D).  Likewise, the diameter of DOX-APP-PCL-NPs stored in PBS remained around 100 nm 
(Fig. 4.12D).  When DOX-APP-PCL-NPs were stored in 10% FBS the mean size increased by 
77% on day 3; from 104 ± 3 nm to 184 ± 8 nm for day 0 and day 3, respectively (p < 0.001; data 
not shown).   
Instability was observed for both APP-H and APP-PCL formulations when incubated in 
10% FBS for more than 2 days.  This may have been the result of proteins adsorbing onto the NP 
surface as a consequence of insufficient hydrophilicity of the NP surface.  Therefore, a follow up 
study was conducted to evaluate if the instability in 10% FBS could be mitigated by increasing 
the surfactant concentration (1-5% w/v; Fig. 4.13).  Increasing the surfactant concentration did 
not change the day on which NPs prepared from APP-H or APP-PCL increased in size when 
incubated in 10% FBS (Fig. 4.13A-B).  At all surfactant concentrations studied the mean size 
significantly increased on day 3 for both APP-H and APP-PCL formulations (p < 0.05).          
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4.4.2.2. Photoresponsive characterization of APP-PCL-NPs   
Photoresponsive characterization of APP-PCL-NPs was conducted by GPC analysis of 
the polymer’s molecular weight before and after photoirradiation (Fig. 4.14).  The chromatogram 
of APP-PCL-NPs not exposed to the photo-trigger had a single peak corresponding to the 
molecular weight of the intact APP-PCL polymer (Fig. 4.14A).  After photoirradiation, the peak 
was broader and shifted toward longer retention times (lower molecular weight) (Fig. 4.14B).  
This is different from the chromatogram obtained from APP-H-NPs after photoirradiation which 
exhibited less broadening, and contained an additional peak corresponding to ca. 2,500 Da 
molecular species (Fig. 4.10A-B).  The trend from the GPC chromatograms indicates that APP-
PCL-NPs are capable of responding the photo-trigger (Sun et al., 2012).  Similar to what was 
observed previously for APP-H-NPs; the effects of exposing APP-PCL-NPs to the photo-trigger 
were heterogeneous, producing lower molecular weight oligomers while also retaining some 
intact polymer chains.  As was observed for APP-H-NPs, the mean size of APP-PCL-NPs as 
measured by DLS was not significantly altered after photoirradiation (p > 0.05; data not shown).  
The retention of hydrodynamic diameter following photoirradiation has been reported previously 
for photoresponsive NPs (Chen et al., 2011b; Liu and Dong, 2012).  
In order to evaluate if the difference in the chromatograms from photoirradiated APP-H-
NPs and APP-PCL-NPs was due to a change in the extent of chain scission, a follow up study 
was conducted in which the conductivity of the NP suspensions (APP-H-NPs and APP-PCL-NPs) 
was measured before and after photoirradiation with varying photonic doses (Fig. 4.15A).  The 
major product of activating APP’s chromophore in an aqueous environment is an electrolyte; the 
phenylacetic acid derivative (Fig. 4.1C) (Givens et al., 2008; Sun et al., 2012).  This species has a 
pKa ca. 3.5, therefore existing as an ionized species in the NP suspensions (pH 7).  Since no other 
components of the NP suspension are ionizable, changes in conductivity reflect changes in the 
concentration of electrolytes present in the solution (i.e. the phenylacetic acid derivative produced 
by chain scission).  Prior to photoirradiation (0 W∙sec/cm2), the conductivity of APP-H-NPs and 
APP-PCL-NPs was comparable to water alone (p > 0.05), confirming that the NP suspensions 
(APP-H-NPs and APP-PCL-NPs) contained a negligible quantity of electrolytes.  Following 
photoirradiation with a photonic dose of 16.2 W∙sec/cm2 the conductivity of both APP-H-NPs 
and APP-PCL-NPs increased significantly compared to NPs not exposed (0 W∙sec/cm2) to the 
photo-trigger (p < 0.001; Fig. 4.15A).  When the photonic dose was increased to 32.4 W∙sec/cm2 
the conductivity was significantly higher than either the 0 W∙sec/cm2 or 16.2 W∙sec/cm2 samples 
(p < 0.001).  The conductivity of APP-H-NPs and APP-PCL-NPs was comparable at all photonic 
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doses (p > 0.05), suggesting a comparable quantity of ionic species (phenylacetic acid derivative) 
existed in both formulations following photoirradiation.  In support of the conductivity 
measurements, are measurements of mean zeta potential of APP-H-NPs and APP-PCL-NPs 
before and after exposure to the photo-trigger (Fig. 4.15B).  The mean zeta potential for both 
APP-H-NPs and APP-PCL-NPs significantly decreased following photoirradiation (16.2 
W∙sec/cm2; p < 0.05).  After photoirradiation, the mean zeta potentials were comparable between 
APP-H-NPs and APP-PCL-NPs (p > 0.05).  The production of negatively charged groups (e.g. 
COO
-
) at/near the surface of the NPs following photoirradiation plausibly accounts for the 
observed reduction in mean zeta potential, thereby supporting that the measurements of 
conductivity reflect the formation of the phenylacetic acid derivative.  Finally, additional 
evidence of the presence of the phenylacetic acid derivative following photoirradiation was 
elicited by measuring the pH of NP suspensions before and after photoirradiation.  Before 
photoirradiation the NP suspensions (APP-H and APP-PCL) had pH 7, which decreased to pH 6 
after photoirradiation (data not shown).  Taken together the measurements of conductivity, zeta 
potential, and pH suggest that the extent of chain scission induced by exposure to the photo-
trigger is comparable between APP-PCL-NPs and APP-H-NPs.  As such, the observed 
differences in the GPC chromatograms of APP-H-NPs and APP-PCL-NPs exposed to the photo-
trigger is not anticipated to be the result of an altered sensitivity to the photo-trigger.  Additional 
studies are warranted to evaluate if the morphological changes induced by photoirradiation are 
the same for both APP-H-NPs and APP-PCL-NPs (i.e. surface or bulk erosion). 
4.4.2.3. Photoresponsive DOX release from APP-PCL-NPs     
Photoresponsive DOX release from DOX-APP-PCL-NPs was evaluated using the 
photoirradiation parameters previously optimized during photoresponsive release studies utilizing 
DOX-APP-H-NPs (16.2 W∙sec/cm2/photoirradiation).  As was done for DOX-APP-H-NPs, the 
photoresponsive release studies evaluated the influence of the following photoirradiation and 
formulation parameters: (i) frequency of photoirradiation, (ii) timing at which photoirradiation 
was administered, and (iii) polymer concentration (Fig. 4.16).   
The frequency of photoirradiation and the timing of photoirradiation were evaluated 
using NPs prepared from the corresponding formulation to that used previously for the 
homopolymer (10 mg/mL APP-PCL; 0.25 mg/mL DOX).  Neither a single (1X) nor multiple 
(3X) photoirradiations produced a meaningful change in the rate or extent of DOX released from 
the DOX-APP-PCL-NPs (Fig. 4.16A).  At the 72 hr time-point, non-irradiated APP-PCL-NPs 
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released 54 ± 4% of entrapped DOX, which slightly increased (p > 0.05) when a single 
photoirradiation was administered (61 ± 6% released).  Three sequential (3X) photoirradiations 
increased the extent of DOX released at 72 hr (67 ± 2%), which was statically significant 
compared to non-irradiated NPs (p < 0.05).  The rate of DOX release, as assessed by the time to 
release 50% (T50%) was virtually unchanged by photoirradiation, with non-irradiated NPs 
achieving T50% at 61 hr, and 3X photoirradiated NPs achieving T50% at 60 hr.  Changing the 
timing at which a single photoirradiation was administered from 0 hr to 24 hr did not significantly 
alter DOX release, which remained comparable to non-irradiated NPs for both NPs exposed to 
the photo-trigger at 0 hr and NPs exposed at 24 hr (p > 0.05; data not shown).  Increasing the 
APP-PCL concentration to 20 mg/mL significantly reduced non-specific DOX release at time-
points beyond 24 hr compared to the 10 mg/mL NP formulation (p < 0.05).  DOX release 
following multiple (3X) exposures to the photo-trigger was only slightly higher than non-
irradiated NPs at time-points beyond 24 hr (Fig. 4.16B).  The rate of DOX released by multiple 
photoirradiations was increased by 30%, with the 3X photoirradiated NPs and non-irradiated NPs 
reaching T30% at 44 hr, and 62 hr, respectively.  At the 72 hr time-point, non-irradiated NPs 
released 32 ± 5% of entrapped DOX, while 3X photoirradiated NPs released 46 ± 5% (p = 
0.0267).  This 14% increase in the extent of DOX released after multiple (3X) exposures to the 
photo-trigger was statistically significant; however, such a mild elevation is not anticipated to 
translate into a difference in therapeutic outcomes.   
A follow up study was conducted in order to evaluate if a meaningful difference in DOX 
release could be achieved from DOX-APP-PCL-NPs by further increasing the polymer 
concentration and number of photoirradiation episodes.  For this study, NPs were prepared at the 
highest APP-PCL concentration assessed during the characterization of APP-PCL-NPs (30 
mg/mL).  The number of photoirradiation episodes was increased from three to five, (5X; 
administered at the 0, 24, 48, 72, and 96 hr time-points), and the duration of study was increased 
to 168 hr.  The DOX release profile for this formulation is shown in Figure 4.16C.  Neither the 
rate nor the extent of DOX released from this formulation was altered by the application of five 
(5X) sequential photoirradiations compared to non-irradiated NPs (p > 0.05; Fig. 4.16C).  The 
data from the release studies using DOX-APP-PCL-NPs demonstrated that the frequency of 
photoirradiation and the polymer concentration influenced the release of DOX from APP-PCL-
NPs.  These same parameters were previously identified as influential in DOX release from APP-
H-NPs.  Unlike APP-H-NPs, these parameters played minor roles in DOX release from APP-
PCL-NPs.   
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The trend obtained from the release studies can be understood in light of the results from 
the DOX loading studies.  The results from the DOX loading studies suggested that DOX in the 
surface/near-surface regions was released during NP purification, depleting DOX from this 
region.  As observed via TEM, photoirradiation disrupted the NPs surface regions, which would 
produce only a minor alteration in DOX release if the surface regions contained only a small 
quantity of DOX.  Any DOX released in response to the photo-trigger would easily be masked by 
the non-specific release of via hydration and/or hydrolytic degradation, which are established 
mechanisms of drug release from formulations containing PCL (Dash and Konkimalla, 2012; 
Kanungo et al., 2013; Shiny et al., 2013; Raval et al., 2014).   
The release mechanism was investigated by fitting the release data from the 20 mg/mL 
DOX-APP-PCL-NP formulation to the Korsmeyer-Peppas and Higuchi release models.  The 
release exponent obtained from the Korsmeyer-Peppas model was largely unchanged by exposure 
to the photo-trigger; with non-irradiated NPs having n = 0.89 (R
2
 = 0.9914) and photoirradiated 
NPs having n = 0.72 (R
2
 = 0.9971).  These release exponents indicate a multifaceted release 
mechanism, possible diffusion and degradation, for both non-irradiated and photoirradiated DOX-
APP-PCL-NPs.  This is supported by the poor correlation coefficients obtained from fitting the 
release data to the Higuchi release model (R
2
 = 0.9629 and 0.9692 for non-irradiated and 
photoirradiated NPs, respectively).  Taken together, the release models suggest that the photo-
trigger had only a minor influence on the mechanism of DOX release from DOX-APP-PCL-NPs.   
Overall, the trend from the DOX release studies utilizing DOX-APP-H-NPs and DOX-
APP-PCL-NPs indicated: (i) exposure to the photo-trigger altered the release of DOX from NPs 
prepared from both APP-H and APP-PCL without causing dose dumping; and (ii) NPs prepared 
from the APP homopolymer were superior to those prepared from the PCL copolymer for 
controlling the release of DOX through exposure to the photo-trigger.  On this basis, only APP-
H-NP formulations were selected for subsequent in vitro and in vivo studies of functional efficacy 
and cardiotoxicity. 
4.4.3. Functional efficacy assessment of DOX released from APP-H-NPs 
 The main goal of the cytotoxicity studies was to verify the functional efficacy of DOX 
was not adversely/undesirably affected by the NP preparation procedure or exposure to the photo-
trigger.  A lung cancer cell line (LLC) was selected for evaluating the functional efficacy of DOX 
on the grounds that lung cancer is responsible for more cancer-related deaths than any other type 
of cancer (Fitzmaurice et al., 2015).  Initial studies in LLC cells established that blank APP-H-
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NPs (0 mg/mL DOX) did not significantly reduce cellular viability compared to the untreated 
controls (p > 0.05; data not shown).  As shown in Fig. 4.17A, the cellular viabilities after 
incubation with DOX alone, DOX-APP-H-NPs, and photoirradiated DOX-APP-H-NPs were 
comparable at the various DOX concentrations studied (p > 0.05).  The data suggest that the 
neither NP preparation nor photoirradiation interfered with the functional efficacy of DOX.  The 
results from the cytotoxicity study were substantiated by the qualitative assessment of apoptosis 
by labeling apoptotic cells with TUNEL.  LLC cells treated with DOX alone, non-irradiated 
DOX-APP-H-NPs, and photoirradiated DOX-APP-H-NPs stained positive for TUNEL (Fig. 
4.17B).  A follow up study was conducted to evaluate the functional efficacy of DOX released by 
multiple photoirradiations.  This study utilized samples of the release medium collected during 
the in vitro DOX release study (20 mg/mL APP-H; 0.5 mg/mL DOX; 3X photoirradiations).  The 
24, 48, and 72 hr release samples were diluted with growth media and incubated with LLC cells 
for 24 hr.  Figure 4.18 shows the results from treating LLC cells with the release samples 
collected at the 24, 48, and 72 hr time-points.  LLC cells treated with samples collected at 24 and 
48 hr from both non-irradiated and photoirradiated NPs produced a comparable reduction in 
cellular viability (p > 0.05).  The 72 hr sample from photoirradiated NPs significantly reduced 
cellular viability compared to the 72 hr sample from non-irradiated NPs (p < 0.001).  This 
difference in cellular viability between samples collected at the 72 hr time-point is in good 
agreement with the results from the DOX release study (Fig. 4.11C).  The results indicated that 
DOX released from NPs subjected to multiple photoirradiations was capable of inhibiting the 
proliferation of LLC cells.  This may be due to the encapsulation of DOX within the NP matrix, 
which shields it during the photoirradiation process, as has been reported previously (Bandak et 
al., 1999).  Furthermore, the comparable cytotoxicity of the 24 and 48 hr samples collected from 
non-irradiated and photoirradiated NPs (i.e. after one and two photoirradiation episodes for the 24 
and 48 hr samples, respectively) provides additional evidence that APP-H-NPs do not undergo 
dose dumping following photoirradiation.   
4.4.4. In vivo cardiotoxicity 
Cardiotoxicity is a life-threatening, dose-limiting toxicity associated with the use of DOX 
as well as other anthracycline antineoplastic agents, and limits their clinical application (Buja et 
al., 1973; Simunek et al., 2009).  DOX encapsulation within nanocarriers has been previously 
reported to reduce DOX-induced cardiotoxicity through altering the biodistribution of DOX 
(Yuan et al., 2013).  Histological assessment of cardiac tissue was conducted by a blinded 
investigator (Fig. 4.19).  Cardiac tissue excised from mice treated with PBS (vehicle) showed 
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compact and neatly arranged myofibrils with normal arterioles (Fig. 4.19A).  Mice treated with 
DOX alone (Fig. 4.19B) exhibited necrotic regions, vacuolar degeneration, arteriole hyalinization 
and myofibrillar disarrangement; all of which are established histopathological indications of 
DOX-induced cardiotoxicity (Bozcali et al., 2012; Reagan et al., 2013; Segredo et al., 2013; 
Yuan et al., 2013).  DOX-APP-H-NPs did not produce obvious histopathological signs of toxicity 
(Fig. 4.19C-D) like that observed for DOX alone.  Both non-irradiated and photoirradiated DOX-
APP-H-NP groups exhibited similar histopathology.  The data demonstrated that mice treated 
with photoirradiated DOX-APP-H-NPs did not show signs of cardiotoxicity like that observed 
following treatment with free DOX. DOX-induced cardiotoxicity was also evaluated 
quantitatively based on the induction of apoptosis in cardiomyocytes, using DNA fragmentation 
as a marker of apoptosis.  Cardiac tissue was labeled with TUNEL in order to identify apoptotic 
cells, and the number of apoptotic cells (TUNEL positive) was expressed as a percentage of the 
total number of cells (Fig. 4.20).  Cardiac tissue from mice treated with DOX alone showed a 
significant increase in the percentage of apoptotic cells relative to PBS treated mice (p < 0.01).  
Mice treated with DOX-APP-H-NPs, both non-irradiated and photoirradiated, showed 
percentages of apoptotic cells that were comparable to that of PBS (p > 0.05).  These results 
substantiate the results from the histological assessment of DOX-induced cardiotoxicity.  The 
trend connotes that photoirradiation of DOX-APP-H-NPs most likely triggers the sequential 
release of entrapped DOX rather than a single release of the entire DOX payload (dose dumping), 
which would have resulted in extensive cardiotoxicity similar to that of free DOX.  
Finally, to preliminarily investigate whether the results from the histological assessment 
will be supported by serum levels of a biomarker of cardiotoxicity (Reagan et al., 2013), serum 
levels of cardiac troponin-I were measured.  The average level of cardiac troponin-I (1.25 ng/mL) 
for mice treated with photoirradiated DOX-APP-H-NPs was statistically comparable (p > 0.05) to 
that of mice treated with non-irradiated DOX-APP-H-NPs.  Furthermore, mice in both 
photoirradiated and non-irradiated DOX-APP-H-NPs groups showed serum levels of cardiac 
troponin-I that were significantly less than DOX alone (p < 0.05).  A measurement in the DOX 
alone group was identified as an outlier using the Grubb’s extreme studentized deviate (ESD) 
method.  Taken together, the data from the cardiotoxicity studies connotes that (a) entrapment of 
DOX in APP-H-NPs was capable of curtailing the risk of DOX-induced cardiotoxicity;  while (b) 
exposure of DOX-APP-H-NPs to the photo-trigger did not lead to DOX dose dumping (one-time 
release of the entire DOX payload) which could lead to undesirable DOX-related cardiotoxicity.  
To further delineate the extent of cardiotoxicity induced by the various treatments, additional 
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studies will be warranted that will involve quantitative analysis of serum biomarkers at various 
time-points during the course of the entire study. 
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4.5. Conclusions 
This work demonstrated that APP is a viable platform for photoresponsive drug delivery 
applications.   Exposure of APP-NPs or DOX-APP-NPs to the photo-trigger effectively disrupts 
the NP matrix; this disruption was more pronounced at the surface/boundary regions than in the 
NP core.  The release of DOX from APP-NPs was most heavily influenced by the frequency of 
photoirradiation, the polymer concentration, and the polymer composition (homopolymer or PCL 
copolymer).  The effect of the polymer concentration on photoresponsive DOX release is 
believed to be propagated though its influence on particle size.  DOX release from NPs prepared 
from the APP homopolymer was more readily altered by exposure to the photo-trigger than NPs 
prepared from the PCL copolymer.  Furthermore, DOX-APP-NPs did not undergo DOX dose 
dumping following photoirradiation as supported by the following observations: (a) the need for 
repeated photoirradiations to achieve sequential release of entrapped DOX; and (b) the reduction 
in DOX-induced cardiotoxicity in mice treated with photoirradiated DOX-APP-H-NPs when 
compared to free DOX.  It is envisioned that potential areas of application of APP-NPs as 
photoresponsive delivery systems could be in superficial anatomical locations such as topical and 
ophthalmic drug delivery.  Photoresponsive delivery to deep-seated tissues could be achieved by 
delivering the photoactivating light via intubation or fiber optics. 
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Table 4.1:  
 
APP-H Concentration 
DOX 
Concentration 
Surfactant 
Concentration 
 
Mean PDI ± SD 
10 mg/mL 0 mg/mL 1% w/v 0.23 ± 0.02 
10 mg/mL 0 mg/mL 3% w/v 0.18 ± 0.09 
10 mg/mL 0 mg/mL 5% w/v 0.17 ± 0.06 
10 mg/mL 0.25 mg/mL 1% w/v 0.26 ± 0.01 
20 mg/mL 0.5 mg/mL 1% w/v 0.29 ± 0.03 
40 mg/mL 0.5 mg/mL 1% w/v 0.22 ± 0.01 
 
Table 4.1: Polydispersity index values of APP-H-NP formulations: All APP-H-NP 
formulations studied had unimodal size distribution and low polydispersity index (PDI) values.  
PDI values were obtained during DLS measurements of particle size.  The PDI values support the 
particle size distribution analysis, and connote the formation of a single population of particles.  
PDI values are presented as the mean ± SD (n = 3-6 separate formulations).    
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Table 4.2:  
Sample Transition 
Type 
Temperature 
of Transition 
Corresponds To: 
Blank APP-H-NPs  
(10 mg/mL APP-H; 0 mg/mL 
DOX) 
Endothermic 40-65ᵒC APP-H glass 
transition 
DOX-APP-H-NPs 
(10 mg/mL APP-H; 0.5 mg/mL 
DOX) 
Endothermic 40-65ᵒC APP-H glass 
transition 
 
Physical Mixture 
(DOX Alone + Blank APP-H-
NPs) 
Endothermic 219ᵒC DOX melting 
Endothermic 40-65ᵒC APP-H glass 
transition 
 
Table 4.2: DSC transitions of APP-H-NPs and DOX-APP-H-NPs: DSC analysis connoted 
entrapment of amorphous DOX in APP-H-NPs.  DSC analysis was carried out using a diamond 
differential scanning calorimeter (Perkin Elmer; Chicago, IL), operated under nitrogen gas at a 
heating rate of 10ᵒC/min. Thermal transitions observed during DSC analysis of lyophilized 
samples of blank APP-H-NPs (no DOX), DOX-APP-H-NPs, and a physical mixture of DOX 
alone and blank APP-H-NPs.  The thermal transition occurring over 40-65ᵒC is believed to 
correspond to the glass transition of APP-H, as previously reported (Sun et al., 2012).  The 
thermal transition occurring at 219ᵒC corresponds to the previously reported melting point of 
DOX (Missirlis et al., 2006).  The absence of the DOX melting transition from the DOX-APP-H-
NPs connotes that amorphous DOX was entrapped within the NP’s matrix.  
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Figure 4.1:  
 
Fig. 4.1: Chemical structure of APP and the products of chain scission: Structure of the APP 
homopolymer and products of photo-induced chain scission.  (A) Chemical structure of APP 
homopolymer (APP-H).  Photoactivation of the alkoxyphenacyl chromophore induces chain 
scission of the polymer, producing the acetophenone derivative (B), and/or the phenylacetic acid 
derivative (C).    
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Figure 4.2: 
 
Fig. 4.2: Spectroscopic analysis of the chosen surfactant Pluronic F-127 ®: The chosen 
surfactant did not absorb light at the wavelengths required for photoactivation of APP.  
Spectrophotometric analysis of the absorbance of the chosen surfactant (Pluronic F-127 ®) was 
performed with water as the reference. The boxed region indicates the wavelengths of light 
required for photoactivation of APP (280-320 nm). The chosen surfactant (Pluronic F-127 ®) did 
not absorb light at the wavelengths required for photoactivation of APP, suggesting that the 
surfactant coating does not impede the process of photo-induced chain scission. 
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Figure 4.3: 
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Fig. 4.3: Characterization of APP-H-NPs and DOX-APP-H-NPs: The size of NPs prepared 
from the homopolymer was dictated by the polymer concentration and DOX loading. (A) Size 
and zeta potential of APP-NPs prepared at varying surfactant concentrations (Pluronic F-127 ®).  
(B) Size of DOX-APP-NPs prepared with various concentrations of APP polymers (10-40 
mg/mL; 0.5 mg/mL DOX).  (C) Effect of DOX concentration on the size and zeta potential of 
DOX-APP-NPs (10 mg/mL APP; 0-0.5 mg/mL DOX).  Each data-point is plotted as the mean ± 
SD (n = 3 separate formulations).   
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Figure 4.4: 
 
Fig. 4.4: Representative particle size distribution of APP-H-NPs: The particle size distribution 
from APP-H-NPs showed the formation of a single particle population.  Particle size distributions 
were obtained via DLS.   
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Figure 4.5: 
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Fig. 4.5: Characterization of DOX-loading in APP-H-NPs: DOX loading into APP-H-NPs 
occurred with high efficiency.  (A) Effect of varying APP-H concentration on DOX entrapment 
efficiency and drug loading.  (B) Effect of varying DOX concentration on entrapment efficiency 
and drug loading for DOX-APP-H-NPs prepared at APP-H concentration of 10 mg/mL.  (C) 
Effect of varying APP-H concentration on particle size stability (30 min, 23ᵒC) in various 
biologically relevant media (water, PBS and 10% FBS in PBS).  # denotes p > 0.05.  Each data-
point is plotted as the mean ± SD (n = 3 separate formulations).    
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Figure 4.6:  
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Fig. 4.6: GPC analysis of DOX entrapment: NP entrapment of DOX was confirmed by the 
GPC.  GPC elution profile of (A) DOX-APP-H-NPs and (B) DOX alone (unentrapped) from a 
Sephadex G-75 column (25 x 60 mm), with 0.22 µm filtered water as the mobile phase (1 
mL/fraction).  (A) Elution profile of DOX-APP-H-NPs (10 mg/mL APP-H; 0.5 mg/mL DOX).  
The intensity (INT; count rate in units of kCPS), measured using a Zetasizer Nano-ZS-90 
(Malvern Instruments; Worestershire, United Kingdom), indicates the presence of NPs.  The 
DOX concentration was determined via florescence spectroscopy (excitation 470 nm; emission 
585 nm).  Co-elution of DOX and NPs in the same fraction (#6) is indicative of DOX entrapment.  
(B) The elution of free DOX (unentrapped) was significantly retarded by Sephadex G-75, eluting 
in fractions #14-16.  
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Figure 4.7:  
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Fig. 4.7: Size stability of DOX-APP-H-NPs over 14 days: DOX-APP-H-NPs were stable in 
water or PBS.  Size stability was retained for the entire duration of study (14 days) for DOX-
APP-H-NPs incubated in water and PBS (p > 0.05).   
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Figure 4.8:  
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Fig. 4.8: Determination of the minimum photonic dose required to alter DOX release from 
DOX-APP-H-NPs: The minimum dose of light required for photoresponsive DOX release from 
DOX-APP-H-NPs was determined to be 16.2 W∙sec/cm2.  DOX-APP-H-NPs (10 mg/mL APP-H 
and 0.5 mg/mL DOX) were photoirradiated immediately after preparation.  The dose of light was 
calculated from the intensity and duration of photoirradiation (0-20 min).  Data-points are shown 
as the mean ± SD (n = 3). * indicates p < 0.05, P values are shown as compared to 0 W·sec/cm
2
 
(i.e. non-irradiated NPs). 
 
 
 
 
 
 
95 
 
Figure 4.9:  
 
Fig. 4.9: Assessment of the effects of photoirradiation on the morphology of APP-H-NPs 
and DOX-APP-H-NPs: Photoirradiation of APP-H-NPs disrupted the surface while leaving the 
core intact.  Representative TEM images of APP-H-NPs and DOX-APP-H-NPs before and after 
photoirradiation.  Photoirradiation disrupted the surface regions of the NPs without visibly 
altering the core.  (A) Blank APP-H-NPs (10 mg/mL APP-H), and (B) DOX-APP-H-NPs (10 
mg/mL APP-H; 0.25 mg/mL DOX) before photoirradiation. (C) Blank APP-H-NPs after 
photoirradiation (photonic dose of 16.2 W∙sec/cm2).  (D) DOX-APP-H-NPs after photoirradiation 
(photonic dose of 32.4 W∙sec/cm2).  Scale bar = 100 nm. 
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Figure 4.10:  
 
Fig. 4.10: Characterization of chain scission in APP-H-NPs exposed to the photo-trigger: 
Photoirradiation of APP-H-NPs caused chain scission of APP-H into oligomers, indicating that 
APP-H-NPs responded to the photo-trigger.  (A-B) GPC elution profile showing the molecular 
weight of APP-H before (A); and after (B) photoirradiation of APP-NPs (10 mg/mL APP; 0 
mg/mL DOX) using a photonic dose of 16.2 W∙sec/cm2.  Arrow indicates peak corresponding to a 
2,500 Da molecule produced by photoactivated chain scission.  (C) Size of APP-NPs (10 mg/mL 
APP) following photoirradiation with different photonic doses.  Each data-point is plotted as the 
mean ± SD (n = 3).   
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Figure 4.11: 
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Fig. 4.11: Photoresponsive release of DOX from DOX-APP-H-NPs: DOX release from DOX-
APP-H-NPs was heavily influenced by the polymer concentration and frequency of 
photoirradiation.  (A) Release of DOX from DOX-APP-H-NPs (10 mg/mL APP-H; 0.25 mg/mL 
DOX) following a single photoirradiation administered at the 0 or 24 hr time-point.  (B) Effect of 
the frequency of photoirradiation on DOX release from DOX-APP-H-NPs (10 mg/mL APP-H; 
0.25 mg DOX).  NPs were photoirradiated sequentially at 24 hr intervals (0, 24, and 48 hr time-
points).  (C) DOX release from NPs prepared at 20 mg/mL APP-H (0.5 mg/mL DOX).  
Photoirradiated NPs were exposed multiple sequential (3X) photoirradiations (0, 24 and 48 hr 
time-points).  Each data-point is presented as the mean ± SD (n = 3).  Photonic dose of 16.2 
W∙sec/cm2/photoirradiation. 
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Figure 4.12:  
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Fig. 4.12: Characterization of APP-PCL-NPs and DOX-APP-PCL-NPs: Compared to APP-
H-NPs, NPs prepared from APP-PCL had smaller mean sizes and lower DOX loading. (A) Effect 
of varying the surfactant concentration on the mean size and zeta potential of the resultant NPs 
(10 mg/mL APP-PCL; 0 mg/mL DOX).  Neither the mean size nor mean zeta potential was 
significantly affected by changing the surfactant concentration (1-5% w/v; p > 0.05). (B) Effect of 
increasing the polymer concentration on the mean particle size.  (C) Comparison of drug loading 
into APP-H and APP-PCL formulations prepared using 10 mg/mL and 20 mg/mL of polymer.  
(D) Size stability of DOX-APP-PCL-NPs in water and PBS over 14 days.  * indicates statistical 
significance (p < 0.05), *** indicates p < 0.001.  Data-points are plotted as the mean ± SD (n = 
3).   
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Figure 4.13: 
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Fig. 4.13: Evaluation of the surfactant concentration on the stability of APP-NPs incubated 
in 10% FBS: Increasing the surfactant concentration did not enhance the stability of APP-NPs 
incubated in 10% FBS.  Size stability of (A) APP-H-NPs and (B) APP-PCL-NPs prepared using 
different concentrations of surfactant (1-5% w/v Pluronic F-127®) when stored in 10% FBS (10 
mg/mL polymer; 0 mg/mL DOX).  Increasing the surfactant concentration did not change the day 
on which the NP formulations destabilized.  All APP-H and APP-PCL formulations significantly 
increased in mean size on day 3 at all surfactant concentration studied (p < 0.05).  Data-points are 
plotted as the mean ± SD (n = 3). 
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Figure 4.14:  
 
Fig. 4.14: Characterization of chain scission in APP-PCL-NPs exposed to the photo-trigger: 
Exposing APP-PCL-NPs to the photo-trigger caused oligomer generation, indicating that APP-
PCL-NPs were responsive to the photo-trigger.  GPC elution profile showing the molecular 
weight of APP-PCL before (A); and after (B) photoirradiation of APP-PCL-NPs (10 mg/mL 
APP-PCL; 0 mg/mL DOX) using a photonic dose of 16.2 W∙sec/cm2.  Photoirradiation shifts the 
peak to longer retention times (smaller molecular weight) without producing any identifiable new 
peaks.     
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Figure 4.15:  
P h o to n ic  D o s e  (W s e c /c m
2
)
C
o
n
d
u
c
ti
v
it
y
 (
m
S
/c
m
)
0 1 6 .2 3 2 .4
0 .0 0
0 .0 1
0 .0 2
0 .0 3
A P P -H -N P s
A P P -P C L -N P s
P h o to n ic  D o s e  (W s e c /c m
2
)
Z
e
ta
 P
o
te
n
ti
a
l 
(m
V
)
0 1 6 .2
0
5
1 0
1 5
2 0
A P P -H -N P s A P P -P C L -N P s
*
A
B
 
Fig. 4.15: Comparison of the effects of photoirradiation between APP-H-NPs and APP-
PCL-NPs:  Photoirradiation produced comparable effects in both APP-H-NPs and APP-PCL-
NPs.  (A) Conductivity of NP suspensions after photoirradiation with varying photonic doses.  
Photoirradiation (photonic dose of 16.2 W∙sec/cm2 or 32.4 W∙sec/cm2) significantly increased the 
conductivity of both NP formulations (p < 0.001), connoting the production of the phenylacetic 
acid derivative (pKa 3.5) via chain scission.  NPs prepared from APP-H and APP-PCL were 
comparable at all photonic doses studied (p > 0.05). (B) Mean zeta potential of APP-H-NPs and 
APP-PCL-NPs before and after exposure to the photo-trigger.  The mean zeta potential was 
significantly reduced for both NP formulations following photoirradiation (p < 0.05), and the 
extent of this reduction was comparable between NP formulations (p > 0.05).  Data-points are 
presented as the mean ± SD (n  = 3).   * indicates p < 0.05. 
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Figure 4.16:  
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Fig. 4.16: Release of DOX from DOX-APP-PCL-NPs exposed to the photo-trigger: Exposing 
DOX-APP-PCL-NPs to the photo-trigger had a modest effect on the release of DOX.  (A) Effect 
of varying the frequency of photoirradiation on photoresponsive DOX release (10 mg/mL APP-
PCL; 0.25 mg/mL DOX). (B) DOX released from NPs prepared at a 2-fold higher polymer 
concentration (20 mg/mL APP-PCL; 0.5 mg/mL DOX).  (C) DOX released from NPs prepared 
using 30 mg/mL APP-PCL (0.5 mg/mL DOX).  Data-points are plotted as the mean ± SD (n = 3).     
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Figure 4.17:  
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Fig. 4.17: In vitro assessment of the functional efficacy of DOX released from DOX-APP-H-
NPs after photoirradiation: Neither the NP preparation procedure nor photoirradiation 
negatively impact the functional efficacy of DOX.  (A) Cytotoxicity of DOX solution and DOX-
APP-H-NPs (10 mg/mL APP-H; 0.25 mg/mL DOX) after incubation (37
o
C; 24 hr) with LLC 
cells.  DOX-APP-H-NPs were incubated with cells after 1X photoirradiation (photonic dose of 
16.2 W∙sec/cm2).  Each data-point is plotted as the mean ± SD (n = 6). (B) Representative images 
from the qualitative apoptosis assessment substantiating the results from the cytotoxicity study.  
DAPI was pseudo-colored blue and TUNEL was pseudo-colored red.   
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Figure 4.18:   
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Fig. 4.18: Functional efficacy of DOX released from DOX-APP-H-NPs after multiple 
photoirradiations: DOX released following multiple (three) sequential photoirradiations of 
DOX-APP-H-NPs retained its functional efficacy.  Samples collected at the 24, 48, and 72 hr 
time-points from non-irradiated and 3X photoirradiated NPs (20 mg/mL APP-H; 0.5 mg/mL 
DOX).  Cellular viability was comparable following treatment with the 24 and 48 hr DOX release 
samples.  Treatment with the 72 hr release sample collected from the 3X photoirradiated NPs 
significantly reduced cellular viability compared to 72 hr non-irradiated NPs sample (p < 0.01).   
*** indicates p < 0.01.  Data-points are plotted as a percentage of the untreated controls (mean ± 
SD; n = 6). 
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Figure 4.19: 
 
 
 
 
 
 
 
 
 
Fig. 4.19: Histological assessment of DOX-induced cardiotoxicity: NP entrapment of DOX 
curtailed cardiotoxicity compared to treatment with free DOX.  Representative images of H&E 
stained cardiac tissues excised from BALB/c mice treated with:  (A) PBS (vehicle), (B) DOX 
alone, (C) non-irradiated DOX-APP-NPs (10 mg/mL APP; 0.5 mg/mL DOX); and (D) 3X 
photoirradiated DOX-APP-NPs (10 mg/mL APP; 0.5 mg/mL DOX).  Photoirradiations were 
performed sequentially every 2 hr using a photonic dose of 16.2 W∙sec/cm2/photoirradiation.  
DOX was dosed twice at the dose of 5 mg/kg per treatment.  Arrows indicate regions of vacuolar 
degeneration, myofibrillar necrosis, hyalinization of arterioles or myofibrillar disarrangement.   
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Figure 4.20:    
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Fig. 4.20: Quantitative assessment of cardiotoxicity via TUNEL staining of cardiac tissue: 
DOX-induced cardiotoxicity was mitigated by NP entrapment, and photoirradiation did not alter 
this trend suggesting that photoirradiation does not induce dose dumping.  (A) Quantification of 
DOX-induced cardiotoxicity through TUNEL staining of cardiac tissue excised from BALB/c 
mice.  DOX-APP-H-NPs (non-irradiated and photoirradiated) were prepared using 10 mg/mL 
APP-H and 0.5 mg/mL DOX.  Photoirradiated NPs received three (3X) sequential 
photoirradiations, administered every 2 hr using a photonic dose of 16.2 
W∙sec/cm2/photoirradiation.  Data-points are plotted as the percentage of apoptotic (TUNEL 
positive) cells (mean ± SD; n = 4 images).  *** indicates p < 0.01, # indicates p > 0.05.  (B) 
Representative images of cardiac tissue stained with TUNEL and DAPI.  (i) PBS, (ii) DOX alone, 
(iii) Non-irradiated NPs, and (iv) photoirradiated NPs.      
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Chapter 5 
Assessment of Photon Upconversion for Controlling Drug Release from APP-NPs with 
Near-Infrared Light 
5.1. Abstract 
 The objective of this portion of the project was the design and development of APP-NPs 
that could respond to NIR light.  Photon upconversion was incorporated into APP-NPs for the in 
situ generation of the UV light (photo-trigger) from NIR light.   Using a solvothermal method, 
upconverting nanocrystals (UCNCs) were synthesized and optimized for emissions in the UV 
region by varying the concentration of the dopants (Yb
3+
 and Tm
3+
) and the particle architecture 
(core and core-shell).  UCNC-loaded APP-NPs (UCNC-NPs) were prepared from the APP 
homopolymer and characterized.  The effect of photoirradiation with NIR light (980 nm) on DOX 
release was evaluated in vitro and in an ex vivo mock tissue model.  The most intense UV 
emissions were observed from the core@active shell@inert shell UCNC formulation.  Increasing 
the UCNC concentration (0.5-5 mg/mL) increased the mean size of the resultant NPs (153-393 
nm), and the morphology of the UCNC-NPs more closely resembled that of the parent UCNCs 
than NPs prepared without UCNCs.  In vitro biocompatibility studies determined UCNC-NPs to 
be comparable to PLGA-NPs on the basis of: cytotoxicity, macrophage activation, and RBC lysis.  
DOX release was not significantly altered following exposure to NIR light (p > 0.05).  The 
inclusion of UCNCs did not alter the biodistribution of APP-H-NPs in tumor-bearing athymic 
mice.  Overall, the results indicated that the UCNCs functioned as NIR-to-UV photo-transducers; 
however, the inclusion of UCNCs in NPs formulation was not sufficient for drug release to be 
controlled with NIR light.  This is plausibly the result of insufficient generation of APP photo-
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trigger due to: (i) insufficient quantity of entrapped UCNCs; and/or (ii) minimal overlap between 
the wavelengths of light emitted from the UCNCs and APP’s photo-trigger.   
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5.2. Introduction 
The utility of light for therapeutic applications was recognized centuries before the light 
bulb was invented.  While modern phototherapy utilizes artificial light sources rather than the 
sun, the attractive attributes of light in medical applications remain the same.  Light is 
inexpensive, clean, noninvasive, and can be precisely controlled through manipulation of one or 
more of its inherent properties (wavelength, intensity, polarity).  One of the most recent adaptions 
of light for medical applications is its use to control drug release from light-responsive delivery 
systems.  Such delivery systems, termed photoresponsive, belong to the rapidly evolving class of 
stimuli-responsive delivery systems which seek to impart spatial and temporal control over drug 
release by releasing drug in response to a specific stimulus or “trigger.”  In the case of 
photoresponsive systems, light of a specific wavelength(s) is used to trigger the release of drug 
through isomer switching, photo-degradation, or photo-cleavage (Fomina et al., 2011; Yuan et 
al., 2012; Fedoryshin et al., 2014) .       
To date, the majority of photoresponsive delivery systems rely on ultraviolet (UV) light 
to trigger activation (i.e. drug release).  While these systems have shown great potential due to 
their exquisite sensitivity and reliable activation their clinical relevance has been stifled by the 
use of UV light as the photo-trigger.  Biological tissues are readily damaged by UV light, and 
light in this region is almost completely attenuated by the epidermis (Sowa et al., 2013).  This 
limits the scope of photoresponsive delivery systems that rely on UV light to superficial 
applications.  By contrast, near-infrared (NIR) light is capable of significant tissue penetration 
without causing damage to the tissue (Yang et al., 2015).  This has prompted extensive efforts in 
the development of NIR-responsive systems.  To date, NIR-responsive systems have not become 
a viable alternative to UV-responsive systems due to low sensitivity, unreliable activation, and 
the requirement of prolonged photoirradiation with high powered femtosecond pulsed lasers for 
activation.  These limitations are inherent to NIR-responsive chromophores due to the multi-
photon mechanism required for activation.  Various strategies to alleviate these limitations have 
been explored including the extension of π-bond conjugated systems, the inclusion of transition 
metal ions, and the utilization of a series of molecular rearrangements to exacerbate the effects of 
the activation of a single NIR-responsive chromophore (Pawlicki et al., 2009; Fomina et al., 
2010; Qian and Wang, 2010; Fomina et al., 2011; de Gracia Lux et al., 2012).  These efforts have 
achieved only modest success and the utility of NIR-responsive delivery systems still suffers 
from the need for prolong photoirradiations with high powered lasers (Fomina et al., 2010) .  
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Recently, the process of photon upconversion has been explored as an alternative to NIR-
responsive chromophores (Liu et al., 2013; Fedoryshin et al., 2014; Michael Dcona et al., 2015).  
These systems capitalize on the exquisite sensitivity and reproducibility of UV-responsive 
chromophores while retaining the benefits of activation with NIR light by generating the UV 
photo-trigger in situ from NIR light via photon upconversion.  Photon upconversion is the process 
in which multiple photons of low energy light are absorbed and then emitted as a single high 
energy photon (anti-Stokes emission) (Auzel, 2004).  This unique phenomenon can be achieved 
by incorporating trivalent lanthanides into nano-scale host crystals, producing upconverting 
nanocrystals (UCNCs).  Lanthanides are rare earth elements with atomic numbers between 57 and 
71.  The utility of lanthanides in photon upconversion is due to their unique electron 
configurations.  The valance electrons of lanthanides occupy the 4f orbitals, and are well shielded 
by electrons in the 5s, 5p, and 6s orbitals.  Lanthanides are well tolerated and are currently used 
in a variety of medical applications (Fricker, 2006).  Gadolinium (Gd) is a widely used MRI 
contrast agent, with at least seven different formulations currently in clinical use.  Neodymium 
(Nd) is a fundamental component of modern MRI machines, and is also used in transcranial 
magnetic stimulation therapy (Leuchter et al., 2015).      
Unlike NIR-responsive chromophores which require the simultaneous absorption of two 
or more photons of light for activation, UCNCs can harvest energy from multiple NIR photons 
absorbed simultaneously or sequentially.  As a result, photon upconversion is a far more efficient 
means of harvesting the energy of NIR light, and can do so without powerful and expensive 
pulsed lasers.  Furthermore, the emission spectrum can be tuned by careful selection of the 
composition and concentration of the trivalent lanthanides.  These characteristics impart several 
significant advantages to the use of UCNCs as NIR-to-UV photo-transducers, namely: (i) 
applicable to a wide range of chromophores; (ii) enables multimodal treatment strategies such as 
coupling drug delivery with photo-thermal ablation, radiosensitization, or photodynamic therapy 
(Xiao et al., 2013; Xing et al., 2013; Wang et al., 2014); and (iii) readily amendable to 
theranostic applications (diagnostics and therapy in a single vehicle) through the use of the 
lanthanide ions as MRI, X-ray, or CT contrast agents or through the simultaneous emission of 
visible/NIR light (Chen et al., 2012; Hou et al., 2012; Li et al., 2013; Xing et al., 2013).  These 
theranostic applications could be used to non-invasively monitor biodistribution in real-time, 
enabling the dose to be tailored to the individual patient (Wang et al., 2011b).  Furthermore, the 
biocompatibility of UCNCs is well reported (Shan et al., 2008; Zhang et al., 2008; Zhou et al., 
2011; Cui et al., 2012; Jayakumar et al., 2012; Das et al., 2014) .      
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The merits of the alkoxyphenacyl-based polycarbonates (APP) in photoresponsive drug 
delivery applications have already been described (Chapters 3-4).  APP’s UV photo-trigger (250-
320 nm) has genotoxic and cytotoxic effects, and restricts the scope of potential clinical 
applications of APP to superficial tissues.  In this chapter, we sought to enhance the safety and 
potential utility of APP in photoresponsive delivery applications without compromising the 
reliability of its single photon activation mechanism.  In pursuit of this, we sought to employ 
UCNCs for the in situ generation of the photo-trigger from clinically relevant NIR light.  The 
ability to control drug release with NIR light could extend the scope of APP’s utility as a 
photoresponsive delivery platform beyond superficial applications.  Furthermore, we envisioned 
that this approach could enhance safety by: (i) allowing drug release to be controlled with 
biologically benign NIR light (for superficial or deep-tissue applications); (ii) minimizing the 
exposure of tissues to UV light; and (iii) confining the UV light to within the APP polymeric 
matrix.  This approach is supported by a recent publication which determined that the UV light 
emitted from UCNCs did not alter cellular viability, inhibit proliferation, or induce DNA damage 
(Jayakumar et al., 2012).  To determine the efficacy of this approach, UCNCs were first 
optimized for emission in the UV region by doping with varying quantities of Yb
3+ 
and Tm
3+
 and 
employing different architectures (core-only and core-shell).  The optimized UCNCs were then 
used to prepare UCNC-loaded nanoparticles (UCNC-NPs) from the APP homopolymer (APP-H).  
The resultant UCNC-NPs were characterized and their biocompatibility assessed in vitro.  
Doxorubicin (DOX) was employed as a model drug, and the effect of NIR irradiation (980 nm) 
on the functional efficacy and release of DOX from the NPs was assessed.  Finally, 
biodistribution/tumor accumulation was studied in a xenograft model of non-small cell lung 
cancer.  This work reports for the first time the development and assessment of an APP-based 
delivery system in which photon upconversion was employed as a photo-transducer for 
controlling drug release with NIR light.     
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5.3. Materials and methods 
5.3.1. Materials 
YCl3, YbCl3, and TmCl3 were obtained from Sigma Aldrich (St. Louis, MO), along with 
India Ink, Intra-Lipid-20%, NaOH, ethanol, NH4F, Dulbecco’s modified eagles medium 
(DMEM), triethylamine (TEA), dansylcadaverine, coumarin-6, 4’, 6-diamidino-2-phenylindole 
dihydrochloride (DAPI), and 1-octadecene.  Dimethyl sulfoxide (DMSO), oleic acid, Pluronic F-
127 ®, penicillin/streptomycin, phosphate buffered saline (PBS), agarose, NaCl, and regenerated 
cellulose dialysis tubing (MWCO 3,500 Da) were obtained from Fisher Scientific (Pittsburg, PA).  
Doxorubicin was acquired from LC Labs (Waburn, MA), and Atlanta Biologicals (Lawrenceville, 
GA) provided the fetal bovine serum (FBS).  AlamarBlue ® dye was obtained from Life 
Technologies (Grand Island, NY).  Poly (lactic-co-glycolic acid) (PLGA) was obtained from 
Boehringer Ingelheim (Ingelheim, Germany).        
5.3.2. Synthesis of UCNCs 
Upconverting nanocrystals (UCNCs) were synthesized by adaptation of a solvothermal 
method described previously (Li and Zhang, 2008).  UCNC formulations were prepared with 
different quantities of Yb
3+ 
(30-50 mol%) and Tm
3+
 (0.15-0.6 mol%) and utilizing different 
architectures (core-only and core-shell).  Briefly, to prepare NaYF4 (30% Yb
3+
/0.3% Tm
3+
) YCl3 
(0.272 g), YbCl3 (0.16 g), and TmCl3 (0.0016 g) were added to a 200 mL flask and solubilized in 
a mixture of 15-30 mL octadecene and 3-12 mL oleic acid at 160ᵒC for 30 min. After cooling to 
room temperature 20 mL of methanol containing NH4F (0.296 g) and NaOH (0.2 g) was added to 
the mixture, and allowed to react for 30 min.  Methanol was removed from the solution by 
heating to 70ᵒC.  The solution was then heated to 110ᵒC, degassed for 10 min, and purged with 
argon.  The solution was then degassed and purged with argon a second time before heating to 
300ᵒC for 90 min under an argon atmosphere.  After allowing the reaction mixture to cool to 
room temperature, the UCNCs were precipitated with ethanol, and collected by centrifugation 
(3,000 x g for 10 min).  The pelleted UCNCs were subsequently resuspended and washed three 
times with ethanol before being dried under vacuum for 3 days.  For the core@active shell@inert 
shell formulation, the core UCNCs were washed with ethanol as described, and resuspended in 
cyclohexane (15-20 mL) for subsequent shell growth.   
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5.3.3. Growth of NaYbF4 and NaYF4 shells on pre-formed UCNC cores 
Epitaxial shell growth on pre-formed core UCNCs was achieved following the procedure 
outlined previously (Chen et al., 2012).  The active shell (NaYbF4) was formed by adding 0.38 g 
YbCl3 to a 200 mL flask and solubilized in 30 mL octadecene and 12 mL oleic acid at 160ᵒC (30 
min).  After cooling to room temperature, the UCNC cores (suspended in cyclohexane) were 
slowly added to the octadecene/oleic acid solution under constant stirring.  The solution was 
stirred at room temperature for 30 min before the cyclohexane was evaporated by heating to 
85ᵒC.  After allowing the solution to naturally cool to room temperature, 20 mL of methanol 
containing NH4F (0.296 g) and NaOH (0.2 g) was added to the mixture and allowed to react for 
30 min.  Methanol was then evaporated by heating to 70ᵒC.  Afterwards, the solution was heated 
to 110ᵒC, degassed for 10 min, and purged with argon.  A second cycle of degassing and purging 
with argon was performed before heating to 300ᵒC for 90 min under an argon atmosphere.  After 
allowing the reaction mixture to cool to room temperature, the UCNCs were precipitated with 
ethanol and collected by centrifugation (3,000 x g for 10 min).  The pelleted UCNCs were 
subsequently resuspended and washed three times with ethanol.  The inert shell (NaYF4) was 
added using the same procedure, with YCl3 (0.55 g) being used in place of YbCl3.   
5.3.4. Characterization of UCNCs  
5.3.4.1. Size, morphology, and emission spectrum of UCNCs 
The size and morphology of the UCNCs were characterized by transmission electron 
microscopy (TEM) using a Tecnai G2 F20 microscope operated at 200 kV.  UCNCs were 
suspended in cyclohexane before 3 µL was deposited onto a copper-coated TEM grid and 
allowed to dry overnight.     
Emission spectra were obtained from dried UCNC powder using a USB-4000 
spectrometer coupled to a UV-VIS optical fiber (Ocean Optics; Dunedin, FL).  The optical fiber 
was positioned to collect light at a 90ᵒ angle relative to the incident 980 nm excitation light (10 
W/cm
2
).  The raw data was recorded using Spectra Suite software platform (Ocean Optics; 
Dunedin, FL).  Raw spectral data was smoothed by application of a Savitzky-Golay algorithm 
(Savitzky and Golay, 1964).  Qualitative assessment of emissions in the UV region was 
conducted by irradiating solutions of UCNCs (2.5 mg/mL) containing the fluorescent probe 
dansylcadaverine (0.1 mg/mL) with the 980 nm laser (10 W/cm
2
).   
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5.3.4.2. Trivalent lanthanide composition of UCNCs 
The incorporation of the trivalent lanthanide dopants was confirmed via inductively 
coupled plasma optical emission spectroscopy (ICP-OES).  Standard solutions of Yb, Tm, and Ga 
were obtained from High-Purity Standards (Charleston, SC).  Briefly, 10 mg of dried UCNC 
powder was weighed out and transferred into a Teflon-coated vial.  Nitric acid (0.5 mL, 40% v/v) 
was then added followed by spiking with gallium as an internal standard.  The vials were placed 
on a hot plate set at 60ᵒC and allowed to digest for 24 hr.  After cooling to room temperature, 4.5 
mL of water was added to each vial, and the solution was passed through a syringe filter (0.45 µm 
pore diameter).  Samples and standards were analyzed in triplicate using an Optima 8000 ICP-
OES system (Perkin Elmer, Chicago, IL).   
5.3.5. Preparation of UCNC-loaded APP nanoparticles 
5.3.5.1. Polymer synthesis 
 The APP homopolymer (APP-H) was synthesized using the condensation polymerization 
method previously reported (Sun et al., 2012).  Briefly, diol monomers were prepared by chain 
extension of hydroxyacetophenone.  The product was converted to the corresponding bromide 
before sodium acetate was added to form the acetate protected derivative.  After deprotection, the 
alkoxyphenacyl diol monomers were reacted with triphosgene to produce the polycarbonate 
polymer. 
5.3.5.2. UCNC-loaded nanoparticle preparation 
UCNC-loaded NPs (UCNC-NPs) were prepared by minor modification of the 
nanoprecipitation method described in Chapter 4.  UCNCs were solubilized in DMSO by 
sonication for 60 min.  APP-H solubilized in DMSO (20 mg/mL) was then added to the UCNC 
solution and vortexed for 5 min before being added dropwise into the surfactant solution (1 mL; 
1% w/v Pluronic F-127 ®) at 40ᵒC under vigorous stirring. After cooling to room temperature the 
resulting UCNC-NPs were purified by dialyzing against purified water.  This procedure was also 
used to load doxorubicin (DOX) into UCNC-NPs (DOX-UCNC-NPs) as a model drug.  DOX 
was first converted to its free base form via the addition of triethylamine as described in Chapter 
4.  DOX (0.5 mg) was added to the solution of UCNCs and APP-H and vortexed for 5 min, 
before drop-wise addition into the surfactant solution.  Upon cooling to room temperature, the 
NPs were purified by dialysis.  DOX was replaced with coumarin-6 to prepare coumarin-6-loaded 
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UCNC-NPs used in the biodistribution assessment.  APP-H-NPs (no UCNCs) and PLGA-NPs 
were prepared using the same nanoprecipitation method by omitting the UCNCs.   
5.3.6. Characterization of UCNC-NPs 
5.3.6.1. Size, stability, and zeta potential of UCNC-NPs       
The size, zeta potential, and size stability of UCNC-NPs was measured via dynamic light 
scattering (DLS) using a Zetasizer Nano-ZS-90 (Malvern Instruments; Worestshire, United 
Kingdom).  In order to obtain a light scattering signal that was within the appropriate range for 
the equipment, the NP suspension was diluted with 0.22 µm filtered water (1:10 v/v) prior to 
measuring.  All size measurements utilized a measurement angle of 90ᵒ and were performed at 
25ᵒC.  The Smoluchowski model was used to calculate zeta potential.  Using the previously 
described procedure (Bi et al., 2013), particle size stability was assessed by diluting the NP 
suspension with different physiologically relevant fluids; water, saline (0.15 M NaCl), or saline 
containing 10% (v/v) FBS. 
5.3.6.2. Determination of DOX loading in DOX-UCNC-NPs 
A similar procedure to that described in Chapter 4 was used to evaluate the efficiency of 
DOX entrapment.  Purified DOX-UCNC-NPs were immediately diluted 1:4 v/v with filtered 
water, and placed in a Microcon Ultracel YM-100 centrifugal device with a molecular weight cut 
off of 10,000 Da (Millipore, Billerica, MA).  After centrifugation for 30 min at 4,000 x g the 
retained fraction was reconstituted to its original volume with water, and DOX was quantified at 
480 nm (Spectramax-340PC plate reader; Bucher Biotec AG, Basel, Switzerland).  DOX present 
in the retained fraction was considered to be NP entrapped.  The entrapment efficiency (%EE) 
was calculated using equation 5.1.   
%𝐸𝐸 = (
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓𝐷𝑂𝑋 𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑 𝑖𝑛 𝑡ℎ𝑒 𝑁𝑃𝑠
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐷𝑂𝑋 𝑎𝑑𝑑𝑒𝑑 𝑑𝑢𝑟𝑖𝑛𝑔 𝑁𝑃 𝑝𝑟𝑒𝑝𝑎𝑟𝑎𝑡𝑖𝑜𝑛
)  𝑥 100     (5.1) 
5.3.7. Cell culture 
RAW 264.7 (murine, macrophage) and A549 (human, non-small cell lung carcinoma) 
cell lines were obtained from American Type Tissue Culture (Manassas, VA).  Lewis lung 
carcinoma (LLC) cells were a gracious gift from Dr. Charles Thodeti.  A549, RAW 264.7, and 
LLC cells were maintained in a humidified incubator (37ᵒC, 5% CO2), in DMEM supplemented 
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with 10% v/v fetal bovine serum (FBS) and antibiotics (100 unit/mL penicillin and 100 µg/mL 
streptomycin).  Regular subcultivation ensured the cells remained in logarithmic growth phase.    
5.3.8. In vitro biocompatibility assessment 
5.3.8.1. Cell-based biocompatibility studies 
The biocompatibility of UCNC-NPs was assessed in RAW 264.7 cells on the basis of (i) 
macrophage activation and (ii) cytotoxicity.  NPs prepared from PLGA (PLGA-NPs) were 
employed as a known biocompatible reference material.  Briefly, the activation of macrophages 
was evaluated by measuring nitrite production in accordance with our established procedure 
described in Chapter 3.   Nitrite production was normalized to protein content (ng nitrite/µg 
protein).  In accordance with ISO 10993-5:2009(E) cytotoxicity was assessed via the MTT assay.  
Untreated cells were used as the reference (100% viability).   
5.3.8.2. Hemocompatibility assessment 
Hemocompatibility was assessed by evaluation of red blood cell (RBC) lysis using the 
same method as that described in Chapter 3.    Briefly, 0.1 mL of citrated pig whole blood (Pel 
Freez Biologicals; Rogers, AR) was mixed with treatment solutions (1:1 v/v) in a 96 well plate.  
After incubating at 37ᵒC (0.5-6 hr) in an orbital plate shaker, intact RBCs were removed by 
centrifugation (600 x g for 5 min) and the supernatant was transferred to a clean 96 well plate.  
Oxyhemoglobin in the supernatant was measured at 540 nm (Spectramax-340PC plate reader; 
Bucher Biotec AG, Basel, Switzerland).  Hemolysis (%) was determined using equation 5.2:   
𝐻𝑒𝑚𝑜𝑙𝑦𝑠𝑖𝑠 (%) =  
(𝐴𝐵𝑆𝑠𝑎𝑚𝑝𝑙𝑒− 𝐴𝐵𝑆𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
(𝐴𝐵𝑆𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙− 𝐴𝐵𝑆𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
 × 100   (5.2) 
where ABS sample is the absorbance of the sample, ABS negative control  is the absorbance of the negative 
control (PBS), and ABS positive control is the absorbance of the positive control (water).   
5.3.9. Functional efficacy assessment  
The functional efficacy of DOX was evaluated in LLC cells via the AlamarBlue ® assay.  
Cells were seeded (10,000 cells/well) in a 96 well plate and allowed to recover overnight.  
Treatment solutions prepared in complete growth media were added and incubated (37ᵒC) for 24 
hr.  The extent of cellular proliferation was determined by reduction of the AlamarBlue ® dye, 
using untreated cells as the reference.  In order to substantiate the AlamarBlue ® results, DNA 
fragmentation, a marker of apoptosis, was assessed by terminal dUTP nick-end labeling 
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(TUNEL).  LLC cells were seeded in a chamber slide (50,000 cells/well), and allowed to adhere 
overnight.  After incubating with treatments for 24 hr (37ᵒC), the cells were fixed with 
paraformaldehyde (4%), and stained with TUNEL (Roche Applied Science, Indianapolis, IN) in 
accordance with the manufacturer’s protocol.  After counterstaining with DAPI, images were 
acquired at 200X magnification using an Axio Imager.M2 microscope (Zeiss; Thornwood, NY).  
DAPI was pseudo-colored blue, and TUNEL was pseudo-colored red.     
5.3.10. Assessment of photoresponsive DOX release 
5.3.10.1. NIR photoirradiation conditions 
 NIR photoirradiation of UCNCs and UCNC-NPs was conducted using a continuous wave 
980 nm diode laser (1.7 W) coupled to a multimode fiber with a core diameter of 1,000 µm 
(Lasermate Group Inc., Walnut, CA).  The laser beam was not recollimated at the distal end of 
the fiber, giving a highly heterogeneous and non-Gaussian beam profile.  To minimize the effects 
of the heterogeneous beam profile, all photoirradiations were conducted at distances less than 10 
mm from the fiber’s tip.  In order to control the power density at this fixed distance, the 980 nm 
laser’s average power output (PAVG) was controlled digitally by transistor-transistor logic (TTL).  
Briefly, a 0-5 VDC input signal with a square wave function was introduced into the laser 
driver’s TTL modulation circuit.  The square wave input signal was generated by a 555 timer 
integrated circuit (Mouser Electronics, Mansfield, TX) operating in astable mode.  Varying the 
resistance (0-10kΩ) at R2 (Fig. 5.1) altered the pulse width and period (0-10 kHz) in order to 
control the average power output.  A handheld multimeter (Mouser Electronics, Mansfield, TX) 
was used to monitor the system.  The average power output (PAVG) and average power density 
(Power DensityAVG) were calculated using equations 5.3 and 5.4, respectively. 
  𝑃𝐴𝑉𝐺 =  𝑃𝑃𝑒𝑎𝑘  𝑥 (
𝑃𝑢𝑙𝑠𝑒 𝑊𝑖𝑑𝑡ℎ
𝑃𝑒𝑟𝑖𝑜𝑑
)    (5.3)   
𝑃𝑜𝑤𝑒𝑟 𝐷𝑒𝑛𝑠𝑖𝑡𝑦𝐴𝑉𝐺 =  
𝑃𝐴𝑉𝐺
𝐵𝑒𝑎𝑚 𝐴𝑟𝑒𝑎
   (5.4) 
PPeak is the laser’s known peak power output (1.7 W), and beam area is the area of the laser’s 
beam measured on an IR card (Edmund Optics; Barrington, NJ) with Vernier calipers.  NIR 
photoirradiation of NPs was performed by transferring the NP suspension into a glass test tube, 
and positioning the distal end of the laser’s fiber 5 mm above the surface of the liquid.  The test 
tube was submerged in 200 mL of distill water in order to maintain the NP suspension at a 
constant temperature.  The samples were photoirradiated for 60 min (Power DensityAVG = 10 
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W/cm
2
).  The duration of photoirradiation was chosen on the basis of what has been reported to 
be effective for NIR-responsive chromophores via two-photon absorption and practical 
limitations (Fomina et al., 2011).   
5.3.10.2. UV photoirradiation conditions 
UV photoirradiation was performed using the same procedure and conditions described 
in Chapter 4.  Briefly, a handheld UV lamp with peak emission at 302 nm (UVM-57, UVP Inc.; 
Upland, CA) was positioned 2.5 cm above the NP suspension (1 mL in a 6-well plate).  Using the 
inverse squares law and the manufacturer’s stated intensity of 0.0015 W/cm2 at 7.6 cm from the 
UV filter, the intensity of the UV light at 2.5 cm was calculated to be 0.0135 W/cm
2
.  We 
previously established the minimum photonic dose required to significantly alter DOX release to 
be 16.2 W∙sec/cm2 (Chapter 4).  As such, UV photoirradiations were conducted at a photonic 
dose of 16.2 W∙sec/cm2. 
5.3.10.3. In vitro DOX release  
DOX release was assessed by implementing the previously established dialysis procedure 
described in Chapter 4.  NIR, UV, and non-irradiated suspensions of DOX-UCNC-NPs or DOX-
APP-H-NPs were transferred into regenerated cellulose dialysis tubing (MWCO 3,500 Da) and 
dialyzed against 15 mL of distilled water.  Sink conditions were maintained by replacing the 
release media at specific time-points.      
5.3.10.4. Ex vivo DOX release  
In order to evaluate the potential utility of DOX-UCNC-NPs in photoresponsive drug 
delivery applications beyond superficial tissues, the release of DOX was evaluated ex vivo using a 
mock tissue model.  Muscle tissue is the predominate barrier to 980 nm light reaching deep-
seated tissues due to its optical properties and anatomical locations (Byrnes et al., 2005).  As 
such, ex vivo release studies utilized a previously reported mock tissue model that has optical 
properties comparable to murine skeletal muscle (Jayakumar et al., 2012).  Briefly, mock tissues 
were prepared from 0.5% (w/v) agarose, with Intra-Lipid (1% v/v) as the scattering agent and 
India Ink (0.1% v/v) as the absorbing agent.  Mock tissues were cast with DOX-UCNC-NPs 
entrapped within the matrix of the mock tissue.  Briefly, 0.3 mL of mock tissue solution (0.5% 
w/v agarose, 1% v/v Intra-Lipid, 0.1% v/v India Ink) was cast in a 24 well plate.  Afterwards, 0.1 
mL of DOX-UCNC-NPs or free DOX was added, and followed immediately by the addition of 
0.3 mL of mock tissue solution.  After gentle swirling the mock tissues were placed in the fume 
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hood for 60 min to solidify.  Treatment groups were as follows: (i) DOX alone (unentrapped), (ii) 
DOX-UCNC-NPs (non-irradiated), (iii) DOX-UCNC-NPs irradiated with NIR light prior to 
incorporation into the mock tissue (“Pre-NIR irradiated DOX-UCNC-NPs”), and (iv) DOX-
UCNC-NPs irradiated with NIR light after incorporation into the mock tissue (“DOX-UCNC-NPs 
+ NIR irradiation”).  NIR photoirradiation of the DOX-UCNC-NPs incorporated within the mock 
tissues (DOX-UCNC-NPs + NIR irradiation) was conducted at an average power density of 0.7 
W/cm
2
 (15 min).  These conditions represent the maximum permissible exposure limit for 980 
nm light as defined by the International Commission on Non-Ionizing Radiation Protection, and 
the maximum duration that did not compromise the structural integrity of the mock tissue due to 
overheating.  DOX release from the mock tissue was assayed by reverse dialysis.  The mock 
tissues and a dialysis bag (MWCO 3,500 Da) containing 1 mL PBS were submerged in 15 mL 
PBS and incubated at 37ᵒC (95 rpm).  Samples (0.5 mL) were collected from inside the dialysis 
bag and replaced with 0.5 mL of fresh PBS.  DOX was quantified via fluorescence (485 nm 
excitation; 600 nm emission).  Initial studies confirmed that free DOX was at equilibrium across 
the dialysis membrane under these conditions, and that no NPs entered the dialysis bag. 
5.3.11. Biodistribution and tumor accumulation 
In order to assess biodistribution and tumor accumulation the fluorescent dye coumarin-6 
was entrapped in UCNC-NPs and APP-H-NPs.  Experiments involving animals were conducted 
in accordance with National Institute of Health guidelines and approved by the Institutional 
Animal Care and Use Committee of Northeast Ohio Medical University.  Tumors were developed 
in 6-8 week old athymic nu/nu mice (Charles Rivers Laboratories; Raleigh, NC) as we have 
reported previously (Wehrung and Oyewumi, 2012).  Briefly, A549 cells (3 x 10
6
 cells/mouse) 
suspended in Matrigel ® were injected subcutaneously into the interscapular region.  When the 
tumor volume had reached approximately 150 mm
3 
the mice were randomly assigned into groups: 
(i) coumarin-6 alone, (ii) APP-H-NPs, and (iii) UCNC-NPs.  NP suspensions were administered 
via the tail vein (0.1 mL/mouse), and the mice were sacrificed 6 hr after injection.  Blood was 
collected via cardiac puncture, and centrifuged at 1,500 x g for 15 min (4ᵒC) to collect plasma.  
Harvested tissues were immediately rinsed with PBS, blotted dry with a paper towel and weighed.  
NP accumulation in tissues was assessed by homogenizing the tissues in the presence of 0.5 mL 
acetonitrile (Wehrung et al., 2012).  The tissue slurry was centrifuged (1,500 x g for 15 min), and 
the fluorescence intensity of the supernatant measured at 540 nm (480 nm excitation).  A 
calibration curve analyzed simultaneously was used to extrapolate the fluorescence intensity 
values into the concentration of courmarin-6.   Coumarin-6 content (ng) was normalized to tissue 
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weight (g) and the injected dose (ng coumarin-6/g tissue/µg’s injected) and plotted after 
deducting the average from the control group (mice treated with coumarin-6 alone).   
5.3.12. Statistical analysis 
Graph Pad Prizm 6.0 (La Jolla, CA) was used to for statistical analysis.  Alpha was set to 
0.05, and the student’s t-test or analysis of variance with Dunnett’s post-hoc test for multiple 
comparisons, were used to determine statistical significance. 
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5.4. Results and discussion 
The objective of this work was to enhance the safety and potential utility of APP-based 
NPs in photoresponsive drug delivery applications by removing the need to apply exogenous UV 
light to induce drug release.  In pursuit of this, we sought to entrap UCNCs within the polymeric 
matrix of APP-NPs which would convert NIR light into the photo-trigger in situ via the process 
of photon upconversion.  A schematic representation of the proposed delivery system is shown in 
Figure 5.2.  We envisioned that this strategy would enable photoirradiation with clinically 
relevant NIR light to control drug release while retaining the reliable activation of the 
chromophore via a single photon mechanism.  Moreover, APP’s phenacyl chromophore is not 
readily amendable to activation with NIR light via a multi-photon mechanism (Specht et al., 
2012).  This approach first required the optimization of UCNCs for emission in the UV region.  
The optimized UCNCs were then included during the preparation of NPs from APP-H to produce 
UCNC-NPs for subsequent studies of the safety and efficacy of this approach.  
5.4.1. Preparation and characterization of UCNCs  
 Using a solvothermal synthetic route described previously UCNCs were prepared with 
different quantities of trivalent lanthanide dopants, and with different architectures.  In order to 
select the optimal formulation for application to an APP-based delivery system, the UCNC 
formulations were characterized for: (i) size, (ii) morphology, (iii) trivalent lanthanide 
composition, and (iv) emission spectrum.  The size and morphology were assessed because of 
their influence on the surface area-to-volume ratio.  The high surface area-to-volume ratio of 
nano-scale particles makes surface quenching a major energy loss pathway that reduces the 
intensity of the upconversion emissions.  The addition of a protective outer shell layer over the 
UCNC core is a well-established way to mitigate surface quenching and increase the emission 
intensity.  On this basis, UCNCs were prepared with two architectures; core-alone and 
core@active shell@inert shell (Fig. 5.3).  In addition to the architecture of the UCNCs, the 
concentration of the dopants (Yb
3+ 
and Tm
3+
) was also evaluated and optimized.  Thulium was 
chosen as the activator on the basis of its ability to emit light with the appropriate wavelength to 
active APP’s chromophore (Jean-Claude G, 2010; Bai et al., 2012; Shen et al., 2013).  Ytterbium 
was selected as the sensitizer due to its strong absorption of NIR light, and the closely matching 
energy gap between its ground state and single excited state with the energy gap separating 
multiple excited states of thulium (Balakrishnaiah et al., 2009; Jean-Claude G, 2010).  This 
overlap in the energy gaps between ytterbium and thulium enables efficient energy transfer from 
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ytterbium to thulium for the population of thulium’s high level excited states.  The doping 
concentrations were selected to facilitate population of the 
1
I6 excited state of Tm
3+
 which emits 
290 nm light upon relaxation to the ground state.  We reasoned that by doping UCNCs with high 
concentrations of Yb
3+
 (30-50 mol%) and low concentrations of Tm
3+
 (0.15-0.6 mol%) 
intermediate excited states of Tm
3+
 could be saturated, facilitating the population of the 
1
I6 excited 
state.  The saturation effect is a well-known phenomenon in photon upconversion that is readily 
observed at high excitation power densities.  By doping UCNCs with very high ratios of 
Yb
3+
/Tm
3+
 we theorized that saturation could be achieved at biologically relevant excitation 
power densities.  To this end, the core@active shell@inert shell architecture was chosen rather 
than the simpler core@inert shell since it permits Yb
3+ 
to be doped at the highest possible 
concentration (100% in the active shell) with minimal energy loss through surface quenching 
(Qiu et al., 2014).   
Representative images of the UCNCs acquired via TEM are shown in Figure 5.4.  Core-
only formulations prepared at an oleic acid/octadecene ratio of 2/5 (v/v), such as the NaYF4 (30% 
Yb
3+
/0.3% Tm
3+
) formulation shown in Figure 5.4A, exhibited a spherical morphology, with 
diameters around 30 nm.  UCNCs prepared using 1/4 v/v ratio of oleic acid/octadecene had a 
predominately nanoplate morphology, and the diameter was approximately 350 nm (Fig. 5.4B).  
This is in good agreement with previous reports that the ratio of oleic acid/octadecene influences 
the morphology and size of the resulting UCNCs (Li and Zhang, 2008; Qian et al., 2009).  The 
core@active shell@inert shell formulation (Fig. 5.4C) had ellipsoid/nanorod morphology; 
approximately 60 nm along the major axis and 30 nm along the minor axis (aspect ratio ≈ 2).  
Reports in the literature indicate that epitaxial shell growth does not occur evenly, and with 
sufficient shell thickness particle morphology can change from spherical to ellipsoid (Zhang et 
al., 2012).  This formulation had two shells prepared at a 1/1 mole ratio (moles Y
3+ 
in the 
core/moles Yb
3+
 in the active shell; moles Y
3+
 and Yb
3+
 in core and active shell/moles Y
3+
 in the 
inert shell).  The thickness and number of shells may have exacerbated the influence of uneven 
shell growth on the final morphology.  A second population of UCNCs with a smaller diameter 
and a more spherical/nanoplate morphology was also observed (Fig. 5.4C).  The presence of this 
second particle population with a smaller size connotes the presence of uncoated UCNCs cores, 
and/or the formation of additional crystal nuclei during shell growth.  Overall, the TEM images of 
the core@active shell@inert shell formulation indicated that epitaxial shell growth was highly 
heterogeneous. 
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A representative emission spectrum is shown in Figure 5.5A.  Pronounced emissions 
occurred at 800 nm, 640 nm, and 477 nm.  The emission at 477 nm was accompanied by a small 
shoulder at 450 nm.  All of the observed emission peaks correspond to reported energy state 
transitions of Tm
3+
 (Fig. 5.5B) (Balakrishnaiah et al., 2009).  The emission at 450 nm is reported 
to be the result of relaxation of a thulium atom in the 
1
D2 excited state to the 
3
F4 state 
(Balakrishnaiah et al., 2009).  The 
1
D2 state is also capable of emitting UV light (360 nm) upon 
relaxation to the ground state (
3
H6 ).  As such, the small shoulder observed at 450 nm suggests 
that this core-alone UCNC formulation may have been capable of emitting UV light when 
irradiated with 980 nm light.  The spectrometer was optimized for the detection of light in the 
visible region which prohibited the positive identification of emissions below 400 nm.  As such, 
the fluorescent probe dansylcadaverine was employed as a means to qualitatively assess 
emissions in the UV region (< 400 nm).   
Dansylcadaverine emits visible green fluorescence when excited with UV light (250-400 
nm) (Hantgan, 1982; Hameau et al., 2011).  When solutions of the UCNCs alone (2.5 mg/mL) 
were irradiated with 980 nm light, only Tm
3+’s blue emissions could be observed by the naked 
eye (Fig. 5.6).  Following the addition of dansylcadaverine (0.1 mg/mL), the visible blue 
emission would be accompanied by green fluorescence for UCNC formulations that emitted UV 
light. Irradiation of dansylcadaverine alone with 980 nm light in the absence of UCNCs did not 
generate any visible green fluorescence (image not shown).  The intensity and distribution of the 
green fluorescence varied depending on the UCNC formulation.  UCNCs prepared with 50 mol% 
Yb
3+ 
and 0.6 mol% Tm
3+
 produced only a weak visible blue emission, and following the addition 
of dansylcadaverine no green fluorescence could be observed (images not shown).  The high level 
of Yb
3+ 
in this formulation may have permitted extensive surface quenching either directly or 
through the migration of energy to the surface via the Yb-Yb lattice.  UCNC formulations doped 
with Yb
3+ 
at 30 mol% were capable of generating strong blue emissions (Fig. 5.6 A&C), and 
some green fluorescence was visible after dansylcadaverine was added to the solution (Fig. 
5.6B&D).  Reducing the concentration of thulium from 0.3 mol% to 0.15 mol% (Yb
3+
 fixed at 30 
mol%) did not produce a perceivable change in the intensity of the green fluorescence (Fig. 
5.6B&D).  UCNCs prepared with the core@active shell@inert shell architecture also emitted 
visible blue light the intensity of which was comparable to that observed for core-only 
formulations (Fig. 5.6E).  After dansylcadaverine was added, this formulation produced the most 
intense visible green fluorescence (Fig. 5.6F).  Additional analysis of the wavelengths and 
relative intensities of emission(s) in the UV region are warranted.   
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The lead formulations were subjected to ICP-OES to quantify the trivalent lanthanide 
dopants.  The quantity of the dopants in the UCNCs was in good agreement with the amounts 
used during UCNC synthesis (Table 5.1).  This confirms that changing the ratio of the dopants 
used during synthesis produced UCNCs with corresponding differences in the ratio of the 
trivalent lanthanides. 
Taken together, the UCNC characterization studies indicated that UCNCs were 
successfully synthesized and doped with different quantities of the trivalent lanthanides.  These 
UCNCs were capable of emitting visible blue light (477 nm) when irradiated with 980 nm light.  
Additional emissions occurred at 640 nm, 800 nm, and in the UV region (< 400 nm).  The 
intensity of emissions in the UV region, as assessed through dansylcadaverine, was greatest for 
the core@active shell@inert shell formulation.  Additional studies are warranted to determine the 
wavelength(s) emitted in the UV region, confirmation of the core-shell structure, determination of 
the quantum yield and crystal phase, and the role of the core@active shell@inert shell structure in 
the observed enhancement of UV emissions.   
5.4.2. Preparation and characterization of UCNC-NPs 
Based on the results from the UCNC characterization studies the core@active 
shell@inert shell formulation was selected for incorporation in APP-H-NPs for subsequent 
studies of the efficacy of photon upconversion as a transducer of APP’s photoactivating UV light 
from NIR light.  UCNC-NPs were prepared at varying concentrations of UCNCs and the resulting 
NPs characterized.  The concentration of the APP homopolymer was fixed at 20 mg/mL on the 
basis of the results obtained in Chapter 4 that identified this to be the minimum polymer 
concentration that did not exhibit extensive nonspecific DOX release.    
The effect of UCNCs on the mean size of the resultant NPs is shown in Figure 5.7A.  NPs 
prepared without UCNCs (0 mg/mL) had a mean size of 160 ± 10 nm, which remained 
comparable (p > 0.05) when 0.5 mg/mL UCNCs were included in the formulation (152 ± 3 nm).  
The mean size increased to 183 ± 8 nm when the UCNC concentration was increased to 1.5 
mg/mL (p < 0.05).  Further increasing the UCNC concentration produced NPs with mean sizes of 
194 ± 7 nm and 393 ± 72 nm for the formulations prepared with 2.5 mg/mL and 5 mg/mL 
UCNCs, respectively.  At the highest UCNC concentration studied (5 mg/mL) visible particles 
were observed following purification, and DLS measurements indicated that the particle 
population was no longer unimodal.  For this reason 2.5 mg/mL was the maximum UCNC 
concentration used in further studies.  Increasing the UCNC concentration also increased the 
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polydispersity index (PDI) of the resulting NPs.  Formulations without UCNCs (0 mg/mL) had a 
mean PDI of 0.11 ± 0.02, which increased to 0.14 ± 0.04 at 1.5 mg/mL UCNCs (p > 0.05).  At a 
UCNC concentration of 2.5 mg/mL the mean PDI (0.25 ± 0.03) was significant higher than that 
for NPs prepared without UCNCs (p < 0.01).          
The mean zeta potential was not significantly affected by the inclusion of UCNCs in the 
formulation (p > 0.05); varying from -5 ± 5 mV to -3 ± 1 mV for the 0 mg/mL and 2.5 mg/mL 
UCNCs formulations, respectively (Fig. 5.7B).  These values are within the range considered to 
represent an uncharged/neutral colloidal system (i.e. -10 to + 10 mV) (Clogston and Patri, 2011).  
The entrapment efficiency (EE) of DOX exhibited a similar trend (Fig. 5.7C) and was not 
significantly altered by the inclusion of UCNCs in the formulation (p > 0.05).  NPs prepared 
without UCNCs had a mean EE of 66 ± 15% which increased slightly to 88 ± 10% for UCNC-
NPs prepared with 2.5 mg/mL UCNCs (p = 0.1127).   
Qualitative assessment of the particle size distributions obtained by DLS was used to 
assess NP entrapment of UCNCs.  The particle size distributions of APP-H-NPs alone (NPs 
alone), UCNCs alone, UCNC-NPs, and a mixture of previously prepared APP-H-NPs and 
UCNCs (NPs + UCNC Mixture) are shown in Figure 5.8.  APP-H-NPs alone produced a single 
particle population near 100 nm.  UCNCs alone aggregated when introduced into an aqueous 
environment, resulting in a particle population near 1,000 nm.  The addition of UCNCs to the 
APP-H-NPs (NPs + UCNC Mixture) resulted in two particle populations; one near 100 nm and 
the other near 1,000 nm (a third minor peak was also observed at 5,000 nm).  When UCNCs (2.5 
mg/mL) were included during NP preparation the resulting UCNC-NPs exhibited a single particle 
population centered near 200 nm.  This single particle population near 200 nm suggests that the 
UCNCs are entrapped during the preparation of UCNC-NPs since unentrapped UCNCs would 
aggregate in the aqueous environment and produce an additional population around 1,000 nm, as 
was observed for the NPs + UCNCs mixture.  Additional quantitation studies of UCNC 
entrapment via thermogravimetric analysis or ICP-OES are warranted.   
In Chapter 4 we reported that DOX-APP-H-NPs stored in water or saline retained their 
original size for the entire duration of study (14 days).  DOX-UCNC-NPs stored under similar 
conditions resulted in the formation of large particles/aggregates which were visible at the bottom 
of the cuvette within 72 hr.  This was observed for all UCNC-NPs formulations regardless of the 
UCNC concentration used during preparation.  To gain insight into the observed precipitation, the 
destabilized UCNC-NP suspensions were irradiated with the 980 nm laser.  The UCNCs’ visible 
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blue emission could be observed from both the precipitated particles and the transparent liquid 
phase. The blue light emitted from the precipitated particles was very bright and easily visible, 
while very little blue light was observed from the suspension.  The observed precipitate formation 
did not translate into a significant change in the measurements obtained via DLS.  The mean size 
of UCNC-NPs prepared from 2.5 mg/mL UCNCs remained comparable at all time-points studied 
when stored in water or saline (p > 0.05; Fig. 5.9A).  Likewise, the mean count rate and PDI 
values obtained by DLS also remained consistent throughout the study (p > 0.05; Fig. 5.9B-C).  
The UCNCs were strongly hydrophobic due to the presence of the oleic acid (OA) capping ligand 
and not soluble in an aqueous environment.  Therefore the ability to form a suspension of UCNCs 
was contingent on the UCNCs being enveloped within the polymeric matrix of the NPs.  UCNCs 
not encased within the polymeric matrix would readily precipitate.  On this basis, it is plausible 
that the observed precipitates were formed from UCNCs that lost the surrounding polymeric 
matrix due to diffusion, hydrolysis, and/or displacement.  The relative intensities of the blue light 
emitted from the precipitate and supernatant upon 980 nm irradiation suggests that the precipitate 
contained the majority of the formulation’s UCNCs.  This observation also connotes that the DLS 
measurements reflected NPs with little or no UCNCs entrapped.  Additional analysis of the 
precipitated material and NPs remaining in suspension via ICP-OES is warranted to verify the 
UCNC content in each of the two phases.  We also consider the merits of additional studies 
employing alternative methods for measuring particle size stability, such as asymmetric flow field 
flow fractionation, which may be better suited than DLS.   
Removal of the OA capping ligand renders UCNCs water soluble.  On this basis, we 
envisioned that UCNC-NPs prepared from UCNCs lacking the OA capping ligand would not be 
subject to precipitation.  This prompted an assessment of the merits of preparing UCNC-NPs 
from bare (ligand free) UCNCs.  The OA cap was removed by suspending UCNCs in water, and 
adjusting the pH to 3 with HCl (Bogdan et al., 2011).  After vigorous stirring (24 hr) the bare 
UCNCs were collected by centrifugation and washed with water to remove residual OA.  Before 
preparing UCNC-NPs from bare UCNCs the effect of removing the OA cap on the upconversion 
emission spectrum was assessed.  The intensity of the visible blue emission was not noticeably 
altered by removal of OA, while emissions in the UV region (as assessed with dansylcadaverine) 
were completely abolished (images not shown).  The nanometer dimensions of the UCNCs make 
surface quenching the predominate mechanism of energy loss, reducing overall emission intensity 
and reducing the population of atoms in high level excited states.  The OA capping ligand 
efficiently shields the UCNCs surface from the surrounding solvent, reducing surface quenching 
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(Wang et al., 2010b; Zhang et al., 2012; Zhong et al., 2014; Arppe et al., 2015).  Further efforts 
to prepare UCNC-NPs from bare UCNCs were not pursued since no UV emissions were observed 
after the OA cap was removed.      
The effect of UCNC loading on the morphology of the resultant NPs was assessed by 
TEM.  TEM images of APP-H-NPs (no UCNCs) showed particles with spherical morphology 
and diameters around 100 nm (Fig. 5.10A).  Images acquired from UCNC-NPs (1.5 mg/mL 
UCNCs) showed: (i) clusters made up of multiple particles, (ii) individual particles, and (iii) large 
aggregates.  A representative image of the particle clusters is shown in Figure 5.10B.  The 
diameter of the clusters was approximately 200 nm, which is slightly larger than the mean 
hydrodynamic diameter determined by DLS (183 nm).  Individual particles (Fig. 5.10B arrows) 
had nanorod morphology that closely resembled that of the parent UCNCs (Fig. 5.4C).  The edges 
of the individual particles were not as well defined as that observed for the parent UCNCs, and 
the dimensions were comparable to the UCNCs alone.  These characteristic have been reported 
previously for polymer-coated UCNCs and may reflect the formation of an APP-H coating on the 
UCNCs (Ren et al., 2012).  Alternatively, these individual particles could be UCNCs that were 
released from a parent particle during sample preparation (dehydration).  Likewise, the large 
aggregates (green arrow in Fig. 5.10C) could also be due to sample preparation or the instability 
(precipitation) noted previously.  Also shown in Figure 5.10C are regions of electron dense 
UCNCs surrounded by a less electron dense material, possibly APP-H.  The diameters of these 
regions were slightly less than 200 nm, which is close to that measured by DLS.  These regions 
may reflect UCNC-NPs that were not obscured by aggregation that occurred during sample 
preparation.  Techniques that do not require sample dehydration prior to imaging, such as cryo-
TEM, are warranted to evaluate the morphology of the UCNC-NPs in their native (hydrated) 
state.  In cryo-TEM, samples are rapidly frozen with liquid ethane and imaged at low 
temperatures to prevent the formation of crystalline ice.  Also, we recognize the merits of 
assessing the morphology of UCNC-NPs prepared using lower concentrations of UCNCs.  It is 
worth noting that the nanorod morphology is seen almost exclusively in the TEM images of 
UCNC-NPs whereas images of the UCNCs alone (Fig. 5.4C) contained nanorods and a large 
population of smaller, spherical crystals.  This suggests that the size and morphology of the 
parent UCNCs may influence their entrapment and retention within UCNC-NPs.  As a 
preliminary assessment of the potential influence of UCNC size and morphology on the resulting 
UCNC-NPs, additional TEM images were acquired from UCNC-NPs prepared using the core-
only NaYF4 (30% Yb
3+
/0.3% Tm
3+
) UCNC formulation.  As noted previously this formulation 
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produced UCNCs with diameters around 350 nm and nanoplate morphology (Fig. 5.4B).  As 
shown in Figure 5.10D the morphology of the resulting UCNC-NPs was semi-spherical/ellipsoid, 
with evidence of the nanoplate morphology of the parent UCNCs also visible.  The diameter of 
these UCNC-NPs was comparable to that of the UCNCs alone.  The observed morphology and 
size suggest that these UCNC-NPs formed by heterogeneous nucleation of a polymer coating on 
the surface of the UCNCs rather than entrapment within APP-H-NPs.    
Taken together, the results from the particle characterization studies demonstrated that: 
(i) UCNC-NPs can be formed without surface modification of the UCNCs; and (ii) the size and 
morphology of the resultant UCNC-NPs are influenced by the size and morphology of the parent 
UCNCs.  UCNC-NPs are likely formed by a combination of entrapment of UCNCs within the 
polymeric matrix and heterogeneous nucleation of a polymer coating on the surface of the 
UCNCs.  The UCNC concentration (number of particles) and the size and morphology of the 
parent UCNCs are expected to influence the balance between these two processes.  UCNC-NPs 
are therefore expected to be a combination of three types of NPs: (i) NPs with UCNCs entrapped 
within the polymeric matrix, (ii) UCNCs coated with APP-H, and (iii) empty APP-H-NPs (no 
UCNCs entrapped).   
5.4.3. In vitro biocompatibility assessment 
The entrapment of UCNCs within APP-NPs was intended to enhance the safety and 
potential utility of APP as a photoresponsive drug delivery platform by permitting drug release to 
be controlled with biologically benign NIR light.  Therefore, evaluating the biocompatibility of 
the proposed delivery system is paramount.  The biocompatibility of APP, and NPs prepared from 
APP was described in Chapters 3, and the biocompatibility of UCNCs has been well documented 
in the literature (Wang et al., 2010; Wang et al., 2011b; Shen et al., 2013; Das et al., 2014).  
Here, we sought to ensure that loading UCNCs into APP-NPs did not compromise the delivery 
system’s biocompatibility.  The in vitro assessment of the biocompatibility of UCNC-NPs was 
based on: (i) cytotoxicity, (ii) macrophage activation, and (iii) induction of RBC lysis.  These 
studies utilized the UCNC-NP formulation containing the highest concentration of UCNCs (2.5 
mg/mL) as a representative formulation.  NPs prepared from the known biocompatible polymer 
PLGA (PLGA-NPs) were included as the known biocompatible reference.     
Cell-based studies were conducted in a murine macrophage cell line (RAW 264.7).  The 
viability of RAW 264.7 cells was not significantly reduced compared to the untreated control 
when treated with UCNC-NPs or PLGA-NPs for 24 hr (p > 0.05; Fig. 5.11A).  When the 
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incubation was increased to 48 hr, the viability of cells treated with UCNC-NPs remained 
comparable to the untreated control at the 25 µg/mL and 50 µg/mL concentrations (p > 0.05).  At 
the highest concentration studied (100 µg/mL) both UCNC-NPs and PLGA-NPs significantly 
reduced cellular viability compared to the untreated control (p < 0.01).  However, the extent to 
which UCNC-NPs reduced cellular viability was comparable to PLGA-NPs (p > 0.05; Fig. 
5.11B).  Time-points beyond 48 hr were not evaluated due to the instability of UCNC-NPs 
observed during the size stability assessment.  The extent of macrophage activation was assessed 
by assaying the extent of nitrite production.  Nitrite production was not significantly elevated 
above that observed for the untreated controls following treatment with UCNC-NPs or PLGA-
NPs for 48 hr (p > 0.05; Fig. 5.11C).  Treatment with the positive control (LPS; 10 µg/mL) 
significantly increased nitrite production compared to the untreated controls (p < 0.001).   
Hemocompatibility, as determined by RBC lysis, is a critical parameter for a 
nanoparticulate delivery system due to the requirement that the NPs remain in the circulation for 
prolonged durations to allow for passive targeting to tumor tissues.  Figure 5.12 shows the results 
of the RBC lysis studies.  After 3 hr incubation at varying concentrations, RBC lysis was 
comparable between UCNC-NPs and PBS (negative control) at the 25 µg/mL and 50 µg/mL 
concentrations (p > 0.05; Fig. 5.12A).  At the 100 µg/mL concentration RBC lysis was 
significantly elevated for both UCNC-NPs and PLGA-NPs compared to PBS (p < 0.05), 
however, treatment with UCNC-NPs was comparable to treatment with PLGA-NPs (p > 0.05).  
The effect of varying the duration of incubation (0.5-6 hr) at a fixed concentration (50 µg/mL) 
was also evaluated. The extent of RBC lysis following treatment with UCNC-NPs was 
comparable to both PBS alone and PLGA-NPs at all time-points studied (p > 0.05; Fig. 5.12B).  
Together, the results from the biocompatibility studies indicated that UCNC-NPs are not overtly 
toxic, and that the in vitro biocompatibility profile of UCNC-NPs was consistent with that of NPs 
prepared from the known biocompatible polymer PLGA.   
5.4.4. Functional efficacy of DOX 
The objective of the functional efficacy studies was to ensure that DOX’s therapeutic 
utility was not adversely affected by NP entrapment or 980 nm irradiation.  Initial studies 
confirmed that UCNC-NPs alone (without DOX) did not significantly affect the proliferation of 
LLC cells (p > 0.05; data not shown).  The extent to which the proliferation of LLC cells was 
inhibited by DOX was comparable following treatment with DOX alone (not photoirradiated), 
DOX-UCNC-NPs, or DOX-UCNC-NPs after NIR photoirradiation (p > 0.05; Fig. 5.13A).  
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Labeling of apoptotic LLC cells by staining with TUNEL identified TUNEL-positive cells in all 
three treatment groups (Fig. 5.13B).  The trend from these studies indicated that DOX’s 
functional efficacy was not negatively impacted by loading into UCNC-NPs or by 
photoirradiation with NIR light.    
5.4.5. In vitro DOX release assessment 
The proposed system employs UCNCs as photo-transducers that convert NIR light to UV 
light in order to generate APP’s photo-trigger in situ.  We envisioned that this approach could 
mitigate the detrimental effects of applying exogenous UV light by localizing and confining the 
UV light.  It has been reported that the UV light generated by UCNCs did not alter cellular 
viability, cellular proliferation, or cause DNA damage (Jayakumar et al., 2012).  These findings 
were attributed to the spatial confinement of the UV light and support the use of UCNCs as NIR-
to-UV photo-transducers in drug delivery. Using DOX as a model drug the efficacy of UCNCs as 
photo-transducers for controlling photoresponsive drug release from APP-H-NPs with NIR light 
was assessed.  After confirming that diffusion of DOX through the dialysis membrane was not the 
rate limiting step (Fig. 5.14A) initial studies were conducted to determine if: (i) the entrapped 
UCNCs could compete for the photoactivating light; (ii) the inclusion of UCNCs in the 
formulation altered DOX release (non-specific and photoresponsive); and (iii) if NIR irradiation 
of APP-H-NPs (no UCNCs) influenced DOX release.   
The ability for UCNCs to compete with APP for the photo-trigger was assessed by 
evaluation of the UCNCs’ UV-VIS absorbance spectrum.  The spectrophotometric analysis of the 
UCNCs demonstrated that the UCNCs did not absorb light at the wavelengths required for 
photoactivation of APP (data not shown).  Subsequently, the effect of including UCNC in the 
formulation on the release of DOX from DOX-UCNC-NPs was assessed.  The DOX release 
profiles obtained from NPs prepared from varying concentrations of UCNCs (0-2.5 mg/mL) is 
shown in Figure 5.14B.  In the absence of the photo-trigger the rate and extent of DOX release 
from all the DOX-UCNC-NP formulations studied was comparable to NPs prepared without 
UCNCs (p > 0.05).  The results connote that the inclusion of UCNCs in the NP formulation does 
not have a pronounced effect on the nonspecific release of DOX.  Next, the potential for the 
UCNCs to influence the release of DOX in response to the photo-trigger (302 nm) was assessed.  
This release study utilized the photoirradiation parameters established in Chapter 4 that 
significantly increased the rate and extent of DOX released from DOX-APP-H-NPs.  The DOX-
UCNC-NPs employed in this study were prepared using the maximum amount of UCNCs (2.5 
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mg/mL) such that the maximum effect(s) would be observed.  UV irradiation of DOX-UCNC-
NPs did not significant increase the rate or extent of DOX release compared to non-irradiated 
DOX-UCNC-NPs (p > 0.05; Fig. 5.15A).  Visible aggregates were observed immediately 
following UV irradiation of DOX-UCNC-NPs.  As previously described in Chapter 4, UV 
irradiation of APP-H-NPs primarily affects the surface of the NPs, and parameters that alter the 
surface area-to-volume ratio through particle size (e.g. polymer concentration) were influential in 
the photoresponsive release of DOX.  As shown in Figure 5.7A the inclusion of 2.5 mg/mL 
UCNCs in the NP formulation significantly increased the mean size compared to NPs prepared 
without UCNCs (28% increase in mean size; p < 0.01).  Furthermore, the morphology, PDI, and 
size stability are also parameters that influence the surface area-to-volume ratio, and these 
aforementioned parameters were previously determined to be altered by including UCNCs in the 
NP formulation.  As such, these parameters are believed to have influenced photoresponsive 
DOX release in this study.  To address this, a follow up study was conducted to investigate the 
possible contributions from the size and size stability.  In this study the effect(s) of UV irradiation 
on the size stability of DOX-UCNC-NPs was evaluated.  The mean size before UV irradiation 
was 162 ± 4 nm, which significantly increased to 188 ± 8 nm 24 hr after UV irradiation (p = 
0.0038).  The particle size continued to increase over time; at the 48 hr and 72 hr time-points the 
mean sizes were 201 ± 9 nm and 227 ± 35 nm, respectively.  On this basis each subsequent UV 
irradiation of DOX-UCNC-NPs in the DOX release study (Fig. 5.15A) is expected to have been 
less effective in inducing photoresponsive DOX release due to the continued increase in the mean 
size over time.  Additionally, visible aggregates were observed immediately following UV 
irradiation during the DOX release study, and this was also observed during this size stability 
study.  This study supports the notion that the size and size stability of DOX-UCNC-NPs likely 
influenced the release of DOX from DOX-UCNC-NPs exposed to the photo-trigger (UV 
irradiation).  A second follow up study was conducted to rule out possible contributes from 
deterioration of the UV light source.  In this study DOX-APP-H-NPs were subjected to UV 
irradiations using the same UV light source and photoirradiation parameters as that used in the 
DOX-UCNC-NP release study.  UV irradiation significant increased the rate and extent of DOX 
released from the DOX-APP-H-NPs compared to non-irradiated NPs (p < 0.05; data not shown).  
These results demonstrated that the UV light source was sufficient for inducing photoresponsive 
DOX release.   
Taken together, the results from these studies suggest that the inclusion of UCNCs in the 
NP formulation did not directly affect photoresponsive DOX release by competing for the photo-
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trigger.  However, DOX release in response to the exogenous application of UV light (photo-
trigger) was affected by the presence of the UCNCs.  This is believed to have been due to a 
combination of factors such as: size, morphology, PDI, and size stability of the DOX-UCNC-
NPs.  Additionally, we consider the potential for DOX release to be altered by interaction(s) 
between DOX and the UCNCs, and/or changes in the predominate mechanism of NP formation 
caused by the inclusion of UCNCs in the formulation.  For example, if DOX-UCNC-NP 
formation occurred primarily by heterogeneous nucleation of a thin APP polymer coating on the 
surface of UCNCs, the thin APP coating would be anticipated to contain a small percentage of 
entrapped DOX that could be released upon exposure to the photo-trigger.  Evaluation of the 
photoresponsive release of DOX from formulations containing lower UCNC concentrations and 
potential interactions between DOX and the UCNCs (e.g. FTI-IR; fluorescence spectroscopy) 
may provide additional insight into the observed DOX release profile.   
DOX release following NIR irradiation of NPs prepared without UCNCs is shown in 
Figure 5.15B.  NIR irradiation of DOX-APP-H-NPs (no UCNCs) did not significantly alter the 
rate or extent of DOX release (p > 0.05).  This was substantiated by assessing possible changes in 
the polymer’s structure via H-NMR.  The NMR spectrum obtained from non-irradiated APP-H-
NPs (Fig. 5.16A) was essentially identical to that obtained from NIR irradiated APP-H-NPs (Fig. 
5.16B).  Overall, these results indicated that the NIR photoirradiation conditions did not have a 
pronounced effect on NPs prepared without UCNCs.  As such, any alterations in the release of 
DOX following NIR photoirradiation of DOX-UCNC-NPs are anticipated to be contingent on the 
presence of UCNCs in the formulation.  
The efficacy of controlling DOX release from DOX-UCNC-NPs with NIR light was 
assessed in vitro by evaluating changes in the rate and/or extent of DOX release.  The DOX-
UCNC-NP formulation prepared from 1.5 mg/mL UCNCs was used as a representative 
formulation in these studies.  This concentration of UCNCs produced a significant increase in 
mean particle size, connoting entrapment of UCNCs in the APP-NPs (Fig. 5.7A).  Increasing the 
UCNC concentration above 1.5 mg/mL did not significantly increase the mean size of the 
resultant UCNC-NPs, suggesting a comparable quantity of UCNCs were entrapped.  Figure 
5.17A shows the release of DOX from DOX-UCNC-NPs with and without NIR irradiation.  NIR 
irradiation of DOX-UCNC-NPs did not significantly increase DOX release relative to non-
irradiated DOX-UCNC-NPs (p = 0.3566).  While the difference between non-irradiated and NIR 
irradiated groups was not statistically significant, the mean percent of DOX released from NIR 
irradiated DOX-UCNC-NPs was consistently higher than that released from non-irradiated DOX-
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UCNC-NPs at all time-points studied.  For example, at the 168 hr time-point NIR irradiated 
DOX-UCNC-NPs released 59% of entrapped DOX, while non-irradiated DOX-UCNC-NPs 
released 42% (individual data-points shown in Fig. 5.17B).  DOX release was highly variable, 
and coincided with the formation and disappearance of visible aggregates in the NP suspensions.  
This observation suggested that colloidal stability may have been more influential than NIR 
photoirradiation status on DOX release.   
5.4.6. Ex vivo DOX release assessment 
DOX release was also evaluated in an ex vivo mock tissue model.  In this study DOX 
release was evaluated from non-irradiated and NIR irradiated DOX-UCNC-NPs.  NIR irradiation 
of DOX-UCNC-NPs was conducted either before or after the DOX-UCNC-NPs were 
incorporated into the mock tissue.  DOX-UCNC-NPs exposed to NIR irradiation prior to being 
incorporated into the mock tissue (“Pre-NIR irradiated DOX-UCNC-NPs”) were subjected to 
NIR irradiation using the same conditions as that used in the in vitro release study (10 W/cm
2
).  
DOX-UCNC-NPs exposed to NIR irradiation after being incorporated into the mock tissue 
(“DOX-UCNC-NPs + NIR irradiation”) used photoirradiation conditions at the maximum 
permissible exposure limit as to mimic what could be used in vivo (0.7 W/cm
2
).  Initial studies 
using dansylcadaverine confirmed that this power density was capable of generating emissions in 
the UV region (images not shown).  This group was meant to assess the potential utility of DOX-
UCNC-NPs in vivo.  The trend from the in vitro release study suggested that colloidal instability 
may have obscured the effect of NIR irradiation on DOX release.  In order to prevent colloidal 
instability from dominating the ex vivo release profile, DOX release was assayed over 24 hr on 
the grounds that this formulation remained stable over this period during the stability studies.  
Furthermore, the decision to evaluate DOX release over 24 hr was also based on the study’s 
objective, which was to assess the potential utility of DOX-UCNC-NPs as a photoresponsive 
delivery system.  In order for a photoresponsive delivery system to impart spatial and temporal 
control over drug release, the release of the therapeutic payload must closely coincide with the 
administration of the photo-trigger.  While no maximum lag time between photoirradiation and 
drug release is currently specified, the majority of photoresponsive delivery systems reported to 
date have a significant alteration in the release of their payloads within minutes to hours after 
exposure to the photo-trigger.  For example, a recently reported photoresponsive system utilizing 
o-nitrobenzene as the photoactive moiety released 77% of its therapeutic payload within 15 min 
of photoirradiation (Fedoryshin et al., 2014).     
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Initial studies indicated that DOX release from the mock tissue was accompanied by the 
release of DOX-loaded NPs.  Attempts to separate NP entrapped DOX from free DOX by 
centrifugation, filtration, and electrophoresis were unsuccessful.  Of all the methods tested, only 
reverse dialysis was capable of separating free DOX from NP entrapped DOX.  The results from 
the ex vivo DOX release study are shown in Figure 5.18.  Free DOX rapidly diffused out of the 
mock tissue; with 48 ± 7% released within 24 hr.  DOX release from DOX-UCNC-NPs was 
markedly slower; with non-irradiated DOX-UCNC-NPs releasing 23 ± 5% of entrapped DOX at 
24 hr.  The rate and extent of DOX released from NIR irradiated DOX-UCNC-NPs, whether 
exposed to NIR irradiation before or after incorporation within the mock tissue, was comparable 
to non-irradiated DOX-UCNC-NPs (p > 0.05).  At the 24 hr time-point, Pre-NIR irradiated DOX-
UCNC-NPs released 19 ± 3% of entrapped DOX while DOX-UCNC-NPs + NIR irradiation 
released 19 ± 2% of entrapped DOX.   
Overall, the trend from the in vitro and ex vivo release studies demonstrated that the 
inclusion of UCNCs in the NP formulation did not allow DOX release to be controlled with NIR 
light.  Initially, colloidal instability was suspected to have obscured DOX released in response to 
NIR irradiation.  However the ex vivo release study, conducted at abbreviated time-points to 
alleviate instability concerns, also showed comparable release between non-irradiated and NIR 
irradiated formulations.  On this basis, the most plausible explanation for the comparable release 
profiles was insufficient generation of the photo-trigger by the UCNCs as a result of: (a) 
insufficient quantity of UCNCs entrapped within the NP; and/or (b) minimal overlap between the 
wavelengths of light emitted by the UCNCs and the chromophore’s photo-trigger.  We envision 
that modifications to the polymer’s structure that allow for UCNC-NPs to be prepared at high 
UCNC concentrations without the formation of multiple particle populations (observed 
previously in Fig. 5.7A) may permit DOX release to be controlled with NIR light.  In this regard, 
replacing the capping ligand (OA) with an amphiphilic di-block APP copolymer (e.g. APP-PEG) 
could be beneficial to both NIR-responsive DOX release and colloidal stability (Ren et al., 2012; 
Sedlmeier and Gorris, 2015).  Additionally, modifications to the chromophore that enhance the 
overlap between the wavelengths of the photo-trigger and the wavelengths of light emitted from 
UCNCs are likely to be beneficial to controlling DOX release with NIR light.  Chain scission of 
APP is triggered by 250-320 nm light.  Light in this region is generated by a single energy state 
transition of excited thulium ions from the highest excited state to the ground state (
1
I6  
3
H6; λ = 
290 nm).  This emission requires the absorption of 5 photons of NIR light to emit one photon of 
290 nm light, and the intensity of the 290 nm emission is ca. 20% of simultaneous UV emissions 
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at 345 nm and 360 nm (Balakrishnaiah et al., 2009; Shen et al., 2013; Qiu et al., 2014).  On this 
basis, alterations to the chromophore that red-shift the wavelengths of the photo-trigger to include 
the 345 nm and/or 360 nm emissions are anticipated to facilitate chromophore activation and 
DOX release by increasing the cumulative number of photons of the photo-trigger emitted.   
5.4.7. Biodistribution and tumor accumulation 
An established xenograft model of non-small cell lung cancer was employed to evaluate 
the biodistribution and tumor accumulation of NPs prepared with UCNCs (UCNC-NPs) and 
without UCNCs (APP-H-NPs).  The fluorescent dye coumarin-6 was loaded into the NPs and 
used to track their accumulation in organs/blood.  Analysis of the tissues and plasma 6 hr post-
administration identified the lungs as the site of preferential accumulation for both UCNC-NPs 
and APP-H-NPs (Fig. 5.19).  Accumulation in the lungs has been suggested as a potential sign of 
instability in blood circulation (Li and Huang, 2008), and may be advantageous in the treatment 
of lung cancer.   Minimal accumulation was observed in the plasma, heart, liver, spleen, brain, 
and tumors.   The biodistribution of UCNC-NPs was comparable to that of APP-H-NPs (p = 
0.0720).  The results from the biodistribution assessment suggest that UCNC loading does not 
alter the biodistribution of the resultant NPs, and that both UCNC-NPs and APP-H-NPs may not 
have been stable in the systemic circulation as evidenced by: (i) minimal retention in the blood, 
(ii) minimal tumor accumulation, and (iii) preferential accumulation in the lungs.   
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5.5. Conclusions 
This work demonstrated that Yb
3+
/Tm
3+
 co-doped UCNCs can function as photo-
transducers capable of generating UV light from clinically relevant NIR light.  The core@active 
shell@inert shell formulation [NaYF4 (30% Yb
3+
/0.15% Tm
3+
)@NaYbF4@NaYF4] produced the 
most intense emissions in the UV region when exposed to NIR light (980 nm).  Using the APP 
homopolymer, UCNC-NPs were prepared by nanoprecipitation with sizes between 153-393 nm 
depending on the UCNC concentration (0.5-5 mg/mL), and their morphology more closely 
resembled that of the parent UCNCs than APP-NPs prepared without UCNCs.  The UCNC-NPs 
were biocompatible based on in vitro studies of: cytotoxicity, macrophage activation, and RBC 
lysis.  UCNC-NPs had poor stability as evidenced by: (i) visible precipitate formation; (ii) 
preferential accumulation in the lungs; and (iii) minimal accumulation in the tumors and blood.  
DOX release from DOX-UCNC-NPs was not altered following exposure to NIR light during in 
vitro or ex vivo release studies.   The utility of this approach could benefit from a complete 
characterization of the UCNCs, and modifications to APP that increase UCNC entrapment and 
increase the overlap between the wavelengths of the photo-trigger and the wavelengths of light 
emitted from the UCNCs.   
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Table 5.1: 
 
Table 5.1: Quantification of trivalent lanthanides in UCNC formulations:  Quantification of 
the trivalent lanthanides doped into the UCNCs as determined by ICP-OES.  Altering the 
quantities of the dopants used during UCNC synthesis produced UCNCs with corresponding 
changes in the concentrations of the dopants.  Each sample was analyzed in triplicate, and the 
mean value reported.  The measured values are in good agreement with the anticipated doping 
quantities.   
 
 
 
 
 
 
 
 
 
 
 
 
 
UCNC Formulation 
Predicted 
Mol%Yb
3+
 
Mol% 
Yb
3+ 
Predicted 
Mol%Tm
3+
 
Mol% 
Tm
3+
 
NaYF4(30% Yb
3+
/0.3% Tm
3+
) 30 33.0 0.3 0.2 
NaYF4(30% Yb
3+
/0.15% Tm
3+
) 30 25.4 0.15 0.1 
NaYF4(30% Yb
3+
/0.15% 
Tm
3+
)@NaYbF4@NaYF4 
44 40.7 0.05 0.1 
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Figure 5.1: 
 
Fig. 5.1: Schematic of the transistor-transistor logic modulation circuit:  Schematic of the 
circuit used to provide the oscillating voltage signal for controlling the 980 nm laser’s average 
power output via transistor-transistor logic (TTL) modulation.  Varying the resistance at the R2 
position allowed the pulse width and pulse duration to be modulated.  The white box represents 
the 555 timer IC with the pins numbered (ground, trigger, output, reset, control voltage, threshold, 
discharge, and power supply for #1-8, respectively).    
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Figure 5.2: 
 
Fig. 5.2: Schematic depiction of the proposed UCNC-loaded APP-NP delivery system:  
Schematic representation of the UCNC-loaded APP-H-NPs.  The generation of the photo-trigger 
(UV light) from UCNCs entrapped within the APP matrix is anticipated to enhance safety by 
circumventing the need to apply exogenous UV light and confining the UV light to a region 
where it will be rapidly attenuated by the surrounding polymer matrix.   
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Figure 5.3: 
 
Fig. 5.3: Schematic depiction of the different UCNC architectures evaluated:  Schematic 
depictions of the core-alone and core@active shell@inert shell UCNC architectures assessed. (A) 
Core-alone and (B) core@active shell@inert shell.  The composition of the core, active shell, and 
inert shell are given in the figure legend.  Cores and shell layers are not drawn to scale. 
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Figure 5.4: 
 
Fig. 5.4: Morphology of three UCNCs formulations:  Representative TEM images of the 
different sizes and morphologies of three UCNC formulations prepared using different synthetic 
parameters (architecture, dopant concentration, and oleic acid/octadecene ratio). (A) NaYF4 (30% 
Yb
3+
/0.3% Tm
3+
) prepared using 2/5 (v/v) ratio of oleic acid/octadecene. (B) NaYF4 (30% 
Yb
3+
/0.3% Tm
3+
) prepared using 1/4 (v/v) ratio of oleic acid/octadecene.  (C) NaYF4 (30% 
Yb
3+
/0.15% Tm
3+
)@NaYbF4@NaYF4 (core@active shell@inert shell).  Scale bars = 50 nm.  
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Figure 5.5:  
 
Fig. 5.5: Evaluation of the wavelengths of the unconverted light: Representative upconversion 
emission spectrum obtained by NIR irradiation of UCNCs.  The UCNCs were capable of 
converting the NIR (980 nm) excitation light into visible (450 nm, 477 nm, 640 nm) and NIR 
(800 nm) light.  (A) Representative emission spectrum obtained from NaYF4 (30% Yb 
3+
/0.15% 
Tm
3+
) under 980 nm excitation (10 W/cm
2
).  Emission spectra were obtained at the Photonics and 
Semiconductor Laboratory at Youngstown State University (Youngstown, OH) using a fiber-
coupled USB-4000 spectrometer.  (B)  List of known emissions from thulium and corresponding 
energy state transitions.  
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Figure 5.6: 
 
Fig. 5.6: Qualitative assessment of the emission of UV light from three UCNC formulations 
upon NIR irradiation:  Images of the light emitted from UCNC solutions (2.5 mg/mL) with and 
without dansylcadaverine (0.1 mg/mL) when exposed to NIR light (980 nm, 10 W/cm
2
).  The 
UCNCs emitted light in the UV region, and the intensity of the UV emission(s) depended on the 
UCNC formulation.  (A) NaYF4 (30% Yb
3+
/0.3% Tm
3+
) without and (B) with dansylcadaverine. 
(C) NaYF4 (30% Yb
3+
/0.15% Tm
3+
) without and (D) with dansylcadaverine.  (E) NaYF4 (30% 
Yb
3+
/0.15% Tm
3+
)@NaYbF4@NaYF4 (core@active shell@inert shell) without, and (F) with 
dansylcadaverine.  Images were acquired with a Nikon S5300 digital camera with no additional 
filters or lenses.  Pink areas are caused by saturation of the camera’s IR filter. 
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Figure 5.7: 
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Fig. 5.7: Characterization of DOX-UCNC-NPs prepared from the APP homopolymer:  
Characterization of DOX-UCNC-NPs demonstrated that the inclusion of UCNCs did not interfere 
with NP formation or DOX loading.  (A) Size measurements determined that formulations 
prepared with a UCNC concentration > 2.5 mg/mL produced multiple particle populations. (B) 
Zeta potential, and (C) DOX entrapment efficiency remained comparable at all UCNC 
concentrations studied.  Data-points are presented as the mean ± SD (n = 3).  * indicates p < 0.05, 
** p < 0.01, and & indicates that the formulation had multiple particle populations.   
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Figure 5.8: 
 
Fig. 5.8: Qualitative assessment of UCNC entrapment:  Particle size distributions obtained by 
DLS of UCNC-NPs, UCNCs Alone, pre-formed APP-H-NPs alone (NPs alone), and a mixture of 
pre-formed APP-H-NPs and UCNCs (NPs + UCNCs Mixture).  The inclusion of UCNCs during 
NP preparation (UCNC-NPs) resulted in a single particle population near 200 nm, whereas a 
mixture of NPs prepared without UCNCs (NPs Alone) and UCNCs resulted in two particle 
populations which correspond to the size distributions obtained for the NPs alone (near 100 nm) 
and UCNCs alone (near 1,000 nm).  This suggests that UCNC-NPs are comprised of UCNCs 
entrapped within the polymeric matrix of APP-H-NPs, since free UCNCs would be expected to 
aggregate and produce an additional particle population near 1,000 nm as was observed for 
UCNCs alone.       
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Figure 5.9: 
0 1 2 3 7 1 5
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
T im e  (D a y s )
P
a
r
ti
c
le
 S
iz
e
 (
n
m
)
W a te r S a lin e
0 1 2 3 7 1 5
0
1 0 0
2 0 0
3 0 0
4 0 0
T im e  (D a y s )
C
o
u
n
t 
R
a
te
 (
k
C
P
S
)
W a te r S a lin e
0 1 2 3 7 1 5
0 .0
0 .1
0 .2
0 .3
T im e  (D a y s )
M
e
a
n
 P
D
I
W a te r S a lin e
A B C
Fig. 5.9: Stability of UCNC-NPs:  UCNC-NPs stored in water or saline produced visible 
precipitates within 72 hr, however, this was not reflected in the DLS measurements of size, PDI, 
or count rate.  (A) Mean particle size, (B) count rate, and (C) PDI as determined by DLS of 
UCNC-NPs prepared from 2.5 mg/mL UCNCs.  UCNC-NPs were diluted (1:10 v/v) with water 
or saline solution (0.154 M NaCl) and stored at room temperature.  Data-points are plotted as the 
mean ± SD (n = 3). 
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Figure 5.10: 
 
Fig. 5.10: Morphology of APP-H-NPs prepared with and without UCNCs:  The morphology 
of UCNC-NPs closely resembled that of the parent UCNCs.  Representative TEM images of (A) 
APP-H-NPs prepared without UCNCs (scale bar = 100 nm).  (B-C) UCNC-NPs prepared using 
the core@active shell@inert shell UCNC formulation (1.5 mg/mL).  Red arrows point to 
individual particles separated from the clusters.  Red circled regions depict areas of UCNCs 
contained within a less electron dense matrix.  Green arrows point to regions containing large 
aggregates (scale bar = 200 nm).  (D) UCNC-NPs prepared using the NaYF4 (30% Yb
3+
/0.3% 
Tm
3+
) core-only UCNC formulation (scale bar = 200 nm).   
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Figure 5.11: 
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Fig. 5.11: Cell-based assessment of the biocompatibility of UCNC-NPs: Biocompatibility 
studies in RAW 264.7 cells demonstrated UCNC-NPs to be comparable to PLGA-NPs.  Cellular 
viability of RAW 264.7 cells treated with UCNC-NPs or PLGA-NPs for (A) 24 hr and (B) 48 hr.  
Cellular viability was comparable between UCNC-NPs and PLGA-NPs at all time-points and 
concentrations studied.  Data-points are plotted as a percentage of the untreated control (mean ± 
SD; n = 6).  (C) Activation of macrophages by UCNC-NPs or PLGA-NPs (48 hr incubation).  
The extent of macrophage activation was assessed by measuring nitrite production and 
normalized to protein content.  The negative control was untreated cells, while LPS treated cells 
served as the positive control.  Data-points are plotted as the mean the mean ± SD (n = 6). 
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Figure 5.12: 
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Fig. 5.12: Hemocompatibility assessment of UCNC-NPs: UCNC-NPs were compatible with 
blood on the basis of the induction of RBC lysis.  (A) Effect of the UCNC-NP concentration on 
RBC lysis after incubating for 3 hr (37ᵒC). The extent of RBC lysis induced by incubation with 
UCNC-NPs was comparable to the PBS treated control at 25 µg/mL and 50 µg/mL (p > 0.05).  At 
100 µg/mL RBC lysis was elevated compared to treatment with PBS, but remained comparable to 
PLGA-NPs (p > 0.05).  (B) Effect of the incubation duration on RBC lysis at a fixed 
concentration (50 µg/mL).  UCNC-NPs were comparable to PBS alone and PLGA-NPs at all 
time-points studied (p> 0.05).  
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Figure 5.13: 
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Fig. 5.13: In vitro assessment of the functional efficacy of DOX: Neither the preparation of 
DOX-UCNC-NPs nor NIR photoirradiation negatively impacted the functional efficacy of DOX.  
(A) Cellular viability of LLC cells following treatment for 24 hr with DOX alone, DOX-UCNC-
NPs, or NIR irradiated DOX-UCNC-NPs.  Data-points are plotted as the mean ± SD (n = 4).  (B) 
Qualitative assessment of DOX’s functional efficacy via TUNEL.  Representative images (200X) 
of LLC cells treated with DOX alone, DOX-UCNC-NPs, or NIR irradiated DOX-UCNC-NPs 
(standardized DOX concentration of 0.5 µg/mL).  DAPI was pseudo-colored blue, and TUNEL 
was pseudo-colored red.  NIR irradiation of DOX-UCNC-NPs was conducted using 10 W/cm
2
 for 
60 min. 
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Figure 5.14: 
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Fig. 5.14: DOX release from DOX-UCNC-NPs prepared at multiple UCNC concentrations: 
The presence of UCNCs in the NP formulation did not markedly alter the release of DOX 
compared to NPs prepared without UCNCs.  (A) Release profile of DOX alone confirming that 
the diffusion of DOX through the dialysis membrane was not the rate limiting step in the release 
of DOX.  (B) DOX release from NPs prepared with different concentrations of UCNCs (0-2.5 
mg/mL).  DOX release was comparable between NPs prepared with and without UCNCs (p > 
0.05).  Data-points are plotted as the mean ± SD (n = 3). 
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Figure 5.15: 
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Fig. 5.15: Effect of photoirradiation on DOX release from DOX-UCNC-NPs and DOX-APP-
H-NPs: DOX released from DOX-UCNC-NPs was increased by exposure to the photo-trigger.  
DOX release from NPs prepared without UCNCs was not affected by NIR photoirradiation.  (A) 
Release of DOX from DOX-UCNC-NPs with and without photoirradiation from an exogenous 
UV light source (302 nm).  UV irradiated DOX-UCNC-NPs were exposed to three 
photoirradiations administered sequentially at the 0, 24, and 48 hr time-points.  Each UV 
irradiation was conducted at a photonic dose of 16.2 W sec/cm
2
.  DOX release is plotted as the 
mean ± SD (n = 4-6). (B) DOX release from DOX-loaded APP-NPs (no UCNCs) with and 
without NIR irradiation (10 W/cm
2
 for 60 min).  Data-points are plotted as the mean ± SD (n = 
3). 
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Figure 5.16: 
 
Fig. 5.16: Effect of NIR photoirradiation on the structure of the homopolymer: H-NMR 
spectra obtained before and after NIR photoirradiation of APP-H-NPs were essentially identical, 
indicating that NIR photoirradiation does not cause alterations in the structure of the polymer. H-
NMR spectra obtained before (A) and after (B) NIR photoirradiation of APP-H-NPs (10 W/cm
2
, 
60 min).  H-NMR spectra were obtained at Kent State University’s Department of Chemistry and 
Biochemistry (Kent, OH).       
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Figure 5.17: 
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Fig. 5.17: Effect of NIR photoirradiation on the release of DOX from DOX-UCNC-NPs: In 
vitro assessment of the influence of NIR irradiation on DOX release from DOX-UCNC-NPs.  
Exposing DOX-UCNC-NPs to NIR light did not significantly alter the rate or extent of DOX 
release (p > 0.05).  (A) DOX release profile from DOX-UCNC-NPs with and with NIR 
photoirradiation (10 W/cm
2
, 60 min).  Each data-point is plotted as the mean ± SD (n = 4).  (B) 
The percentage of DOX released at the 168 hr time-point from each of the four DOX-UCNC-NP 
preparations in each group (non-irradiated and NIR irradiated).   
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Figure 5.18: 
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Fig. 5.18: Ex vivo assessment of DOX released by NIR photoirradiation of DOX-UCNC-
NPs: Release of DOX from an ex vivo mock tissue model was not significantly altered by NIR 
photoirradiation (p > 0.05).  DOX-UCNC-NPs were prepared using 1.5 mg/mL core@active 
shell@inert shell UCNCs.  Pre-NIR irradiated DOX-UCNC-NPs were exposed to NIR irradiation 
(10 W/cm
2
 for 60 min) prior to being incorporated into the mock tissue.  DOX-UCNC-NPs + NIR 
irradiation were exposed to NIR light at the maximum conditions able to be used in vivo (0.7 
W/cm
2
 for 15 min) after being incorporated into the mock tissue.  Data-points are presented as the 
mean ± SD (n = 3).   
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Figure 5.19: 
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Fig. 5.19: Biodistribution and tumor accumulation of UCNC-NPs and APP-H-NPs in tumor 
bearing mice: The biodistribution of fluorescently labeled UCNC-NPs and APP-H-NPs (no 
UCNCs) 6 hr after intravenous administration to tumor bearing mice.  Minimal accumulation of 
NPs in the tumors accompanied by minimal retention in the blood suggests that the NPs were not 
stable in blood circulation.  Tumors were developed in athymic mice by subcutaneous 
implantation of A549 cells.  Date-points were normalized to tissue weight (grams) and the 
injected dose of coumarin-6 (µg), and the mean background from coumarin-6 alone deducted 
before being plotted as the mean ± SD (n = 3).   
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Chapter 6 
Conclusions 
 The current limitations to the clinical application of photoresponsive delivery systems 
are: (i) the lack of biocompatible and biodegradable photoresponsive materials and (ii) the 
reliance on UV light for reliable activation.  Herein, we sought to address these limitations and 
facilitate the translation of photoresponsive delivery systems to the clinic.  To address the lack of 
biocompatible and biodegradable photoresponsive materials we evaluated a new class of 
photoresponsive polymers, the alkoxyphenacyl-based polycarbonates.  We sought to circumvent 
the need to apply exogenous UV light for reliable activation of drug release by generating APP’s 
UV photo-trigger in situ from biologically benign and tissue transparent NIR light via the process 
of upconversion.     
 The objection of specific aim #1 was to determine the suitability of the APP polymers in 
nanoparticulate drug delivery applications by characterizing their biocompatibility.  We 
demonstrated that the APP homopolymer and copolymers with PCL and PEG were biocompatible 
before and after photoirradiation.  NPs prepared from the homopolymer and PCL copolymer were 
stable, biocompatible, and had diameters near 100 nm.  NPs prepared from the PEG copolymer 
had diameters near 200 nm and were not stable beyond the day of preparation.  Overall, the 
homopolymer and PCL copolymer were determined to be suitable candidates for further 
assessment as photoresponsive nanoparticles.   
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The objective of specific aim #2 was to characterize the effect of the photo-trigger on 
drug release from APP-NPs.  We demonstrated that stable, DOX-loaded APP-NPs could be 
prepared with sizes between 70-180 nm depending on the polymer concentration (10-40 mg/mL) 
and composition.  Exposure to the photo-trigger was induced chain scission as demonstrated by 
changes in the molecular weight distributions, and the effects of the photo-trigger were most 
pronounced at/near the surface of the NPs with no visible alterations in the NP core.  
Furthermore, exposing DOX-APP-NPs to the photo-trigger increased the rate and extent of DOX 
released without causing dose dumping, and multiple photoirradiations administered sequentially 
were required to continue to drive the release of DOX.  These studies identified the polymer 
composition, frequency of photoirradiation, and polymer concentration as key parameters that 
influenced photoresponsive efficacy.  The difference in the release of DOX following exposure to 
the photo-trigger was most pronounced for NPs formulated from the homopolymer.  The 
functional efficacy of DOX was not negatively impacted by exposure to the photo-trigger, as 
assessed by the reduction of cellular viability of LLC cells treated with DOX released after 
photoirradiation.  Loading DOX into APP-NPs curtailed its cardiotoxic effects and this trend was 
not altered by photoirradiation, indicating that DOX-APP-NPs are not prone to dose dumping 
following photoirradiation.  Overall, photo-induced chain scission was determined to be a viable 
mechanism for altering drug release from APP-NPs with light.   
The objective of specific aim #3 was to enhance the safety and utility of APP-NPs by 
utilizing photon upconversion to control drug release with clinically relevant NIR light.  We 
demonstrated that UCNCs synthesized via a solvothermal synthetic procedure with a NaYF4 host 
lattice and doped with Yb
3+
 and Tm
3+
 emitting UV light when exposed to NIR light.  UCNC-NPs 
were prepared from the APP homopolymer and loaded with the model drug doxorubicin via 
nanoprecipitation.  The resulting UCNC-NPs had sizes between 153-393 nm depending on the 
UCNC concentration and were unstable, forming visible precipitates within 72 hr.  The 
morphology of UCNC-NPs more closely resembled that of the parent UCNCs than that of APP-
NPs prepared without UCNCs.  In vitro biocompatibility assays demonstrated that UCNC-NPs 
were comparable to PLGA-NPs on the basis of: cytotoxicity, macrophage activation, and RBC 
lysis.  The inclusion of UCNCs in the formulation did not alter the loading of doxorubicin or the 
biodistribution of APP-NPs in tumor-bearing athymic mice.  The rate and extent of drug release 
were not altered by irradiating the as-prepared DOX-UCNC-NPs with NIR light.  Overall, the 
incorporation of photon upconversion did not enhance the safety or potential utility of APP-NPs 
as a photoresponsive delivery system.   
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Chapter 7 
Future Directions 
7.1. Potential therapeutic applications of APP-based delivery systems 
APP represents a promising class of photoresponsive materials due to their 
biocompatibility, biodegradability, biologically benign photo-products, excellent thermal and 
mechanical properties, and ability to release drug in response to the photo-trigger.  The major 
limitation to the utility of APP as a platform for photoresponsive drug delivery is the wavelength 
of the photoactivating light (250-320 nm), which largely precludes potential applications beyond 
drug delivery to superficial tissues.  Nevertheless, its thermal and mechanical properties, 
transparency to wavelengths > 320 nm, and sustained release profile could be beneficial to 
applications in ophthalmic drug delivery.  Additionally, the response of the surface regions to the 
photo-trigger and lack of dose dumping are also potentially advantageous traits that make APP 
well suited for the development of photoresponsive ocular implants (e.g. drug eluting contact 
lenses). 
APP-based delivery systems could be exposed to the photo-trigger prior to application in 
vivo.  In this setting, photolithographic techniques enable the development of complex 
geometries, patterned surfaces, and nanometer-sized pores which could not be produced with 
conventional manufacturing methods.  Careful selection of the geometry and/or pore size enables 
the drug release kinetics to be selectively tailored to the application.  In this type of application 
the photoresponsive attributes of APP, namely its photosensitivity, short wavelength of the photo-
trigger, and surface erosion, are likely to be advantageous.   
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7.2. Proposed modifications to extend the utility of APP as a platform for photoresponsive 
drug delivery 
Modifications to APP aim to address the limitations encountered in Chapter 5, 
specifically: (i) minimal generation of the photo-trigger due to limited overlap between the 
wavelengths of the photo-trigger and the wavelengths of light emitted from the UCNCs, and (ii) 
instability of UCNC-NPs.  These limitations could be met by modifications to APP’s 
chromophore and/or structure as well as through modifications to the UCNC doping strategy.  
7.2.1. Modifications to APP’s chromophoric unit 
Modifications to the APP’s chromophoric units are aimed at extending the wavelengths 
of the photo-trigger towards/into the UV-A region of the spectrum.  Conrad et al. have reported 
that the addition of methoxy groups at the 3’ and 5’ positions can extend the phenacyl 
chromophore’s absorption to include ca. 350 nm (Conrad et al., 2000).  This approach has merit 
due to the robust nature of the phenacyl chromophore, which is largely unaffected by the addition 
of a variety of auxochrome moieties (Givens et al., 2011).  Alternatively, substitution of the 
phenacyl chromophore for a nitrobenzene or coumarin-derivative would further diversify the 
wavelength of the photo-trigger.       
Thulium’s 290 nm emission capable of activating APP’s chromophore arises from the 
relaxation of thulium from the 
1
I6 excited state to ground (
3
H6) (Balakrishnaiah et al., 2009).  A 
multitude of additional, intermediate energy states capable of generating radiative emissions are 
positioned between the 
1
I6 and the 
3
H6 states (Fig. 7.1).  Radiative emissions from these 
intermediate levels and cross-relaxation pathways are constantly competing with the energy 
pathways that populate the 
1
I6 state.  Extension of the photo-trigger to include the 345 nm and/or 
360 nm emissions could greatly increase photo-induced chain scission by increasing the 
cumulative intensity of the UV light emitted.  Both the 345 nm and 360 nm emissions have 
intensities that exceed that of the 290 nm emission by ≥ 5-fold (Balakrishnaiah et al., 2009; Wang 
et al., 2009b; Qiu et al., 2014).  Furthermore, emissions at 345 nm and 360 nm have been 
reported at biologically benign excitation power densities (Jayakumar et al., 2012; Shen et al., 
2013; Fedoryshin et al., 2014; Khaydukov et al., 2014).   
7.2.2. Modifications to APP’s structure 
The observed instability and formation of visible precipitates was closely associated with 
the presence of UCNCs (as evidenced by the emission of blue light upon NIR excitation).  On this 
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basis, the formation of visible precipitates is plausibly the result of the release of entrapped 
UCNCs.  In addition to negatively impacted stability, the premature release of UCNCs reduces of 
the number of UCNCs loaded within the NPs thereby reducing overall emission intensity.  This 
effect could compromise efficacy in vitro and in vivo since these applications will necessitate a 
significant lag time between NP preparation and NIR photoirradiation to permit cell uptake 
and/or passive accumulation in tumor tissue.    
It is envisioned that the best approach to resolving the aforementioned limitations is the 
modification of the architecture of the delivery system, specifically by utilizing an amphiphilic di-
block copolymer (APP-PEG) to entrap UCNCs or as the capping ligand rather than OA.  This 
approach is anticipated to mitigate instability and possible reduction in efficacy caused by 
premature release of entrapped UCNCs.  Furthermore the biocompatibility of the system could 
also benefit from such a modification by avoiding potential toxicities due to accumulation of 
insoluble UCNCs in tissue(s) and/or disruption of membranes by dissociated oleic acid (Das et 
al., 2014; Sojka et al., 2014).  Furthermore, by capitalizing on the high affinity of inorganic 
phosphate groups for the surface of the UCNCs (Li et al., 2013b) concerns of potential instability 
in environments with high phosphate concentrations could be alleviated (e.g. cytosol and 
phosphate buffers).  Finally, this modification would permit the use of larger UCNCs without 
exceeding the optimal diameter for cellular uptake and passive targeting to tumors.  In this regard, 
50 nm nanospheres has been reported to be the most efficient size and morphology for UV 
emissions; balancing surface quenching with the spatial confinement of photons of exciting light 
inside the crystal (Shi et al., 2011).   
7.2.3. Modifications to the UCNC doping strategy  
In the case of an Yb
3+
/Tm
3+ 
co-doped system, the intense emission at 477 nm (blue) 
achievable under low excitation power densities could be harnessed for subsequent UV emissions 
by the addition of an outer shell doped with praseodymium (Pr
3+
) ions.  Pr
3+ 
has a large cross 
sectional absorbance in the 450-490 nm range and is capable of emitting UV light (260-380 nm) 
via excited state absorption (ESA) of two blue photons (Remillieux et al., 1996; Martin et al., 
1998; Hu et al., 2006; Cates et al., 2011; Tkachuk et al., 2014).  A critical distinction is that ESA 
is an upconversion mechanism and therefore proceeds through a real, metastable intermediate 
state and not a virtual intermediate excited state like two-photon absorption.  Thulium’s 1G4 
excited state, which generates the intense blue emission at 477 nm, is resonant with 
praseodymium’s 1I6 excited state, allowing excited thulium atoms in the 
1
G4 state to efficiently 
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transfer energy to Pr
3+
, promoting it from the ground state into the 
1
I6 excited state or from the 
1
I6 
excited state into the 4f5d band for subsequent emission of UV light.  The lack of electron 
shielding of the 5d orbital causes emissions from d-f transitions to be broad compared to 4f-4f 
transitions, and the wavelength center can vary depending on the environment.  This could be 
rectified by the addition of a suitable trivalent lanthanide to produce a narrow emission band with 
a predictable wavelength.  The best candidate for this application is gadolinium (Gd
3+
).  
Gadolinium
 
is ideally suited for this role due to its half full f-shell (4f
7
) which stabilizes the 
ground state such that the lowest excited state is 
6
P7/2.  Relaxation from the 
6
P7/2 excited state (
6
P7/2 
 8S7/2) produces an emission at 315 nm.  With no lower excited states separating the 
6
P7/2 from 
the ground state (
8
S7/2) there is no energy loss through lower order emissions or cross-relaxation 
pathways.  (n.b. the 
6
P7/2 excited state of Gd
3+ 
cannot be directly populated by energy transfer 
from Yb
3+ 
or Tm
3+ 
and therefore was not employed in the doping strategy described in Chapter 
5.)  Finally, the large energy gap between 
6
P7/2 and the ground state (
8
S7/2) makes this transition 
favorable through the energy gap law.  The energy gap law refers to the exponential increase in 
the probability of a radiative transitions as the energy gap between excited states increases 
(Shalav et al., 2007).  As the energy gap between two excited states increases the probability of 
quenching via phonons decreases since an increasing number of phonons are required to bridge 
the energy gap.  Preliminary studies in our lab utilizing NaYF4 (50% Yb
3+
/0.5% 
Tm
3+
)@NaYF4(0.1% Pr
3+
) UCNCs have shown promise for the utility of this approach for 
enhancing the intensity of UV emissions.  Using the fluorescent probe dansylcadaverine to 
qualitatively assess emission in the UV region, we observed intense UV emissions from this 
UCNC formulation (Fig. 7.2).  At biologically benign excitation power densities (e.g. 0.3 W/cm
2
) 
green fluorescence from dansylcadaverine could still be observed (Fig. 7.2).  It is important to 
note that Pr
3+ 
is capable of emitting green light (530 nm) from the relaxation from the 
3
P0 excited 
state to 
3
H5 excited state (Hölsä et al., 2014).  Therefore, spectral data of the emitted light is 
required in order to validate the utility of this co-doping strategy.   
7.3. Considerations for selection of the optimal excitation light source  
The heating of water by 980 nm light was easily mitigated in vitro by the addition of a 
heat sink; however, this unavoidable phenomenon prohibited the UCNC-NPs described in 
Chapter 5 from being applied in vivo.  The absorbance spectra of water and Yb
3+ 
show significant 
overlap in the 900-1,000 nm region, however, the overlap is far less pronounced at wavelengths 
closer to 900 nm.  At 925 nm, Yb
3+ 
is reported to retain ca. 60% of its absorption relative to its 
980 nm peak while the absorption of 925 nm light by water is less than 20% of its value at 980 
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nm (Zhan et al., 2011).  The utility of exciting UCNCs with light at 915 nm rather than 980 nm 
has been reported to profoundly decrease tissue heating upon irradiation at the same power 
density with minimal effects on upconversion emissions (Zhan et al., 2011).   Furthermore, 
alternative doping strategies may enable the wavelength of the excitation light to be shifted to 
wavelengths where water does not significantly absorb.  The trivalent lanthanide Nd
3+
 can be 
excited by 800 nm light, and by doping Nd
3+
, Yb
3+
, and Er
3+ 
into concentric shells of UCNCs the 
deleterious back-transfer of energy can be avoided (Li et al., 2013).  Tissue heating in response to 
irradiation with 800 nm light was negligible compared to 980 nm light at the same power density 
(3 W/cm
2
), and the 800 nm light was able to more efficiently penetrate tissue.  To this end, 808 
nm light has been reported to have more than twice the tissue penetrating capacity of 980 nm 
light (Hudson et al., 2013).  Finally, coating UCNCs with a gold shell is an emerging strategy that 
has shown promise for enhancing the absorption of the NIR excitation light and increasing the 
overall intensity of the upconverted emissions (Ling et al., 2015).    
Tissue heating is not intrinsically bad.  Mild hyperthermia of tumors increases blood 
flow, increases the permeability of the tumor vasculature, increases tumor oxygenation (reversing 
hypoxia), and enhances the tumor accumulation of nano-carriers (Gaber et al.; Karino et al., 
1988; Cope et al., 1990; Song et al., 2005; Ping et al., 2015).  With respect to NIR light 
penetrating into tissues, mild heating via 980 nm laser irradiation has been reported to increase 
the penetration of optical clearing agents into the skin, allowing subsequent NIR light to penetrate 
42% deeper in vivo (Stumpp et al., 2005).  
Finally, while upconversion can be achieved with continuous wave lasers, excitation with 
femtosecond pulsed lasers may provide enhanced efficiency.  Delivering light as tightly spaced 
pulses has been reported to exhibit a “photo-bleaching phenomenon,” where the first pulse causes 
temporary photo-bleaching of the tissue allowing the next pulse to retain more of its energy as it 
passes through the tissue (Kusnetzow et al., 2001).  Furthermore, delivering the excitation light as 
high-powered pulses may have two additional benefits.  The first is that precise tuning of the 
pulse width and pulse repetition rate allows tissue heating to be kept in check by matching the 
pulse delivery rate to the thermal relaxation time (τr), which is the time required for the tissue to 
cool down via conduction and convection after photo-induced heating.  Choi and Welch used 
mathematical modeling of energy flow to derive an equation that can be used to calculate the 
appropriate pulse width to prevent tissue heating above baseline (Choi and Welch, 2001).  
Second, under high excitation power density, the process of upconversion experiences saturation, 
reducing the number of photons required to produce a given emission by exhausting the number 
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of ions in the intermediate and ground states (Shi et al., 2011; Bai et al., 2012; Singh et al., 2013).  
By combining high powered delivery of the excitation light via femtosecond pulsed delivery with 
an appropriate doping strategy, it is plausible that the UCNCs could be deliberately saturated in 
order to increase the intensity of short wavelength emissions.   
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Figure 7.1: 
 
Fig. 7.1: Diagram of excited thulium energy states and corresponding radiative emissions:  
Graphical illustration of the thulium’s excited energy states and the radiative emissions generated 
by various relaxations.  The population of high level excited states (e.g. 
1
I6) is constantly 
competing with all lower order energy pathways and emissions.  Figure adapted from 
(Balakrishnaiah et al., 2009). 
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Figure 7.2: 
 
Fig. 7.2: Preliminary assessment of the utility of a Pr
3+
co-doping strategy for enhancing the 
intensity of UV emissions at biocompatible NIR excitation power densities:  Images acquired 
from the qualitative assessment of UV emission via dansylcadaverine.  (A) NaYF4(50% 
Yb
3+
/0.5% Tm
3+
)@NaYF4(0.1% Pr
3+
) UCNCs alone under NIR (980 nm) excitation.  (B) UCNCs 
and dansylcadaverine (0.1 mg/mL) under NIR excitation (10 W/cm
2
).  (C) UCNCs and 
dansylcadaverine (0.1 mg/mL) under a biologically benign NIR excitation power density (0.3 
W/cm
2 
).  The green fluorescence from dansylcadaverine, connoting UV emissions, remained 
visible even at 0.3 W/cm
2
.   
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Appendix A: Photon Upconversion 
 
A.1. Energy Transfer Mechanisms in Photon Upconversion 
In stark contrast to other nonlinear optical phenomenon, such as multiphoton absorption-
excitation and second harmonic generation, photon upconversion utilizes real, metastable excited 
intermediate states rather than virtual excited intermediate states.  This difference greatly 
enhances efficiency as it permits multiple photons of light to be absorbed sequentially as well as 
simultaneously (transitions through virtual excited intermediate states require the simultaneous 
absorption of multiple photons). The four major mechanisms by which the energy from 
sequentially absorbed photons is harvested are: (i) excited state absorption, (ii) energy transfer 
upconversion, (iii) cooperative sensitization upconversion, and (iv) cross-relaxation (Fig. A.1).  
Photon avalanche is another mechanism, however, it is simply a combination of excited state 
absorption and cross relaxation, and therefore will not be described here.  Careful analysis of the 
decay rates of the excited states, combined with determination of the number of photons required 
to achieve each emission enable the energy transfer mechanism to be determined.         
The simplest mechanism of energy transfer is excited state absorption (ESA), in which 
multiple photons of light are absorbed sequentially by a single ion.  The absorption of each 
photon promotes the ion into the next energy state (Fig. A.1.A).  In order for this mechanism to 
occur, the energy levels must be equally spaced such that energy gaps between them match the 
energy of the photons being absorbed.  The excited states must also have sufficiently long half-
lives to permit the sequential absorption of multiple photons before decaying to the ground state.  
In this regard, the enhanced stability of 4f electrons by the electrons in the 5s and 5p orbitals 
permits efficient ESA in trivalent lanthanide ions.   
Energy transfer upconversion (ETU) involves two ions; termed “sensitizer” and 
“activator” (Fig. A.1.B).  The sensitizer absorbs a photon of light, promoting it to its first excited 
state.  Resonance between the energy levels of the excited sensitizer and a nearby activator permit 
the energy to be passed from the sensitizer to the activator.  Upon passing the energy to the 
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activator, the sensitizer decays back to its ground state, and the activator is promoted from its 
ground/excited state to the next energy level.  The successive transfer of energy from multiple 
photons of light, absorbed by multiple sensitizer/activator pairs enables ETU to be a highly 
efficient mechanism for harvesting the energy of incoming photons.  Yb
3+ 
is commonly used as 
the sensitizer due to its large absorption cross section in the tissue transparent window (λMAX = 
980 nm), and its single excited state (Wu et al., 2003; Balakrishnaiah et al., 2009).  By having 
only a single excited state, Yb
3+ 
is unable to undergo ESA, which would decrease the efficacy of 
the ETU process.  Furthermore, it permits Yb
3+ 
to be doped at high concentrations (>20%) 
without losing energy through cross-relaxation.  
When energy is transferred from two sensitizers to the same activator simultaneously 
(Fig. A.1.C), the process is referred to as cooperative sensitization upconversion (CSU).  The 
efficiency of CSU is far lower than that of ETU.  This is due in part to the spatial constraints of 
having two sensitizer ions within range of the same activator ion, and is why CSU is extremely 
sensitive to changes in the distance between the sensitizers and activator ions. It has been 
suggested that CSU may be an important means for efficiently populating the highest energy 
excitation states required for producing emissions in the UV region (Balakrishnaiah et al., 2009).   
Cross-relaxation (CR) is the last of the major energy transfer mechanisms involved in 
upconversion, and is usually considered to be deleterious to efficient upconversion.  In CR, two 
ions (one or both in an excited state) transfer energy such that the ion in the higher energy state 
transfers some/all of its energy to the other ion (Fig. A.1.D).  The process is written out in a 
similar fashion to that of a chemical reaction, except with the energy states of the two interacting 
ions taking the place of the chemical formulas.  For example: E3 (ion 1) + G (ion 2)  E2 (ion 1) 
+ E2 (ion 2).  In this CR process, ion 1 was in the third excited state (E3), and upon interacting 
with ion 2, transferred energy that excited ion 2 from its ground state (G) to its first excited state 
(E1).  In doing so, ion 1 relaxed from its third excited state (E3) to its second excited state (E2).  
While the depopulation of the E3 state is considered to be deleterious to the overall efficiency of 
the system, CR is essential in order to achieve some emissions.  An example is the relaxation of 
the 
1
D2 excited state of Tm
3+
 which produces an emission at 450 nm.  Insufficient overlap 
between the energy gap of excited Yb
3+ 
and the 
1
G4  
1
D2 excited state transition of Tm
3+
 inhibits 
the direct population of the 
1
D2 state via ETU.  Instead, the 
1
D2 excited state can be efficiently 
populated by CR between two Tm
3+ 
ions (Balakrishnaiah et al., 2009).  One possible CR pathway 
that populates the 
1
D2 state is CR between two ions in the 
1
G4 and 
3
F3 states respectively (
1
G4 + 
3
F3  
3
H5 + 
1
D2).   
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The average distance between ions dictates the extent of CR that occurs within the 
system.  Since the primary means of controlling the average distance between ions is by 
controlling the concentrations at which they are doped, CR is also known as “concentration 
quenching.”  Therefore, altering the doping concentration provides a means for tuning the 
emission spectrum.  Wang et al. reported that increasing the Tm
3+
 concentration from 0.01% to 
1.5% decreased the intensity of the blue emission at 477 nm, and increased the intensity of 
emissions from the 
1
D2 state (450 nm and 365 nm) (Wang et al., 2008).  Likewise, Chan et al. 
used the CR mechanism to shift the emission spectrum toward red or green by co-doping an Er
3+ 
system with different trivalent lanthanides (Tm
3+ 
, Pr
3+ 
, Ho
3+ 
), thereby introducing new CR 
pathways into the system (Chan et al., 2012).  It is worth noting that substitution of the atoms that 
make up the host lattice with ones of larger/small ionic radii is also capable of altering the 
average distance between ions; however, the observed effect on luminescence has been attributed 
to changes in the local crystal field rather than changes in the average distance between ions 
(Wang et al., 2010b).   
It is noteworthy that Yb
3+
 does not undergo concentration dependent quenching because 
of its single excited state.  As such, the Yb
3+ 
can be doped at concentrations up to 100% without 
deleterious effects on luminescence intensity caused by CR.  However, such large networks of 
Yb
3+ 
ions are capable of passing energy to the surface of the particle, when it can be lost due to 
quenching by crystal defects, capping ligands, or solvent molecules (Wang et al., 2011c).   
A.2. Suppression of nonradiative pathways 
  Energy can be lost from a system via nonradiative pathways; specifically the quenching 
of excited ions located at the crystal’s surface.  Ions at the surface are subject to quenching by 
interactions with capping ligands, solvent molecules, and/or structural defects at the surface that 
impose high phonon energy.  The high surface area-to-volume ratio that exists on the nanoscale 
exacerbates the effects of surface quenching, necessitating additional measures be taken to 
suppress surface quenching.  The most well established means for decreasing surface quenching 
is through the addition of an inert outer layer or shell.  Silica, NaYF4, NaGdF4, and CaF2 have all 
been used with great efficiency to prevent surface quenching (Qian and Zhang, 2008; Chen et al., 
2012; Dai et al., 2012; Zhang et al., 2012; Shen et al., 2013).  In this regard, luminescence 
intensity can be enhanced further by incorporating additional Yb
3+ 
sensitizing ions into the shell 
layer, creating an “active shell.”  Recently, Qiu et al. reported one such system, utilizing a 
core/active shell/inert shell architecture (Qiu et al., 2014).  They prepared NaYF4(30% Yb
3+
/0.5% 
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Tm
3+
) nanocrystals which were then coated with an active shell doped with 100% Yb
3+
 (NaYbF4), 
followed by an inert shell (NaYF4), such that the final formulation was NaYF4(30% Yb
3+
/0.5% 
Tm
3+
)@NaYbF4@NaYF4.  The incorporation of an inert shell on top of the active shell forced 
energy harvested by Yb
3+ 
ions in the active shell to migrate towards the Tm
3+
-containing core, 
improving the luminescence intensity by 240-fold over core alone, and 11-fold over inert shell 
alone (i.e. NaYF4(30% Yb
3+
/0.5% Tm
3+
)@NaYF4 ). 
A.3. Nonlinearity of emission intensity 
The nonlinear nature of photon upconversion means that the intensity of the emission(s) 
varies nonlinearly as the power density of the excitation light changes.  The relationship between 
the power density of the excitation light and the intensity of the emitted light is described by 
equation A.1: 
𝐼𝑁𝑇(𝜆) = 𝑃𝑛       (A.1) 
Where INT(λ) is the intensity of the emitted light at a specific wavelength (λ), P is the power 
density of the excitation light, and n is the number of photons of excitation light required to 
produce an emission at the specified wavelength.  This nonlinear relationship between the 
excitation light and the emitted light has important implications in determining the quantum yield.  
Moreover, it illustrates that the excitation power density controls the wavelength(s) of light 
emitted.  Increasing or decrease the excitation power density can increase or decrease the 
emission intensity at a specific wavelength, as long as the process is not saturated.  Furthermore, 
each energy transfer mechanism is affected differently by changes in excitation power density, 
allowing the dominate energy transfer mechanism, and therefore dominate emission wavelength, 
to be controlled through the power density (Wang et al., 2008).  This characteristics was 
exploited by Boyer et al. who reported that by varying only the excitation power density they 
could control the emission spectra; emitting UV light under high intensity excitation, or visible 
(blue) light under low intensity excitation (Boyer et al., 2010).  They employed this strategy to 
reversibly modulate the photoisomerization reaction of dithienylethene between ring-closing (365 
nm) and ring-opening (450 nm).  In the context of drug delivery, the capacity to reversibly turn 
drug release “on” or “off” remotely is enormously attractive, imparting an additional layer of 
spatiotemporal control over drug release.  
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Figure A.1: 
 
Fig. A1: Upconversion energy transfer mechanisms:  Schematic representation of the four 
major energy absorption and transfer mechanisms in upconversion. (A) Excited stated absorption 
(ESA), (B) energy transfer upconversion (ETU), (C) cooperative sensitization upconversion 
(CSU), and (D) cross-relaxation (CR).  Adapted from (Chen et al., 2014).     
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Appendix B: Dynamic Light Scattering 
 
Dynamic light scattering (DLS), also known as photon correlation spectroscopy, was 
employed to determine the size, and size distribution of the NPs.  While this technique can be 
used to measure any appropriately sized particle or molecule, the following discussion will refer 
to the species being measured as simply a “particle.”  DLS utilizes the constant movement of 
particles in suspension due to Brownian motion to calculate size via the Stokes-Einstein equation. 
A laser provides monochromatic light that illuminates the sample.  Particles in the light’s 
path scatter the photons, and these scattered photons are detected by the systems detector (e.g. 
photomultiplier tube).  Since the particles are constantly moving due to Brownian motion, the 
intensity of the scatter light varies over time.  By comparing the measured intensity of the 
scattered light at multiple time points, the degree of difference (or correlation) between the initial 
measurement and each subsequent measurement is determined.  This is the correlation function, 
and decreases from 1 (perfect correlation) to 0 (no correlation) exponentially over time.  Because 
Brownian motion causes smaller particles to move more quickly than larger particles, the rate at 
which the correlation function decreases is proportional to the size of the particles.  Thus the 
particle’s size is subsequently calculated from the rate at which the correlator function decays.  
The calculated size is the hydrodynamic radius of the particle (i.e. Stokes radius), and therefore 
includes the size of any ions/molecules that move concertedly with the core particle.    
Light scattered as a result of interacting with a particle can be scattered in any direction.  
Therefore, in theory, the detector can be placed at any position relative to the path of the laser.  
The most common positions for the detector are 90ᵒ (classic) or 173ᵒ (back-scatter).  When the 
detector is positioned at 173ᵒ (back-scatter) the distance through the sample that the light has to 
travel before reaching the detector is greatly reduced.  This reduces the probability that scattered 
light will be scatter a second time by a second particle (multiple scattering), thereby permitting 
the accurate measurement of samples with higher concentrations.  Also, the effects of large 
contaminates are largely mitigated by this approach since large particles scatter mostly in the 
forward direction (Mie scattering).  Contamination with large particles such as dust poses a 
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serious challenge to accurate DLS measurements.  As per Rayleigh’s approximation, the intensity 
of the scattered light is proportional to the size of the particle (Equation B.1). 
𝐼𝑁𝑇 ∝ 𝑑6    (B.1) 
Where the INT is the intensity of the scattered light, and d is the diameter of the particle.  The 
consequence of this is that DLS is extremely sensitive to the presence of large particles.  The 
presence of only a small quantity of large particulate contamination, such as dust, can 
significantly skew the size measurement to a larger diameter. 
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Appendix C: Zeta Potential 
 
Zeta potential is a measure of the direction and magnitude of the electrostatic charge at 
the surface of a particle or macromolecule.  The high surface-area to volume ratio of materials on 
the nanoscale makes surface characteristics, such as electrostatic charge, of paramount 
importance.  A charged particle suspended in an environment containing electrolytes will attract 
counter-ions to its surface.  This layer of counter-ions surrounding the particle is known as the 
electrical double layer and is comprised of two regions.  The inner-most region (Stern layer) 
consists of counter-ions in close proximity to the particle’s surface, and move with the particle as 
it moves under Brownian motion.  Ions that are located outside the Stern layer are only loosely 
associated with the particle and do not move in tandem with it.  The point at which the associated 
ions no longer move in concert with the particle is the slipping plane, and the electrical potential 
here is termed the “zeta potential.” 
By applying an electrical field to a suspension, the zeta potential can be determined via 
electrophoresis.  Charged particles in the dispersion are attracted to the electrode with the 
opposite charge, and repelled by the electrode with the same charge.  The particles move toward 
the oppositely charged electrode with a specific velocity (electrophoretic mobility, UE) which is a 
function of the strength of the applied electrical field, the dielectric constant of the medium (ε), 
the zeta potential (z), and the viscosity of the medium (η).  The relationship between these 
variables is described by the Henry equation (Equation C.1): 
 
     𝑈𝐸 =  
2𝜀∙𝑧∙𝑓(𝐾𝑎)
3η
    (C.1) 
The value of Henry’s function [f(Ka)] is determined by the composition of the medium in which 
the measurement is performed in.  Application of the Henry equation allows for the zeta potential 
of a colloidal system to be determined from the measured electrophoretic mobility.  Two 
important factors that are capable of changing the measured zeta potential are: (i) the ionic 
composition of the medium, and (ii) the pH of the medium.  Changes in the ionic composition 
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(either ionic strength or ionic composition) of the medium can alter the thickness of the electrical 
double layer.  Increasing ionic strength, or changing the ionic composition to ions with higher 
valency (e.g. from monovalent K
+
 to divalent Ca
2+
) decrease the thickness of the electrical double 
layer by compressing it.  The thickness of the electrical double layer is accounted for in the Henry 
function in Equation C.1. The pH of a sample is directly related to the zeta potential through the 
ionization state of functional groups present on the particle’s surface.  Increasing or decreasing 
the pH can impart, reverse, or remove a surface charge.  For example, consider a particle with 
carboxyl groups present at its surface.  These particles would have a negative surface charge at 
neutral and basic pH, but would become uncharged if the pH was sufficiently decreased.  
Therefore, such a system would be expected to be more stable at neutral and high pH, and 
unstable at low pH.  If the pH of a sample is unknown, interpreting the meaning of the measured 
zeta potential is virtually impossible.   
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Appendix D: Transmission Electron Microscopy 
 
Transmission electron microscopy (TEM) is a form of electron microscopy that is 
commonly used to characterize the size, size distribution, and morphology of nanoparticles.  The 
general principles are the same as that of traditional light microscopy; however, the two 
techniques differ in how the sample is visualized.  In tradition light microscopy, the sample is 
visualized by illuminating with photons of light, whereas electron microscopy utilizes electrons to 
visualize the sample (at the quantum level all particles exhibit wave-particle duality).  The 
wavelength of electrons is far smaller than that of light.  This enables samples to be visualized 
with much higher resolution (0.3-1 nm) than traditional light microscopy, which has a lower limit 
around 200 nm (Klang et al., 2012).   
The major components of a transmission electron microscope are the electron gun, main 
column, electromagnetic lenses, sample holder, detector/viewing screen, and vacuum pump (Fig. 
D.1).  The electron gun is operated at high voltage (200-400 kV) in order to fire electrons into the 
main column.  Increasing the voltage of the electron gun increases the velocity of the electrons, 
increasing imaging resolution but at the cost of image contrast.  The main column is maintained 
at high vacuum by the vacuum pump in order to prevent unwanted interactions between the 
electrons and molecules of air.  A series of electromagnetic condenser lenses focus the electrons 
onto the sample, which is held in place above the detector/viewing screen by the sample holder.  
Additional electromagnetic lenses then magnify the image for viewing via the detector (e.g. 
charge-coupled device), and/or viewing screen (fluorescent screen).   
Images of the sample are produced by the interaction (or lack thereof) of the electrons 
with the sample.  Images obtained in bright field mode are comprised of bright and dark regions, 
with the bright regions corresponding to regions that the electrons passed through with little or no 
effect from the sample, and the dark regions corresponding to areas where the electrons were 
unable pass through, and were scattered away from.  As such, the image produced by TEM is a 
two-dimensional “map” of the relative transparency of the sample to electrons.  The extent to 
which the electrons are scattered is determined by the material composition of the sample as well 
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as its thickness.  Additionally, the high degree of structural order in crystalline samples causes the 
electrons to be scattered in a diffraction pattern, enabling quantitative information about the 
sample to be obtained.   
Sample preparation is a simple, straightforward process; however, care must be taken to 
avoid the introduction of artifacts.  A suspension of nanoparticles is placed on a carbon-coated 
copper grid, and dried either under ambient conditions or under vacuum.  A stain may be required 
to improve the contrast of materials that do not strongly scatter electrons.  Commonly employed 
stains contain a heavy metal such as tungsten (e.g. phosphotungstic acid) or uranium (e.g. uranyl 
acetate).  The requirement that the samples are dried before imaging can introduce artifacts 
caused by destabilization and/or structural changes that are caused by the dehydration process.  
This can be circumvented by imaging the sample via cryo-TEM, which permits a sample to be 
imaged without dehydration. 
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Figure D.1: 
 
Figure D.1: Schematic representation of a transmission electron microscope: Schematic 
depiction of the major components of a transmission electron microscope.   
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Appendix E: Electromagnetic Spectrum 
 
Figure E.1:  
 
Figure E.1: Schematic depiction of the portion of the electromagnetic spectrum containing 
the UV, visible, and IR regions: The wavelength associated with various colors of light in the 
visible region is shown.  Wavelengths above 700 nm constitute the infrared (IR) region while 
wavelengths below 400 nm make up the ultraviolet (UV) region.  Figure adapted from (Frank L. 
Pedrotti, 2006). 
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Appendix F: Photoirradiation Procedures 
 
F.1. UV photoirradiation procedure 
UV photoirradiation was conducted with a handheld UVM-57 UV lamp (UVP Inc.; 
Upland, CA) with peak emission at 302 nm.  As depicted in Figure F.1, NP suspensions (1 mL) 
were photoirradiated by placing the NP stock suspension 2.5 cm from the UV filter.  Using the 
manufacturer’s stated intensity of 0.0015 W/cm2 at 7.6 cm; we calculated the light’s intensity at 
2.5 cm to be 0.0135 W/cm
2
 by the inverse square law (equation F.1): 
                                 
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦1
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦2
=  
(𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒2)
2
(𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒1)2
                  (F.1)                       
Where “Intensity1” is the intensity of the light (0.0015 W/cm
2) at “Distance1” (7.6 cm) from the 
light source, and “Intensity2” is the calculated intensity of the light at “Distance2” (2.5 cm) from 
the light source.  The photonic dose was controlled by manipulating the duration of 
photoirradiation.  Irradiation for 20 min at 2.5 cm from the lamp’s UV filter resulted in the 
administration of a photonic dose of 16.2 W∙sec/cm2.  Airflow through the fume hood was 
confirmed to be sufficient to prevent temperature changes during photoirradiation.     
F.2. NIR photoirradiation procedure 
NIR photoirradiation of was conducted using a continuous wave 980 nm diode laser (1.7 
W) coupled to a multimode fiber with a core diameter of 1,000 µm (Lasermate Group Inc., 
Walnut, CA).  The beam was not recollimated at the distal end of the fiber.  In order to control the 
power density the 980 nm laser’s average power output (PAVG) was controlled digitally by 
transistor-transistor logic (TTL).  The average power output (PAVG) and average power density 
(Power DensityAVG) were calculated using equations F.2 and F.3, respectively. 
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  𝑃𝐴𝑉𝐺 =  𝑃𝑃𝑒𝑎𝑘  𝑥 (
𝑃𝑢𝑙𝑠𝑒 𝑊𝑖𝑑𝑡ℎ
𝑃𝑒𝑟𝑖𝑜𝑑
)    (F.2)   
𝑃𝑜𝑤𝑒𝑟 𝐷𝑒𝑛𝑠𝑖𝑡𝑦𝐴𝑉𝐺 =  
𝑃𝐴𝑉𝐺
𝐵𝑒𝑎𝑚 𝐴𝑟𝑒𝑎
   (F.3) 
PPeak is the laser’s known peak power output (1.7 W), and beam area is the area of the laser’s 
beam measured on an IR card with Vernier calipers.  NIR photoirradiation was performed by 
transferring the NP suspension into a glass test tube and submerging the test tube in 200 mL of 
distilled water as a heat sink (Fig. F.2).  The distal end of the laser’s fiber was positioned 5 mm 
above the surface of the liquid, and the laser turned on for 60 min (Power DensityAVG = 10 
W/cm
2
).   
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Figure F.1: 
 
Fig. F.1: Schematic depiction of the setup used to expose NPs to UV light: Photoirradiation of 
APP-NPs (with and without DOX) and DOX-UCNC-NPs with UV light (302 nm) was conducted 
with a handheld UV lamp.  The NP suspension (1 mL) was transferred to a 6 well plate, and 
positioned directly below the UV lamp 2.5 cm from the UV filter.   
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Figure F.2: 
 
Fig. F.2: Schematic depiction of the setup used to expose NPs to NIR light: Photoirradiation 
of APP-H-NPs, DOX-APP-H-NPs and DOX-UCNC-NPs with NIR light (980 nm) was 
performed using a fiber coupled continuous wave diode laser system.  The NP suspension was 
transferred to a glass test tube and submerged in 200 mL of water.  The distal end of the fiber was 
introduced into the test tube, and positioned 5 mm above the surface of the NP suspension.   
 
